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ABSTRACT
THE IDENTIFICATION OF BIOLOGICAL ACTIVITIES OF PREGNANCY-ASSOCIATED
PROTEINS OF THE HORSE
by Richard Lea, BSc
Antisera were raised in rabbits against serum samples taken from 
pregnant and non-pregnant mares. Using these antisera in two- 
dimensional crossed Immunoelectrophoresis, a protein (32-hors.PP) was 
found to be pregnancy specific and first detectable in the maternal 
circulation 6 days after mating. (32-hors.PP detection as a pregnancy 
test during the first 21 days after mating was found to be significant 
at the 10% level. Levels of the protein were also found to increase 
during this period. The protein, of possible uterine origin, may have a 
biological activity associated with implantation (day 37) as levels of 
82”hors.PP were elevated from around days 21 to &3. For the remainder 
of gestation, the concentration of 32~hors.PP in the serum decreased. 
It is possible that 32“hors.PP detection may be a means of monitoring 
foetal well being.
Equine epitheliochorial placental extracts, taken from 2 mares 60 days 
and 80 days after mating, were found to induce a dose-dependent 
inhibition of lymphocyte proliferation in the mixed lymphocyte reaction 
(MLR) and mitogen stimulated assay (MSA), MLR supernatant reversed the 
inhibition and the addition of foetal tissue extracts to previously 
activated lymphocytes suppressed lymphocyte proliferation. This 
suggests suppression at the IL-l/IL-2 level of the immune response. 
Commercially available eCG inhibited lymphocyte proliferation. The 
presence of endometrial cup secretion containing high levels of eCG had 
no additive effect on the inhibitory activity of an extract of 
allantochorion (day 80), previously shown to induce less than 100% 
inhibition. This suggests that the commercially available eCG may 
contain an immunosuppressive contaminant.
Equine and bovine epitheliochorial placental extracts (allantochorion) 
inhibited collagen and ADP-induced platelet aggregation respectively. 
The mode of action of the anti-aggregatory factors may be related to 
the vascularity of the placentae.
Overall, it appears that local immunomodulatory and haemostatic 
mechanisms are important in the maintenance of pregnancy in species 
with epitheliochorial placentation.
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ml Millilitre
MLR Mixed lymphocyte reaction
mM Millimole (10“3 mole)
Mol.wt Molecular weight
MPP-1 Mare pregnancy protein-1
MO Macrophage
Mr Molecular range
MSA Mitogen stimulation assay
NaCl Sodium chloride
NK cell Natural killer cell
nm Nanometre (10"*9 metre)
PAF Platelet activating factor
pAP Porcine acidic protein
PAPP-A Pregnancy-associated plasma protein-A
PBL Peripheral blood lymphocytes
PBS Phosphate buffer saline
PGE2 Prostaglandin E2
PGF Prostaglandin F2alpha
PGFM Prostaglandin F2alpha metabolite
PHA Phytohaemagglutinin
Phase A cells Hormone dependent uterine suppressor cells in 
the mouse
Phase B cells Trophoblast dependent uterine suppressor cells 
in the mouse
PMSF Phenylmethylsulphonyl fluoride
PMSG Pregnant mare serum gonadotrophin
PP (5,12,14,15) Placental protein (5,12,14,15)
PPP Platelet poor placenta
PRP Platelet rich placenta
RIA Radioimmunoassay
RIT Rosette inhibition titre
RNA Ribonucleic acid
SDS PAGE Sodium dodecylsulphate-polyacrylamide ge 
electrophoresis
SIF Suppressor inducer factor
T cells T lymphocyte
T antigens Surface molecules on human lymphocytes (ol 
nomenclature)
Tc (cTL) Cytotoxic T lymphocytes
TCA Trichloroacetic acid
Th Helper T lymphocyte
TLX Trophoblast-lymphocyte cross-reactive antigens
TNF Tumour necrosis factor
Ts Suppressor T lymphocytes
TsF T cell suppressor factor
U Units
v/v Volume to volume ratio
w/v Weight to volume ratio
Wl-Wll Lymphocytes alloantigens of the horse (class 1)
a Alpha
3 Beta
Y Gamma
1 Microlitre
M Micromole
xg Gravity (relative centrifugal force)
% Per cent
°C Degrees centigrade
> Greater than
< Less than
CHAPTER -1-
MAMMALIAN PLACENTAL CLASSIFICATION
1.1 Introduction
In 1937, Mossman stated that the placenta consists of an "apposition of 
foetal and parental tissues for purposes of physiologic exchange". This is 
a broad definition, but necessarily so, such is the variety of 
structurally different placentae found within mammals. It must be 
remembered however that no matter how vastly placentae differ from one 
another, they all do the same thing. The ’what* is always the same, only 
the ’how' differs (Ramsey, 1982).
Research is presented in this thesis relating to the biological activities 
of the horse placenta. Data obtained has been compared to existing data 
on the more widely researched activities associated with the human 
placenta. In this regard, the project can be considered as a comparative 
study of placenta associated activities in the horse and human.
Placentae can be classified according to their origin, shape, internal 
structure, relation to maternal tissues and also by the composition of the 
placental membrane. When classified according to the composition of the 
placental membrane, the equine and human placentae can be considered as 
being at either end of the mammalian placental spectrum. When the 
placentae are classified according to their origin, however, both are 
chorioallantoic, that is, during placental development the allantois fuses 
with the chorion and vascularization is effected by the allantoic vessels 
(Bjorkman and Dantzer, 1987). When placentae are classified according to 
the composition of the placental membrane, the major determining factor
with respect to the type of placenta is the degree of ’trophoblastic 
invasive activity’, that is the extent of implantation of trophoblast into 
the uterine wall. The other placental classifications, however, overlap 
in that the degree of trophoblastic invasive activity is a key determining 
factor in classifications based on shape, internal structure and relation 
to maternal tissues. The classification based on trophoblastic invasive 
activity only applies to chorioallantoic placentae. The differences in 
placental structure between the human, horse and cow, which has a similar 
placenta to the horse, are summarized in Table 1.1.
1.2 Classification of Placentae by the Composition of the Placental 
Membrane *
The trophoblast is a layer of large cells making up the blastocyst wall 
prior to implantation; it is the outermost layer of cells of the 
conceptus. The conceptus initially implants into the endometrium by the 
insertion of trophoblast cells (in small numbers) between surface 
epithelial cells into the stroma, and this usually occurs in the close 
proximity of a maternal capillary. These invading clumps of trophoblastic 
cells are known as the cytotrophoblast, A number of these areas of 
cytotrophoblast penetrate further into the uterine wall and lose their 
cell margins to become a multinucleated cytoplasmic mass, a synctium, the 
syncytiotrophoblast.
The syncytiotrophoblast lies external to the cytotrophoblast, nearer to 
the maternal tissue. Most if not all of the trophoblastic invasive 
activity comes from the syncytiotrophoblast. In villous placentae the 
syncytiotrophoblastnormally coats the villi except in haemochorial 
placentae (such as human) where it lines the intervillous space. In most 
mammals, at least one layer of trophoblast persists throughout the 
gestation period, the relative amounts, however, may vary.
Table 1.1
Placental Structure - Difference between Human, Horse and Cow
_P^CENTAL_CLASSIFICATION_ ____ HumaN______ _____ HORSE______ ______ COW______
1) Origin Chorioallantoic Chorioallantoic Chorioallantoic
2) Shape Discoid Diffuse Cotyledonary
3) Internal structure Villous Villous Villous
4) Relation to maternal 
tissues
Deciduate Adeciduate* Adeciduate
5) Composition of 
placental membrane
Haemochorial Epitheliochorial Epitheliochorial
3
Trophoblastic invasive activity exhibits three variables, depth of 
penetration, manner of penetration and duration of invasive activity. The 
Grosser classification of placental structure (1927) is essentially 
concerned with the depth of penetration and is based on the number of 
layers of tissue separating the foetal and maternal blood streams thus 
comprising the placental membrane. Grosser originally proposed four basic 
categories of placental structure as outlined in Table 1.2.
In the epitheliochorial placenta (eg horse), there are six layers of 
tissue: three maternal and three foetal, whereas the haemochorial (eg 
human) placental membrane is composed of three layers of tissue, all of 
which are foetal and the foetal trophoblast is bathed in maternal blood.
The type of placenta present depends on the number of placental tissue 
layers eroded by the trophoblast during placental development. The human 
is thus at one end of this mammalian placental spectrum with a 
haemochorial placenta, where all three maternal layers are eroded away by 
the trophoblast. The horse and cow are at the other end of this placental 
spectrum where no layers of maternal tissue have been eroded away and 
there is simple apposition of foetal to maternal tissue (Fig.1.1).
The cow was originally placed in the syndesmochorial group but electron 
microscopic findings have shown the presence of maternal epithelium in the 
bovine placenta and the placentas of other animals placed in this group, 
e.g sheep, goat and some deer. The basis of the syndesmochorial placenta 
has been so weakened that the Grosser classification has been narrowed to 
three categories:- epitheliochorial, endotheliochorial and haemochorial.
Both of these alternatives, however, have been disproved by examination of
the proposed placentae with the electron microscope.
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(Ramsey, 1982)
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Differences also exist between placentae within a category, for example 
there are three recognised subdivisions of the haemochorial placenta. 
Electron microscopy has revealed that the trophoblast portion of the 
foetal membrane may be one, two or three layers thick resulting in a 
haemomonochorial, haemodichorial or haemotrichorial placenta respectively. 
The human placenta is haemomonochorial (Fig.1.2).
Although both the horse and cow have epitheliochorial placentation, 
there is a slight structural difference between the two in terms of the 
thickness of the barrier betweenthe maternal and foetal blood streams 
(Fig.1.3).
As illustrated in Fig,1.3, only slight differences exist between 
the equine and bovine placentae in terms of epitheliochorial placentation 
and these are as follows:
a) The maternal uterine epithelium in the cow is thicker than same layer in 
the horse between capillaries.
b) The distance between the uterine epithelium and the maternal capillaries 
is greater in the cow than in the horse.
c) Fibrocytes are found in the intervening space in the cow but not in the 
horse,
d) Only in the cow are large binucleate cells found on the foetal side. 
These, however, do not constitute part of the placental membrane.
The initial assumption accompanying Grosser’s placental classification 
scheme was that the number of tissue layers assumed to be present could be 
directly related to the permeability of the placental barrier. As a 
consequence of this, the epitheliochorial placenta appeared to be the 
greatest obstacle to the transfer of diffusable materials from one
7
(a) Haemomonochorial
e.g. man. Note that in the 
mature placenta the 
cytotrophoblast does 
not normally intervene 
between the foetal 
capillary and the 
syncyliolro 
phoblost.
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Fig.1.2 The haemochorial placenta. Variations in structure.
(Steven, 1975)
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circulation to another. As early as 1946, however, reservations were 
expressed regarding such assumptions: Sir Joseph Barcroft in his
'Researches on Prenatal Life' pointed out that "with very few exceptions 
the greater the number of placental layers, the more fully developed the 
animal at birth". In Barcroft's publications, he gives an account of how 
Sir John Hammond and assistants spent some time trying to catch a newborn 
foal. Upon withstraining the animal, one exhausted knight remarked to the 
other, "not a bad advertisement for a six-layered placenta!". This 
illustrates that for such complete foetal development the passage of 
nutrients across the epitheliochorial placenta must occur with reasonable 
ease. It has in fact been shown that both maternal and foetal capillaries 
penetrate their coverings (connective tissue and epithelium on the 
maternal side and mesoderm plus trophoblast on the foetal side) to come 
very close to each other facilitating exchange of nutrients (Ramsey, 
1982).
This demonstrates the dangers of assuming too much from initial 
observations of different placental structure. One objective of this 
project was to investigate some biological activities of placental samples 
taken from the equine epitheliochorial placenta and to compare the results 
to existing data relating to the human haemochorial placenta. The 
rational behind this work was that if the different placentae exhibit 
different biological activities then it may be possible to equate the 
results with differences in placental structure. This in turn may throw 
further light on the biological roles of placental membranes.
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CHAPTER -2-
THE IMMUNOLOGY OF PREGNANCY
2.1 Introduction
The foetuses of all outbred mammalian species present an immunogenetic set 
of paternal antigens that are foreign to the mother. One enigma of 
pregnancy is that the foetus will survive throughout gestation despite the 
fact that the mother will reject foetal or paternal tissues grafted at any 
other site. Research into mechanisms by which the foetus is not rejected 
by the mother could have beneficial offspins in other research areas such 
as transplantation biology and cancer immunotherapy. Prior to assessing 
the validity of the most popular theories put forward to explain the 
enigma of the foetal allograft, the immunological mechanisms operating 
in graft rejection will be described briefly.
2.2 Graft Rejection and Pregnancy
Grafting or transplantation is defined as the transfer of living cells, 
tissues or organs from one part of the body to another or from one 
individual to another. The tranplanted cell, tissue or organ is the graft 
or transplant. There are essentially 4 different types of graft:
1. Allograft: Graft transplanted between genetically different individuals 
of the same species,
2. Autograft: Graft taken from and replaced in the same individual.
3. Syngraft (Isograft): Graft transplanted between genetically identical 
individuals.
4. Xenograft: Graft transplanted between individuals of two different 
species,
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During normal pregnancy, the foetus is often referred to as the foetal 
allograft. Graft rejection exhibits the two major features of adaptive 
immunity, memory and specificity, and the major histocompatibility complex 
(MHC) plays a key role in specificity. The MHC is a group of closely 
linked gene loci, which code for molecules that restrict the specificity 
of antigen recognition by T lymphocytes. Although the MHC gene complex as 
a whole has a similar function in different species, the detailed 
arrangement of the genes differs. For example, in mice the H-2 complex is 
divided into 4 regions: K, I, S and D. The common terminology for the MHC 
loci of a number of species is outlined in Table 2.1. The MHC loci code 
for MHC proteins and these can be divided into three different generic 
types as determined by their structure and function. Class I antigens 
consist of 2 polypeptides, the larger of which is encoded by the MHC and 
is non-covalently linked with the polypeptide 32“mi-croSl°bulin which is 
encoded outside the MHC. In the human HLA complex, 3 loci, HLA-A, B and 
C, encode for the class I antigens The human HLA-A and -B regions are 
analogous to the murine H2 K and D antigens in that they code for cell 
surface molecules which can be identified by cytotoxic T cells.
In the horse, serological studies have revealed that lymphocyte 
alloantigens consist of a series of 11 codominant alleles (Wl-Wll) encoded 
by one locus (Lazary et al., 1980). It has been suggested that these 
ELA specificities are analogous to class I antigens (Lazary et al., 
1986).
Class II antigens consist of 2 non-convalently associated peptides (a and 
3) both encoded by the MHC. In the human HLA, the D region contains genes 
for class II proteins which are involved in the cooperation and 
interaction between cells of the immune system. The analogous region in
12
Table 2.1
MHC Terminology 
Species MHC Loci
Mouse Histocompatibility 2 (H-2)
Rat Rat Locus 1 (RT1)
Guinea Pig Guinea Pig Leucocyte Antigen Locus (GPLA)
Human Human Leucocyte Antigen (HLA)
Horse Equine Leucocyte Antigen (ELA)
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the mouse is known as the I region and products of this region are termed 
la antigens, which is also the generic term of antigens encoded by the 
human D region.
In the horse, analogous structures appear to be present on membranes which 
are separate from the Wl-Wll series. One such specificity, the B1 
antigen, has been shown to govern the interactions occurring between cells
in mixed lymphocyte reaction (Lazary et aJU , 1986). Indeed, the
characterisation of the B1 antigen and anti-Bl antiserum respectively are 
identical to the behaviour of calss II antigens/antisera in humans.
Class II proteins are those complement components which are coded by the 
MHC. Class I antigens are found on all nucleated cells in varying amounts 
whereas those antigens encoded by the D region have a restricted 
distribution. Although the MHC was identified as a consequence of its 
role in graft rejection, its physiological role is the process of antigen 
recognition by T cells as outlined in the following section.
2.3 The Cellular Components of Graft Rejection
Adaptive immunity defined as exhibiting specificity and memory is effected 
primarily by lymphocytes and phagocytes which are derived from bone marrow 
stem cells. Phagocytes are primarily responsible for taking up foreign 
particles and breaking them down in phagolysosomes. Lymphocytes are 
responsible for recognizing and differentiating the various antigens which 
the immune system encounters. In the development of an immune response, 
both of these cells interact and cooperate with each other. For example, 
phagocytes process antigens such that they are recognised by lymphocytes 
(antigen presentation) and lymphocytes secrete lymphokines and antibody 
which enhance the ability of phagocytic cells to take up antigenic 
material and eliminate it.
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Lymphocytes, comprising 20% of blood leucocytes, are of two types, 
B cells which differentiate into antibody producing cells and T 
cells which differentiate in the thymus and serve a number of functions. 
Some of the major T cell functions are helping B cells to make antibody, 
killing virally infected cells, regulating the level of the immune 
response and stimulating the microbicidal and cytotoxic activity of other 
immune effectors such as macrophages. Communication between cells is 
effected by cell/cell contact or by soluble factors.
T cells have a number of defined surface molecules on the cell surface 
some of which are used to distinguish between different subsets. Until 
recently, the cell surface markers of human T lymphocytes were designated 
a T number (Tl, T2 etc.), however, to avoid confusion of nomenclature 
between species, all lymphocyte surface molecules are now referred to as 
CD antigens and this designation has been given to equivalent molecules in 
different species. Where CD antigens are described in this text, the old 
nomenclature will also be given in parentheses.
A major feature of T cells is that they will only recognize antigen when 
it is presented to them in association with molecules encoded by the MHC. 
B cells, however, can recognize an unmodified antigen free in solution or 
on the surface of a cell. The presentation of antigens to T cells is 
carried out by antigen presenting cells (APC).
T cells recognize antigen and MHC molecules via a receptor which is 
associated with the glycoprotein molecule CD3 (T3) identified on all 
mature human and murine T cells. In man, the marker antigens CD5 (Tl) and 
CD2 (Til) are also present on all T cells, while in mice, Thyl is the 
characteristic marker (the human equivalent of Thyl is uncertain).
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Activated T cells also carry MHC class II molecules and express 
interleukin-2 (IL-2) receptors. In terms of function and surface 
proteins, T cells can be divided into three main types, helper, suppressor 
and cytotoxic lymphocytes.
Helper T lymphocytes (T^) are stimulated by an antigen in association with 
a particular class II MHC molecule on the surface of an antigen presenting 
cell. Tft cells cooperate with most B cells in the production of antibody 
in response to antigen although some B cells produce antibody without T 
cell help, stimulate cytotoxic lymphocytes to mature and interact with 
other cells by secreting lymphokines (see later). cells are
characterised by the surface marker CD4 (T4-human; L3T4-mouse) which 
appears to be involved in the recognition of MHC class II molecules.
To date, no surface molecule has been identified which differentiates 
cytotoxic cells (Tc) and suppressor cells (Ts). The two populations are, 
however, distinct in terms of function. Both Tc and Ts cell sub­
populations express the CD8 molecule (T8-human; Ly2,3-mouse) which is 
involved in the recognition of class I MHC molecules. Tc cells kill other 
cells by changing the permeability of the target cell membranes. In order 
to become effective killing cells, Tc precursor cells must be stimulated 
by an antigen in association with class I MHC molecules. Allogeneic class 
I MHC molecules can activate cytotoxic T cells in the absence of other 
antigenic differences. Ts cells suppress the function of other cells 
either directly or via suppressor factors. Precursors of Ts cells are 
activated in a similar way to Tc cell precursors by antigen in association 
with class I MHC molecules.
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2.4 Interaction of the Cellular Components
The interaction of cells of the immune system is effected by a combination 
of direct cell/cell contacts and by the release of various mediators. Of 
greater relevance to graft rejection are those soluble substances produced 
by stimulated lymphocytes known as lymphokines which regulate the immune 
response, largely by affecting the behaviour of other cells. Lymphokines 
are produced from both B and T cells, A wide range of activities have 
been attributed to lymphokines but few can be associated with single 
molecules. Some of the better characterized activities are listed in 
Table 2.2.
2.5 The Proposed Mechanism of Graft Rejection
As described above, the type of T cell stimulated by antigen is dependent 
on the MHC molecule presented to the T cell in association with the 
antigen. The antigen presenting cells thus play a key role in the 
induction of an immune response. B lymphocytes can also be stimulated by 
APC' s as shown by follicular dendritic cells which take up immune 
complexes via their complement 03b receptors. It is apparent that an 
individual MHC haplotype plays a major part in determining the level and 
specificity of the immune response.
The observation of small lymphocyte infiltration into an allogeneic skin 
graft led to the assumption that these cells were responsible for graft 
rejection and that cytotoxic T cells were the main effectors. Further 
investigations, however, have indicated that T^ cells are the effectors in 
rejection reactions elicited by MHC gene differences. This led to the 
second theory in which graft rejection was likened to a specialized form 
of delayed type hypersensitivity where monocytes and macrophages were 
recruited to the site. These two hypotheses are outlined in Fig.2.1.
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Table 2.2 
Lymphokines and their Activities
1. Regulation of other lymphocytes (non-antigen specific factors)
interleukin-1 (a and 3) (IL-1)
interleukin-2 (IL-2)
interleukin-3 . (IL-3)
interferon ( a andy ) (IFN)
soluble immune response suppressor (SIRS)
inhibitor of DNA synthesis (IDS)
allogeneic effector factor (AEF)
T cell replacing factor (TRF)
B cell growth factor 11 (BCGF11) or (IL-5)
B cell stimulation factor 1 (BSF-1) or (IL-4)
B cell differentiation factor (BCDF) or (IL-6)
2. Regulation of other lymphocytes (antigen specific factors)
assorted antigen specific helper factors (^HF)
assorted antigen specific suppressor factors (TgF)
3. Induction of inflammation and mononuclear cell infiltration 
skin reactive factor (SRF)
4. Modulation of the function of phagocytes
migration inhibition factor 
leucocyte migration inhibition factor 
chemotactic factor 
interferons (a and y ) 
colony stimulating factor 
macrophage fusion factor
5. Regulation of other tissues
colony stimulating factor (1,11,III) (CSF)
osteoclast activating factor (OAF)
6. Destruction of non-leucocyte target cells
lymphotoxins (heterogenous) (LT)
tumour necrosis factor (a and y) (TNF)
(MIF)
(LIF)
(CF)
(IFN)
(CSF)
(MFF) or (IL-4)
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F ig .2.1 Two ways in which the graft cell antigens may induce 
cytotoxic activity.
(Roitt et a l . , 1986)
A / MHC class I I  antigens in association with antigen on the graft cell
stimulate Th cells to secrete a lymphokine(s) which stimulates Tc cells 
to destroy the tissue. Tc cells recognize the graft via foreign 
MHC class I antigens.
B / Th cells reacting to the graft release lymphokines which stimulate 
macrophages to enter the graft and destroy it .
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It must be stressed that the above mechanisms relate to the generation of 
cytotoxic activity which will, in turn, lead to graft rejection. In 
response to these reactions and to the presence of foreign antigens, other 
immune responses will also be occurring but will have a lesser role in 
graft rejection. Thus, cells will stimulate B cells to synthesize 
antibody by direct interactions with the B cells across an antigen bridge 
and/or by releasing factors which may act by first binding to APC's. The 
interaction between the Th cells and B cells is also affected by the 
lymphokines IL-2, B cell growth factor (BCGF) and differentiation factor 
(BCDF).
2.6 Interleukins and Graft Rejection
The proposed mechanisms of graft rejection outlined in Fig.2.1 include 
cell/cellinteraction involving the secretion and activity of lymphokines, 
particularly the interleukins. The two interleukins of prime importance 
in the mechanisms of T cell interactions are interleukin-1 (IL-1) and 
interleukin-2 (IL-2).
2.6.1 Interleukin-1 (IL-1)
IL-1 is a peptide of 17,500 daltons produced by cells of 
monocyte/macrophage series and which acts on T cells. It is also produced 
by a number of other cell types such as skin keratinocytes, endothelial 
cells and kidney mesangial cells. Most normal cell types and a number of 
cell lines only produce IL-1 in response to a variety of stimulants. It 
is believed that reports of a constitutive production of IL-1 by normal 
cells can be attributed to a continuation in vitro of a response to prior 
stimulation in vivo or alternatively, are due to the presence of a 
contaminating stimulant (Oppenheim et al., 1986). In terms of graft 
rejection, the most important stimulus to the macrophage for IL-1
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production comes from activated T cells. Two basic mechanisms have been 
proposed whereby T cells induce macrophages to produce IL-1 during the 
immune response.
1. Cell contact occurs in the MHC class II (la) restricted region between 
activated T cells and macrophages (Fig.2.2) (Farr et al., 1977). IL-1 
is released due to a releasing stimulus from la molecules on the 
macrophage membrane.
2. Chao et al. (1977) have suggested that IL-1 release occurs in response 
to lymphokines such as colony stimulating factor. IL-l-inducing/releasing 
agents have been found: antigen-antibody complexes are weak inducers but 
stronger in the presence of complement, C5a is also a potent IL-1 inducer 
as is platelet activating factor (PAF). Furthermore, a number of IL-1 
inducing agents have been partially purified from human mixed lymphocyte 
culture supernatants. This latter mechanism is the most widely accepted 
but it is possible that both mechanisms act together.
It is thought that IL-1 is synthesized as a larger molecular weight 
product (35 kD) which is subsequently subjected to post-translational 
modification (March et al. , 1985). Furthermore, there appears to be a 
number of genes coding for an IL-1 family as illustrated by the 
development of two human cDNA clones which code for products termed IL-1a 
and IL-18 (March et al., 1985). IL-la and 8 have similar molecular 
weights, only about 30% amino acid sequence common, but apparently have 
similar activities.
IL-1 evokes a variety of responses as a short range mediator in the immune 
response. The known effects of IL-1 on T and B cells is listed in Table 
2.3.
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Table 2.3
Effects of IL-1 on Immune Cells
I. T cells: Co-mitogenic with lectins or Ag + la
Increased lymphokine secretion (IL-2, BCGF, CSF, etc.) 
Increased expression of IL-2 receptors 
Chemotaxis 
Radioprotection
II. B cells: Induces maturation of pre-B cells
Cofactor in clonal expansion
Oppenheim et al. (1986)
22
In terms of lymphoproliferation, the major effects of IL-1 are on cells 
resulting in an increase in IL-2 release and IL-2 receptor expression. In 
addition, IL-1 enhances the activity of Th cells by raising body 
temperature and it also protects Th cells from T cell suppressor factor 
(TsF) (Durum at al., 1985).
In response to IL-1, macrophages release prostaglandin E2 (PGE2) and 
produce tumour necrosis factor (TNFa). It is uncertain, however, whether 
the cells that respond to IL-1 also produce it. Since PGE2 inhibits IL-1 
production by macrophages and decreases class II MHC expression, the 
process of IL-1 production appears to be self limiting (Durum et al. , 
1985),
Little is known about the IL-1 receptor although initial investigations 
indicate a structure of 80 kDA. Furthermore, all forms of IL-1 (IL-1 a 
and 3 and the precursor molecule) have been shown to bind to the same 
receptor (Dower et al., 1985).
2.6.2 Interleukin-2 (IL-2)
IL-2 is a mitogenic lymphokine as it induces T cell proliferation and 
provides a means by which antigen-triggered T cells can be clonally 
expanded in vitro. IL-2 is a single peptide (15.4 kD) produced by T 
cells within hours of stimulation with antigen (Smith, 1984). IL-2 
exhibits variable glycosylation but the carbohydrate has been shown to 
play no part in the growth promoting activity of variably sialylated IL-2 
molecules (Robb and Smith, 1981). IL-2 is also produced by natural killer 
(NK) cells which are known to produce a variety of cytokines such as IL-1, 
BCGF and interferon i following stimulation with lectin or antigen (Smith, 
1984).
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Activated T cells express both high affinity and low affinity IL-2 
receptors (Robb et al,, 1984). Binding studies using radiolabelled IL-2 
and radiolabelled monoclonal antibody against an IL-2 receptor protein 
(anti-Tac) have revealed that the major proportion of IL-2 receptors are 
of low affinity (Robb et al., 1981; Depper et al., 1984). In general, the
high affinity receptors comprise 5-10% of the total number of IL-2
receptors (Robb et al., 1984). The function of the low affinity
receptors is uncertain but IL-2 appears to bring about its growth- 
promoting effects by interaction with the high affinity receptor. In 
addition, the high affinity but not the low affinity receptor undergoes 
receptor-mediated endocytosis (Weismann et al., 1986). It is thought that 
the internalization of the high affinity receptor is involved in signal 
transduction. Monoclonal antibodies have been used to isolate and 
characterize the IL-2 receptor (Tac protein) and it appears to be a 
membrane glycoprotein of 55 kD.
IL-2 receptors are only transiently expressed on T cells following antigen
activation but there is evidence to suggest that after cell division,
antigen triggering must occur again before the IL-2 receptors are 
expressed at high density (Depper et al., 1984). The response to IL-2 is 
therefore restricted by the availability of IL-2 receptors. Since the 
density of IL-2 receptor expression is dependent on stimulation of the 
responding cells by antigen, the process remains antigen specific although 
IL-2 is itself a non-specific effector molecule. All three functional T 
cell subsets (Th, Tc and Ts) can be induced to develop IL-2 receptors and 
will proliferate in the presence of IL-2. It is, however, unclear whether 
a given T cell can both produce and respond to IL-2 at the same time, or
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whether production and response to this lymphokine is restricted to 
certain phases of the cell cycle. The events that occur during T cell 
activation are summarised in Fig.2.2.
To summarise, antigen presenting cells process and present antigens to T 
cells (Tft in Fig.2.2) together with class II MHC antigens. IL-1 produced 
by antigen-presenting cells augments the response of some T cells. In 
response to these stimuli, Th cells produce IL-2 which allows those T 
cells with IL-2 receptors to proliferate. IL-2 receptor expression is 
increased following antigen presentation (shown in Fig,2.2 for class II- 
restricted T cells) and it is therefore probable that the same cell can 
both produce and respond to IL-2 as well as trigger other cells.
The above mechanisms are not the only immune responses that occur during 
graft rejection although they are of prime importance. For example, IL-2 
is reported to induce interferon- Y production from T cells which 
augments T cell expression of IL-2 receptors (Kasahara et al., 1983). 
IL-2 receptors are also found on B cells and thus IL-2 acts as a growth 
factor (Tsudo et al., 1984). Tumour necrosis factor (TNF$) is also 
released by T cells in response to IL-2 which has a synergistic effect 
with interferon y in killing target cells (Male et al., 1987).
2.6.3 Lymphocyte Proliferation Assays
During pregnancy, many factors/proteins, produced by the foeto-placental 
unit, are described as being able to suppress the maternal immune response 
(Section 2.7.6.1). The activity of these factors are often assessed by 
their inhibitory activity on in vitro lymphocyte stimulation assays. One 
of these assays is the mixed lymphocyte reaction (MLR) in which two 
populations of peripheral blood lymphocytes from two donors are incubated
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Fig.2.2 T^, Tc and Ts respond to IL-2 and proliferate in its presence,
Male et al. (1987)
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together. The cells are stimulated to grow in the presence of foreign 
class II antigens, the cells must differ at the HLA-D region (human), 
ELA-B1 region (horse) or I region (mouse) for stimulation to occur. 
Consequently, both populations of cells proliferate in response to each 
other. The other type of lymphocyte proliferation assay is the mitogen 
stimulation assay (MSA) in which lymphocytes are stimulated to grow and 
proliferate by lectins. A lectin is a protein which binds and cross-links 
specific cell surface carbohydrate determinants and will polyclonally 
stimulate lymphocytes. Lectin-induced lymphoproliferation is not 
therefore dependent on the presentation of MHC molecules.
2.7 Immunomodulatory Activity during Pregnancy
During mating, implantation, placental development and throughout 
gestation, the maternal immune system is being challenged by foetal and 
MHC antigens and the efferent arm of the immune reaction is often 
activated but does not lead to a rejection reaction. It has been 
suggested that the immune responses to the foetus following a recognition 
of its foreign status, may play an important or even essential role in the 
immunological protection of the foetus from the time of implantation to 
parturition (Beer & Sio, 1982). The actual process of parturition has been 
likened by some to the rejection of a previously tolerated .graft. The 
many changes in hormone and protein levels at birth are well documented 
and thus it is proposed that these changes remove the immunoregulatory 
influences which have maintained the foetal allograft throughout 
gestation.
There has been much theoretical speculation to explain the lack of 
rejection of the histoincompatible foetus and placenta and each theory has 
been investigated to a greater or lesser extent in a number of mammalian 
species. As a consequence of this , it must be emphasized that in an
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interspecies comparative study such as this, there is need for caution 
when extrapolating immunologic and reproductive events in the human to 
mammals with different placentation and gestational length. An 
immunological interpretation of these differences between animals with 
haemochorial placentation may lead to a further understanding of the 
functions of different types of placentation and the maintenance of 
mammalian pregnancy.
Recent research findings indicate that there is more than one mechanism 
involved in the establishment of an immunological endocrine equilibrium 
necessary for the maintenance of pregnancy. The following is a summary of 
the proposed mechanisms relating to the non-rejection of the foetal 
allograft.
The cell-mediated immunological mechanisms of graft rejection (as 
previously described) are summarised in Fig.2.3.
The early theories put forward to explain the non-rejection of the foetal 
allograft were based on the idea that the mother did not react 
immunologically to the embryo.
2.7.1 The Uterus is an Immunologically Privileged Site
The poor lymphatic drainage of the endometrial epithelium as compared to 
the rapid drainage of the myometrium suggested that the uterus may be an 
immunologically privileged site. It has been demonstrated in rodents 
that allogeneic skin transplants were rejected from the uterus as quickly 
as those placed elsewhere but show prolonged survival in the pregnant 
uterus (Kaye et al., 1974). Prior active sensitization to the donor
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alloantigens resulted in prompt rejection of the allograft in utero. It 
was subsequently concluded that pregnancy in no way blocks the efferent 
limb of the uterine immunological reflex arc (Kaye etal., 1974).
2.7.2 The Placenta Acts as a Mechanical Barrier
If the uterus responds immunologically to the presence of a foetus 
then perhaps the graft has some physical characteristic which prevents it 
reacting with the maternal immune system. In the haemochorial placenta, 
there is a fibrinoid layer around the syncytiotrophoblast (Bardawil & 
Toy, 1959). Bradbury et al. (1969) demonstrated that this layer consisted 
of highly sulphated glycoprotein (sialoprotein) which could 
electrostatically repulse negatively charged lymphocytes. Recent 
investigations however have shown that there is no consistent fibrinoid 
layer between the decidua and the trophoblast (Tekelioglu-Uysal et al., 
1975). The concept is further weakened by numerous observations of the 
exchange of maternal and foetal cells throughout gestation (Ikle, 1964).
2.7.3 Lack of MHC Antigen Expression on Foeto-Placental Tissue
It was suggested that the trophoblast may be poorly immunogenic in vivo 
due to the lack of class I and class II antigens.
2.7.3.1 Class I MHC Antigen Expression Associated with Foeto-Placental 
Tissue
The expression of MHC antigens by human and murine placental tissue has 
been extensively investigated but some confusion still remains. MHC 
expression by the human morula or blastocyst is unknown. Classical MHC 
class I antigens have not been detected on the non-villous trophoblast, 
villous trophoblast or syncyt iotrophoblast (Sunderland et al., 1981). 
The non-villous trophoblast, however, exhibits a class I-like antigen
30
throughout gestation (Redman et al., 1984), Similar unusual class I
antigens have been detected in the mouse and rat (Cook et al.,
1983; Smith et al., 1982),
Implantation in horses occurs 37 days after mating (Allen et al., 1973). 
This is typified by the invasion of the uterine endometrium by specialized 
gonadotrophin-secreting trophoblast cells of the annulate chorionic girdle 
region of the foetal membranes (Section 3.6). These cells develop into 
endometrial cups. Two to four weeks after the development of the cups, 
more than 90% of primigravid mares exhibit high titres of anti-paternal 
cytotoxic antibody in their serum (De Week et al., 1978). Cytotoxic 
antibody is reported to persist throughout gestation, show strong 
specificity for the mating stallion and is absent in mares carrying 
foetuses that are histocompatible with regard to class I MHC antigens 
(Antczak et al. , 1984), In addition, throughout the 80-100 day lifespan 
of the cups, increasing numbers of lymphocytes accumulate in the stroma 
around each cup. This maternal response occurs in both MHC class I 
compatible and incompatible pregnancies and in hybrid matings between 
equine species (Allen et al., 1984). No similar reaction, however, 
occurs at the border between endometrium and non-invasive trophoblast.
These and other observations suggest that the invasive trophoblast may 
express MHC antigens. It has in fact been suggested that cytotoxic 
antibody production and the endometrial cup leucocyte reaction represent 
respectively the humoral and cell-mediated arms of the maternal immune 
response to paternally-derived foetal alloantigens on endometrial cup 
cells (Kydd et al., 1982).
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Recent investigations in this area have involved the use of well 
characterised anti-MHC monoclonal antibodies in an immunoperoxidase 
labelling system. Crump et al. (1987) were unable to demonstrate class 
I MHC antigen expression on mature endometrial cup cells or non-invasive 
trophoblast, although the progenitor tissue of the cups, the chorionic 
girdle, stained heavily. Moreover, it appears from antibody absorption 
and elution experiments that endometrial cups might express very low 
levels of paternal MHC antigen. Crump et al. (1987) also tested the 
immunogenecity of endometrial cup tissue by immunising naive recipients 
with the tissue and also by giving booster immunisation to a mare with 
endometrial cup tissue from her own pregnancy. No increase in cytotoxic 
anti-paternal antibody occurred suggesting that if endometrial cup cells 
express paternal MHC antigen, it is not expressed in a form that is highly 
immunogenic.
Despite the fact class I MHC antigens cannot be detected on mature 
endometrial cup cells histochemically, class I antigen expression by 
chorionic girdle tissue and the close temporal association between 
cytotoxic antibody production and endometrial cup formation still imply 
that the invasive component of the trophoblast is the source of 
alloantigen in equine pregnancy. In 1986, Zuckerman and Head found that 
when murine trophoblast cells were cultured in vitro with interferon T, 
the level of expression of class I MHC antigens increased. It has been 
postulated that an equivalent type of stimulus may modulate temporarily 
the expression of MHC antigens on chorionic girdle cells in equids (Crump 
et al., 1987). Further speculation by Crump led to the idea that the 
proposed modulation of MHC antigens on chorionic girdle and endometrial
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cup cells could also regulate the composition of maternal leucocytes that 
surround the endometrial cups, uterine suppressor cells may have an 
important role as described in the mouse (Clark et al., 1984),
2.7.3.2 Class II MHC Antigen Expression Associated with Foeto-Placental 
Tissue
The expression of class II MHC products in the placenta is of particular 
interest because these are a major stimulus for the rejection of 
allografts. Research groups generally agree that class II antigens are 
not expressed on trophoblast derived tissues at any stage throughout 
gestation both in the mouse (Chatterjee-Hasrouni and Lala, 1981) and in 
the human (Faulk and Temple, 1976; Sunderland et al., 1981; Bulmer et al,,
1984). To date, no data is available regarding the expression of class II 
MHC antigens on equine foeto-placental tissue,
HLA-DR positive cells have been found in the decidualised endometrium 
(Bulmer and Sunderland, 1984), the stroma of term chorionic villi (Sutton 
et al. , 1986) and the foetal mesenchyme of the term amniochorion (Sutton 
et al«, 1983). These cells label with monoclonal antibodies specific 
for monocytes and macrophages (Bulmer and Johnson, 1984),
2.7.3.3 Non-Histocompatibility Antigen Systems
The body of evidence implicating important immunological roles of non-MHC 
antigen systems in the foeto-maternal relationship is rapidly increasing. 
Of these, the trophoblast-specific and trophoblast-lymphocyte cross­
reactive TLX antigens have attracted most attention.
The human TLX antigen system refers to antigens shared by both trophoblast 
and lymphocytes and is described as a possible modification of the class I 
MHC antigen recognition system (Bulmer and Johnson, 1985). The TLX
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antigen system is believed to be involved in the maintenance of normal 
pregnancy by virtue of maternal recognition and initiation of protective 
blocking antibodies but there is no direct evidence for this (Section
2.7.5).
In the horse, the slow deterioration of endometrial cups over a 60 day 
period (Section 3.6) has been likened to the rejection of skin grafts 
across minor histocompatibility antigen barriers (Crump et al., 1987). One 
possibility is that the endometrial cups express the TLX antigen (Section
2.7.5) (Allen et al., 1987). A further suggestion, however, is that 
antigens specific for trophoblast tissue are more likely to be expressed 
on cup cells than minor histocompatibility antigens. That a great 
increase in the leucocyte response to endometrial cups occurs in hybrid 
equine pregnancies (Allen et al., 1984) suggest that species related 
antigens may also be expressed on at least the invasive portion of the 
trophoblast (Allen et al., 1987).
2.7.4 Maternal Immunoregulation
Generally speaking, there are essentially two possible mechanisms by which 
the maternal immune response may be altered resulting in the failure of 
foeto-placental rejection. One way is the production of immunomodulatory 
substances in the placenta with non-specific effects on maternal cellular 
immunity, e.g. hormones/proteins. The other way involves circulating 
specific antipaternal immunosuppressant substances of which the main 
suppressants have become known as 'blocking antibodies'.
2.7.5 Circulating Blocking Factors
A humoral response to mammalian pregnancy has been demonstrated in many 
species. 15 to 25% of primiparous women and 40 to 60% of multiparous 
women produce anticlass I and class II HLA agglutinating and cytotoxic
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antibodies (Doughty and Gelsthorpe, 1976; Terasaki et al., 1970). Anti 
HLA (Faulk et al. , 1974) and anti-H2 (Bell and Billington, 1981) can be 
detected in placental eluates. In contrast, 90% of primiparous mares 
develop high titre antipaternal alloantibody (Antczak et al., 1984).
Pregnancy sera is well known to contain certain blocking factors which 
inhibit a variety of in vitro assays of T lymphocyte proliferation and 
function and a number of these effects have been attributed to blocking 
antibodies. Antipaternal antibodies in parous serum (Stimson et al., 
1979) or eluted from placenta (Stewart et al., 1984) have been shown to 
block lymphokine release, MLR against paternal lymphocytes and the 
generation of cytotoxic killers in vitro (Rocklin et al., 1979).
The three most likely mechanisms by which blocking antibodies are believed 
to prevent lymphocyte-target cell recognition are represented in 
diagramatic form below (Fig.2.4).
A deficiency in blocking antibodies in women suffering from recurrent 
spontaneous abortion has been described suggesting that a maternal humoral 
response may be important for the survival of the foetal allograft 
(Rocklin et al. , 1976; Power at al. , 1983). Indeed, it has been shown 
that when women suffering from spontaneous abortion 'are pre-immunized with 
paternal lymphocytes, the rate of abortion is significantly decreased 
compared to a group of women treated with their own lymphocytes (Mowbray 
et al. , 1985). The apparent benefit of pre-immunization with paternal HLA 
has not been adequately explaLned but has been related to the appearance 
of anti-HLA antibodies.
Similar results to these have been obtained from studies of the
extra-species donkey-in-horse pregnancy, that is the transfer of donkey
embryos to horse mares. Endometrial cups do not develop in this type of
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lymphocyte-target cell recognition.
Scott et al. (1987)
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pregnancy and 80% of donkey foetuses are aborted between days 80 and 100 
of gestation (Allen, 1982). Furthermore, a dense leucocyte response in 
the mare's endometrium is associated with the death of the foetus. In 
1987, Allen et al. reported that the immunization of mares carrying 
donkey conceptuses with washed donkey peripheral blood lymphocytes 
increased the survival rate from 20% to 67%. These results were 
consistent when the immunized lymphocytes were taken from the genetic sire 
and dam of the donkey embryo or from unrelated male and female donkeys. 
The immunization of mares carrying donkey foetuses with serum from mares 
carrying normal intra-species pregnancies at a similar stage of gestation 
had a similar effect. These results suggest that similar imraunoprotective 
systems operate in the human and the horse, possibly due to the 
development of anti-TLX antibodies (Faulk and McIntyre, 1986; Allen e_t 
al. , 1987). Alternatively or in conjunction with blocking antibodies, 
specific suppressor cells may be induced in the uterus as described in the
mouse (Clark et al^ . , 1984) and in the human (Clark et al. , 1986e)
(Section 2.7.6.2).
2.7.6 Maternal Immunosuppression
The response of maternal lymphocytes to mitogen stimulation during 
pregnancy has shown normal or decreased T and B lymphocyte function 
(Lawrence et al. , 1980). It is proposed that there is an involved
suppression of the maternal response by various hormones and pregnancy 
proteins during pregnancy. This theory has been proved with respect to 
many hormones and pregnancy proteins but the mechanisms by which they 
interact with the maternal immune system is less clear. Any 
hormone/protein ascribed an iramunoregulatory role could influence any one 
of a complex series of regulatory events, the net result being suppression 
or enhancement of the immune response. At the humoral level, regulatory
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factors include antibody and immune complexes in addition to a large 
number of less well-characterised substances. At the cell-mediated level, 
immuno-regulation could result from the release of helper or suppressor 
factors which interact with other cells either in the afferent or efferent 
limb of the immune system or from the generation of a cell population 
which suppress the maternal immune response. It is thus clear that there 
is much overlap between the production of blocking antibodies and other 
immunoregulatory substances such as immunosuppressants.
2.7.6.1 Human Immunoregulatory Hormones and Proteins
In the human, a number of proteins have been identified as being secreted 
either specifically during pregnancy (pregnancy-specific) or at an 
enhanced rate (pregnancy-associated). The pattern of secretion of these 
proteins falls into 2 groups.
Pattern A: Those proteins at maximal levels during the first few 
weeks of gestation and thus are likely to have an important role 
during the implantation and placentation processes such as 
immunoregulation, e.g. human chorionic gonadotrophin (hCG) 
(Braunstein et al., 1976)
Pattern B: Those proteins the secretion of which appear to relate 
to the overall size of the placenta and whose levels increase 
throughout gestation, e.g. anticoagulants such as placental 
protein-5 (Soma et al., 1985).
There has been much interest in those proteins/factors produced locally in 
the foeto-placental unit which may have an immunomodulatory activity 
during the critical early stages of pregnancy. In this regard, the more 
important hormones and proteins secreted during this time are described 
below.
38
(a) Progesterone
Progesterone is described as the essential hormone for the maintenance of 
pregnancy and subsequently, much attention has been focused on it as a 
potential immunosuppressant. Placental progesterone production appears to 
be (in part) dependent on the type of placental structure with high 
concentrations produced by haemochorial placentae and relatively low 
concentrations produced by epitheliochorial placentae (Stites and Siiteri,
1983).
A number of in vivo studies using mice have illustrated that 
progesterone has a pronounced local immunosuppressive effect but little 
effect on systemic immunity (Siiteri et al. , 1977; Van Vlasselaer and 
Vandeputte, 1985).
Progesterone in vitro has been shown to inhibit T cell activation by 
mitogens, antigens and allogeneic cells and the concentrations required 
were equivalent to levels found at the placenta/decidua border (Kumar 
et al. , 1963; Clemens et al., 1979). Stites and Siiteri (1983)
confirmed the above findings and reported that progesterone inhibited 
mainly the recognitive and proliferative phases of the allogeneic T cell 
response. Further investigations by Stites and Siiteri revealed the 
following in vitro effects of progesterone:
1/ Progesterone has no inhibitory effect on monocyte proliferation but 
has a relatively selective action on T lymphocytes,
2/ Progesterone is effective in blocking the mitogenic activity of IL-1.
It was not shown, however, that IL-1 production was blocked.
3/ Oxygen consumption by monocytes is inhibited by progesterone in 
phagocytosing culture. This may account for the in vivo anti­
inflammatory action of progesterone.
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Progesterone has also been reported to block cytotoxic T cell induction 
(Van Vlasselaer and Vandeputte, 1985) and to independently depress the 
function of alloreactive suppressor cells generated in the MLR (O'Hearn 
and Stites, 1983).
An important step in the process of antigen recognition and lymphocyte 
proliferation is the capacity of lymphocytes to form aggregates and 
neither antigen or major histocompatibility differences are involved in 
this. This property is believed to allow the local exchange of 
immunologic information by the presentation of antigens, by the secretion 
of lymphokines, or both. In 1980, Nussenzwaig and Steinmann reported the 
capacity of dendritic cells to aggregate with lymphocytes around their 
cellular protrusions enabling the exchange of immunologic information with 
neighbouring cells. Lymphocyte populations depleted of dendritic cells 
are unable to form clusters. In 1984, Hamann et al. reported that after 
3-5 days stimulation by PHA, blast formation and ^H-Tdr incorporation 
occurred only in the clustered lymphocytes. In 1986, Van Vlasselaer 
e t al. examined the effect of progesterone and trophoblast culture 
supernatants on lymphocyte aggregation and found that diminished cell-cell 
contact occurred when progesterone was added to autologous lymphocytes. 
Trophoblast supernatants were found to have an_identical effect to 
progesterone and the inhibition of lymphocyte clustering was counteracted 
by the addition of anti-progesterone serum. Furthermore, when a 
preparation containing lymphokines with a definite IL-2 activity was 
added, this effect was reversed (Gillis et al., 1979). Progesterone does 
not inhibit IL-2 production and thus Van Vlasselaer suggests that the 
decreased cluster formation may be due to an interaction of progesterone 
with the lymphocyte membrane leading to a decreased sensitivity for IL-2 
molecules. This may have some significance during pregnancy in that once
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maternal lymphocytes leave the placental bed, they regain their immune 
competence. Although the above experiments suggested that progesterone 
was the major immunosuppressant in trophoblast supernatant, the 
progesterone concentration in the supernatant was found to be too low to 
cause immunosuppression in vitro and it has subsequently been suggested 
that progesterone is bound to another factor which increases its 
immunosuppressive effect (Van Vlasselaer et al«, 1986).
b) Human Chorionic Gonadotrophin (hCG)
Human chorionic gonadotrophin is a glycoprotein of molecular weight 38,000 
with a carbohydrate content of 30%. The molecule consists of two 
dissimilar non-covalently linked subunits, alpha and beta, and these are 
located in the cytotrophoblast and syncytiotrophoblast respectively (Tojo 
et al. , 1982). The detection of hCG in serum or urine is used for the 
early diagnosis of pregnancy. hCG can first be detected in the maternal 
blood at 8-12 days post conception which is the time of implantation. 
Levels then rise rapidly and reach a maximum at the tenth week of 
pregnancy after which the concentration declines rapidly and remains 
constant from the fourth month onwards. A similar pattern is found in 
the urine.
As a consequence of the early appearance of hCG in pregnancy, much 
attention has been focussed on the hormone as a potential immuno­
suppressant (Braunstein et al., 1976). All of the evidence indicating an 
immuno-suppressive role for hCG was based on work using a crude 
commercially available hCG extract from pregnancy urine. 
hCG-mediated immunosuppression has been reported in PHA-induced 
lymphocyte transformation, mixed lymphocyte reactions and antigen induced 
blastogenesis using doses of 50-100 iu/ml (Siiteri and Stites, 1982).
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More recently .however, hCG has been further purified from the crude 
extracts to 10,000-15,000 iu/ml. This more highly purified hCG is not 
immunosuppressive (Rolfe et al. , 1983). Since this discovery, research 
has been carried out to try and find the immunosuppressive substance(s) in 
crude hCG preparations. One finding of interest in this area is that 
crude hCG preparations contain an immunosuppressive pregnancy protein 
known as early pregnancy factor [see (c) below] and it has been suggested 
that this may be entirely responsible for the immune-suppression 
observed (Rolfe et al., 1983).
hCG has thus been shown not to be immunosuppressive but this does not rule 
out an immunological role, indeed membrane-bound hCG may play an important 
role in blocking certain events in cellular recognition which could play 
an important role in foetal-maternal tolerance.
c Early Pregnancy Factor (EPF)
One development that has received much attention over a number of years 
has been the detection of an early pregnancy factor (EPF) in the serum 
within hours of fertilisation and before implantation of the embryo.
EPF is an activity detected by an in vitro rosette inhibition assay which 
measures the capacity of antilymphocyte serum (ALS) to inhibit rosette 
formation between T cells and heterologous erythrocytes, a high rosette 
inhibition titre (RIT) being indicative of a high concentration of 
specific antibody (Smart et al., 1981). Morton et al.(1976) adapted this 
assay to look for the presence of suppressor activity in pregnant mice 
and found that the activity of the ALS to inhibit rosette formation (RIT) 
in the test could be enhanced by a factor (EPF) present in pregnant mouse 
serum.
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EPF has been detected by this technique in all species so far studied 
which include the mouse, sheep, pig (Morton et al., 1983), horse (Morton 
et al. , unpublished), human and wallaby (unpublished) and the sensitivity 
of the system has been shown to vary between species. The mechanism of 
action of the EPF assay has recently been further investigated by Morton 
(1985) and it appears to measure soluble suppressor substances released by 
EPF-bound lymphocytes. It is these suppressors rather than EPF per se 
which are believed to increase the RIT of ALS. The lymphocytes involved 
in this assay are T helper cells and Morton suggests that these 
suppressors affect receptor mobility thus reducing red blood cell receptor 
availability resulting in a decrease in rosette formation.
EPF is as yet uncharacterised but it may be a unique pregnancy protein 
worthy of further investigation. EPF activity is detectable very early in 
pregnancy. In the mouse, the RIT is increased six hours after 
fertilisation, returning to normal four to six days before parturition. 
Thus far, research of this nature has been limited in other species but 
preliminary studies have shown that in humans, pigs and sheep, EPF is 
present in serum within 24 to 48 hours of a fertile mating (Morton,
1985). EPF production has also been shown to be dependent on the presence 
of a viable conceptus.
In sheep, it has been shown that embryonic death is preceded by a decline 
in EPF activity. Abortion leads to a decline in activity with no EPF 
activity detectable within 8 to 24 hours (Morton et al., 1979). Similar 
results have been obtained in humans and pigs (Morton, 1985).
In 1981, Nancarrow et al. found that EPF in cows could be detected 3 to 
4 dys after artificial insemination. The use of EPF as a bovine pregnancy 
test has been problematic although the testing sensitivity has been
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improved by adoptive transfer of contact sensitivity (ATCS) (Klima, 1985). 
In 1987, Klima et al. described a pregnancy specific serum component 
identified by crossed immunoelectrophoresis using rabbit antiserum 
produced against bovine early pregnancy serum and intensively absorbed 
with non-pregnancy serum. The early pregnancy-associated protein could be 
identified within 8 days of artificial insemination and was also shown to 
behave like EPF in sheep (Noonan et al. , 1979) in suppressing the 
delayed cutaneous hypersensitivity in mice (Klima et al., 1987). It
appears that the new protein described by Klima is very closely related to
EPF.
During human pregnancy, levels of EPF activity have been reported to be 
very high during early pregnancy and then to decrease with continuing 
gestation, finally disappearing from the maternal blood 8 weeks before 
delivery (Zhihai and Zhen-Qun, 1987).
Despite these findings, the inability of some laboratories to detect EPF
reliably in pregnant sera has made EPF a controversial topic (Cooper and
Aitzen, 1981),
From the EPF studies reported thus far, it is clear that EPF in serum
provides the earliest indication that fertilization has taken place. The
following is a brief account of the production of EPF, as this may have 
considerable bearing on the further development of the research outlined 
later.
Prior to implantation, the fertilized egg is unable to produce EPF until 
it reaches the blastocyst stage. Before this, EPF is produced from
maternal tissue as two components, EPF-A and EPF-B.
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MATERNAL TISSUE 
[OVIDUCT] [OVARY]
INACTIVE EPF-A 
(Pre-fertilisation)
V
EPF-B
ACTIVE EPF-A
BINDS TO.LYMPHOCYTES
SIGNAL FROM 
PITUITARY
SIGNAL FROM FERTILISED EGG 
(Ovum Factor)
RELEASE OF SUPPRESSOR SUBSTANCES
Fig.2.5 EPF secretion and activation.
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EPF-A produced by the maternal oviduct is not pregnancy dependent and is 
produced prior to fertilisation. EPF-A is the component of EPF which 
binds to lymphocytes but it will only do so after activation by EPF-B. 
The activation process is poorly understood but once activated it binds to 
lymphocytes either on its own or in combination with EPF-B (Smart et al., 
1981),
EPF-B is the pregnancy dependent component of EPF and is produced by the 
ovary in response to a signal from a fertilized egg. This signal, called 
ovum factor, is produced by the ovum on penetration of a fertilizing 
spermatozoon and production continues until at least biastulation. Thus 
far, it has been found that ovum factor is produced from human ova 
(Cavanagh, unpublished data), pig and sheep ova (Morton, unpublished) and 
mouse ova. Furthermore, the activity of the substance has been found not 
to be species specific; ovum factor from cultured human or pig embryos 
acts in the mouse similarly to mouse ovum factor (Cavanagh et al., 1982).
In addition, there is evidence that in the mouse the release of EPF-B by 
ovum factor is dependent on the presence of prolactin (Morton et al., 
1982; Cavanagh et al. , 1982), This has yet to be demonstrated in other 
species.
After implantation, foetal tissue replaces maternal tissue as a source of 
EPF. The cross-over point is not detectable in the species studied with 
the exception of the pig where biphasic production is clear (Morton 
et al., 1983).
All of the work quoted thus far has involved the use of the RIT in EPF 
detection. The RIT is, however, a non-quantitative assay, the value of 
the rosette inhibition titre is more a reflection of the quality of EPF 
rather than the quantity.
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In conclusion, the capacity of EPF to enhance the activity of ALS in 
inhibiting rosette formation has resulted in the factor being classified 
as immunosuppressive. The pre and post implantation reactions involving 
EPF form a cascade initiated by the conceptus leading to the immuno­
suppression of the maternal immune system; thus it appears that the 
conceptus ensures its own defence against immunological rejection.
d) Alpha Foeto-Protein (AFP)
Alpha foeto-protein is a glycoprotein synthesized in the yolk sac and 
foetal liver and present in high concentrations in the blood and amnio tic 
fluid of the foetus. Concentrations of AFP increase in relation to the 
size of the foeto-placental unit.
AFP is a well documented inhibitor of cellular and humoral immunity 
(Tomasi, 1978). Research to date indicates that AFP acts by preventing the 
cell surface expression of la antigens (Lu et al., 1984) and/or the 
generation of suppressor cells (Murgita et al., 1981),
Initially, Murgita and Tomasi (1975) reported that AFP isolated from 
murine amniotic fluid inhibited mitogen induced and mixed lymphocyte 
proliferation as well as primary and secondary humoral antibody responses. 
In 1977, Murgita et al. reported that AFP suppresses antibody production 
in vitro in mouse spleen cells by activation of a suppressor cell 
population. Yachin and Lester (1979) speculated that human AFP acts to 
inhibit mitogen stimulated human lymphocyte cultures through a similar 
mechanism. In 1985, Hoskin et al. demonstrated that AFP induces the 
generation of one population of non-T suppressor cells.
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Finally, it has been observed that AFP, which is present at high 
concentrations in the placenta, down-regulates class II MHC expression on 
macrophages and dendritic cell lines, both at the cell surface (Lu et al.,
1984) and at the messenger RNA level (Craimie et al. , unpublished). It 
is thought that such cells which lack the surface expression of class II 
MHC molecules may prepare the antigen specifically for suppressor cells 
(Streilin and Wegmann, 1987).
e) Placental Protein 15 (PP15)
Very little has been published on this particular placental protein. Bohn 
e t al. (1980) isolated PP15 from human term placentae and found that it 
had a significant inhibitory effect on the mixed lymphocyte reaction 
(Bohn et al., 1980),
f) Placental Protein 14 (PP14)
PP14 is a glycoprotein with a molecular weight of 42,000 to 43,000 daltons 
containing 17.5% carbohydrate. The isoelectric point of PP14 is 4.6 and 
it has an electrophoretic mobility between the alpha-1 and alpha-2 
globulins (Bohn et al. , 1982). A number of independent groups have 
described proteins which are immunologically similar to PP14 some of which 
may be identical.
PP14 was first isolated from human term placenta (Bohn et al., 1982). 
Since then, the development of a radioimmunoassay for PP14 (Bolton et al.,
1983) has revealed that PP14 is not placenta specific and the culture of 
endometrial and decidual tissues has shown that these tissues secrete 
PP14 (Julkunen etal., 1986c).
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During pregnancy, PP14 levels rise rapidly, particularly in the deciduum 
where a 100 fold increase has been measured during the first 10-12 weeks 
of gestation. After this period, PP14 levels decrease throughout 
gestation (Julkunen et al. , 1985b). In non-pregnant women, circulatory 
levels of PP14 show a cyclic variation (Julkunen et al., 1986b), and 
it is probable that the synthesis and/or release of PP14 is controlled by 
progesterone.
The localisation and pattern of secretion of PP14 suggests a possible 
local immunosuppressive activity. PP14 has been shown to suppress both 
the allogeneic and mitogenic stimulation of peripheral blood lymphocytes 
(Bolton et al. , 1986; Pockley et al. , 1987), It has been demonstrated 
that the immunosuppressive activity of decidual tissue extracts is closely 
related to the PP14 content as measured by radioimmunoassay (Bolton 
et al. , 1986). Furthermore, it was found that when the decidual
extracts were iramunoadsorbed with a monoclonal anti-PP14, there was a 
significant decrease in immunosuppression as measured by the allogeneic 
mixed lymphocyte reaction. This effect was also observed using purified 
PP14 and seminal plasma (Bolton et al., 1987).
More recent work has focussed on the action of PP14 on the production/ 
action of lymphokines from mitogenically stimulated lymphocytes (Pockley 
and Bolton, unpublished). It was found that the immunosuppressive 
activity of decidual extracts and purified PP14 was partially reversed by 
the addition of both recombinent-IL-2 and culture supernatant from 
allogeneically stimulated lymphocytes, Pockley and Bolton suggest that 
PP14 may exert its suppressive activity at the IL-2 level of the immune 
response.
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Work on PP14 to date suggests that PP14 may be an important local immuno­
suppressant in the human reproductive process, being present in seminal 
plasma, uterine luminal fluid, cervical mucous and decidual tissue. The 
levels of PP14 in all of these tissues/fluids are high enough to mediate 
such an immunoregulatory role,
2.7.6.2 Endometrial/Decidual Immunoregulatory Activity
During normal pregnancy in mice and humans, suppressor cells accumulate at 
the implantation site in the uterine decidua (Clark et al., 1986a). These 
cells have been shown to suppress the ability of maternal T cells to 
proliferate in response to concanavalin A. In the mouse, these cells are 
predominently small granule containing non-T lymphocytes from which a 
soluble factor can be obtained which blocks the action of IL-2 
(Clark et al. , 1985). In addition, these cells appear to be trophoblast 
dependent. A similar population of cells appears to be present in the human 
(Clark et al. , 1986e; Clark et al., 1987). A second population of large 
sized, probably hormone dependent cells have been isolated from the 
endometrium taken during normal menstrual cycles. The suppressive 
activity associated with this cell is reported to occur only in the luteal 
phase with maximal activity occurring at the time when implantation would 
normally take place. These cells prevent the generation of cytotoxic T 
lymphocytes (CTL's) from precursors (pCTL), but do not affect antibody 
responses. As these larger cells appear during the luteal phase of the 
menstrual cycle, they appear before the smaller granular suppressor cells 
during pregnancy. Consequently, local active suppression is described as 
being bimodal and accomplished by two populations of suppressors, phase A 
cells (hormone dependent) and phase B cells (trophoblast dependent) (Clark 
et al., 1986).
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Analogous research in species with epitheliochorial placentation has been 
limited. In the horse, techniques have been developed to isolate the 
population of cells that accumulate around the endometrial cups (Kydd and 
Allen, 1986 and personal communication). Investigations into the 
functional activities of the lymphocytes has shown that cells recovered 
between days 55 and 70 of gestation fail to proliferate in response to 
Con.A. The same cells have also been shown to abrogate the normal 
mitogenic response of peripheral blood lymphocytes from the donor of the 
cup lymphocytes and also the same response of lymphocytes from unrelated 
horses (Kydd and Allen, 1986; Allen et al., 1987). It thus appears that 
at least one population of cells attracted to the endometrial cups have 
suppressor rather than cytotoxic activity.
Studies of murine xenogeneic pregnancy failure (Mus caroli transferred 
to the Mus Musculus uterus) have shown that the activity of the 
decidua associated suppressor cells is deficient whereas suppressor cell 
activity was evident in a normal Mus caroli pregnancy (Clark et al.,
1984). Similarly, it is suggested that in the donkey-in-horse model of 
pregnancy failure, the lack of endometrial cups may result in a lack of 
suppressor cell activity (Allen et al., 1987). The deficiency in both 
models of xenogeneic pregnancy failure has been related to a failure of 
trophoblast to recruit suppressor cells (Clark et al., 1984; Allen et^  
al. , 1987). This results in cytotoxic cell activation and infiltration 
into the embryo and subsequent susceptibility to anti-paternal 
transplantation immunity (Clark et al., 1986b).
A number of cell types with suppressor activity have been isolated from
human and murine decidua. Human decidual cells (Parhar and Lala, 1986)
and murine macrophages from the decidua (Tawfik et al., 1986) appear to
suppress T cell reactivity by the release of prostaglandin E£ (PGE2)
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which inhibits the production of IL-2 (Parhar and Lala, 1986). In 1986
(b), Clark et al. investigated the soluble suppressor activity released 
by decidual tissue in vitro. Activity was only obtained from non-T cells 
of pregnancy-associated decidua and not from hormone-stimulated 
endometrium or deciduoma cells. Clark et al. (1986c) found that
indomethacin did not block production of suppressive supernatants showing 
that prostaglandin is not the mediator of suppression. HPLC studies of 
human decidual supernatant revealed peak immunosuppressive activity at two 
molecular weights, namely 43,000 and 21,000 daltons with a smaller peak of
activity at 60,000 daltons (Daya e^ t al. , 1986). Clark e t al.
(unpublished) found suppressive activities in murine decidual supernatant 
with similar molecular weights. Indeed, PP-14 is similar in molecular 
weight to one decidual supernatant factor (43,000) and it also exhibits 
similar immunosuppressive activity (Bolton et al., 1986; Clark et al., 
1987). The decidua derived inhibitor is not T cell dependent, is selective 
for IL-2 dependent cells and does not appear to be a ganglioside since the 
latter blocks the binding of IL-2 to its receptor whereas decidual derived 
inhibitor does not (Daya et al., 1986). The decidual inhibitor factor 
appears to inhibit the capping of IL-2 receptors but whether this explains 
the inhibition of T cell proliferation is unknown.
Other types of suppressive factor have been described. In 1983, Badet et 
al. obtained a 60,000 dalton factor from the decidua of syngeneically 
mated C3H mice and also from deciduomas in the absence of trophoblast. 
Hardt e t al. (1981) identified a 50,000 dalton T cell-derived factor in 
the serum of mice which blocked the response to IL-2. To date, no data 
are available regarding the existence of similar factors in the horse.
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The decidua associated anti IL-2 activity in the human and mouse has 
provided some insight into the mechanism of spontaneous abortion. 
Administration of a highly potent rat anti-mouse IL-2 receptor antibody to 
the xenogeneic pregnancy Mus caroli in Mus musculus was found to block 
totally the maternal mononuclear infiltration of Mus caroli foetuses 
resulting in the birth of large foetuses with apparently healthy placentae 
(Croy et al. , 1987). This provides evidence that maternal killer cell 
infiltration of the foetus occurs due to a lack of IL-2 blocking and that 
maternal killer T cells accelerate embryo destruction. It is unknown at 
present whether a similar anti-IL-2 activity is associated with 
endometrial/placental tissue of species with epitheliochorial 
placentation.
Recent studies of spontaneous abortion suggest that a deficiency of local 
suppression in the decidua will lead to an increased susceptibility to 
para-immune effector cell systems in the uterus. This is reflected in the 
immunosuppressive properties found in murine pregnancy decidua 
supernatants. Jadus et al. (1986) reported the inhibition of IL-3 action 
preventing natural killer (NK) cell activation. Similarly, Clark et al. 
(1987) have observed an inhibition of macrophage activation to toxicity by 
lipo-polysaccharide (LPS) and interferon.
Finally, it is possible that suppressor cells may secrete growth factors 
as described in the immunostimulation hypothesis. The basis of the 
hypothesis is that maternal immune recognition of foetally derived cell 
surface antigens results in the secretion of factors that promote the 
growth of placental tissue, which in turn provides a fortified barrier to 
external damage from maternal immunity or microbes. Athanassakis et al. 
(1987) found that certain T cell lymphokines were capable of stimulating
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placental growth and activation of foetally derived cells in vitro. It 
was found that the entire proliferative effect could be ascribed to 
lymphokines of the CSF family namely CSF-GM, CSF-1 and IL-3. IL-2 and 
B cell derived growth factor (BCDF) had no effect either alone or in 
conjunction with CSF-GM. Furthermore, the proliferating cells were found 
to be of the macrophage lineage (Guilbert, 1985). Anti-T cell antibody 
has been found to reduce trophoblast cell mass in vivo providing the 
specificity was anti-Lyt 2 and/or anti-Thy 1 (Athanassakis et al., 1987) 
It has been shown that decidua derived supernatants that contain 
suppressor activity can also stimulate placental cell growth in vitro 
(Athanassakis and Wegmann, 1986). Clark et al. (1987) suggest that the 
failure of xenogeneic trophoblast to recruit suppressor cells could also 
mean failure to recruit non-T cells that elaborate growth factors and this 
would lead to defective placental development and embryo death.
2.7.6.3 Placental Immunoregulatory Factors
Four placental Immunoregulatory factors have been described in the 
literature and partially characterised. In 1977, Chaouat et al . reported 
that multiparity results in the emergence of suppressor T cells able to 
transfer hypo-responsiveness to a paternal stain allograft and to block 
maternal anti-paternal MLR and cell-mediated lympholysis (CML). The 
induction of these cells appeared to depend upon the activity of placental 
molecules and subsequently the term ’Suppressor Inducer Factor1 (SIF) was 
introduced to describe the active moiety in the placental extracts or 
supernatants (Chaouat, 1987). This factor has been shown to induce 
suppressor cells of the GVH reaction (Chaouat and Chaffaux, 1984).
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In 1984, Chaouat and Kolb reported that placental supernatants contain a 
product able specifically to block an MLR and CML, The supernatant can 
also enhance the survival of a murine foetal heart allograft (Chaouat, 
1987). This factor has been termed the 'Afferent Suppressor Factor' 
(ASF).
Finally, placental resistance to NK and CTL-mediated lysis has been 
investigated. The anti-lytic property has been related to the production 
of CTL and NK inhibiting factors termed CTL-IF and NK-IF. The factors are 
different molecular entities as shown in Table 2.4.
Despite the above findings, there are problems in the interpretation of 
the data. Firstly, there is no real proof of their trophoblastic origin, 
i.e. a small percentage of decidual cells may be the producers. Decidual 
factors are different molecular entities but have the same properties 
(Clark and Chaouat, unpublished). Secondly, apart from some evidence for 
low NK activity in the peripheral blood of pregnant women, there is no 
conclusive evidence for any in vivo role during pregnancy (Chaouat, 1987). 
Thirdly, there is an intrinsic capacity of trophoblast populations to 
resist lysis and in some cases no CTL and NK-IF is detectable.
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TABLE 2.4
Biochemistry of placental factors
Factor Mol.Wt
(xlOOO)
Pi L. Lectin 
bind.
Tryps/Neuram
Sens.
IgG bd
ASF 30-40 4.5-5 Yes(EL +) + - +
SIF 40-60 7 No + ? +
CTL-IF 50-60 4.5-5 Yes(EL +) + + ?
NK-IF 50-60 5.5-5 No + - ?
L, Lectin Bind., binding (and subsequent elution with alpha-methyl 
mannoside) to lentil lectin-coated Sepharose 4b; Tryps/Neuram.Sens: 
sensitivity (loss of activity) upon treatment with trypsin and 
neuraminidase; IgG bd, Binding to, and elution from (at acidic pH) 
mouse IgG-coated Sepharose 4b column (Chaouat, 1987),
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CHAPTER -3-
PREGNANCY ASSOCIATED/SPECIFIC PROTEINS IN THE HORSE AND THEIR 
INTERACTION WITH THE ENDOCRINE SYSTEM
3.1 Introduction
Research into pregnancy associated proteins and hormones in the horse has 
been limited in comparisonto that into human pregnancy. The major focus 
of this chapter and of the research findings presented later in this 
thesis is on early equine pregnancy. In order to facilitate an 
understanding of the biological events that occur during early equine 
pregnancy, ’time-scale' figures (Figs.3.1, 3.2) have been drawn which 
summarize the events relevent to the content of this thesis.
3.2 The Establishment of Equine Pregnancy
During early equine pregnancy, stable placentation is not established 
until approximately thirty-seven days after ovulation compared to five to 
eight days in the human (Allen et al., 1973). The consequence of this is 
that throughout this period the conceptus is entirely dependent on uterine 
secretions for nourishment and protection. Indeed all animals with 
epitheliochorial placentation rely upon uterine secretions for development 
of the conceptus to a greater extent than do those animals with a 
haemochorial placenta. Many proteins are found in uterine secretions and 
these have been shown to serve as enzymes, carrier molecules for hormones, 
vitamins and minerals (Bazer et al., 1978), in fact these secretions have 
been likened to a complex embryo culture medium.
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One area of equine reproduction receiving much attention in recent years 
is the study of the maternal recognition of pregnancy, those signals that 
inform the mare of the presence of an embryo, and the subsequent 
biological changes that occur. Knowledge of the way in which the embryo 
signals its presence could be of great benefit to the animal breeding 
industry in a variety of ways, the most obvious being the ability to 
diagnose pregnancy early, 14 to 16 days after ovulation. Furthermore, 
such information may clarify why a mare sometimes fails to recognize a 
viableembryo and also why pseudopregnancy occurs. As a consequence of 
this, much work has been done on the uterine fluid environment during the 
oestrous cycle and early pregnancy. It has been found that uterine 
secretory function progressively increases after ovulation and then 
decreases sharply after corpus luteum regression in non-pregnant mares 
(Zavy et al., 1978). It appears that the secretion of protein in the 
uterine lumen results primarily from the influence of progesterone, 
progesterone production and the protein content of the uterine lumen both 
increase markedly after ovulation and both decrease after luteolysis 
(Sharp, 1980). The increase in uterine protein content reflects uterine 
specific and non-uterine specific proteins which together produce an 
environment condusive to embryo survival and development. The overall 
message from such studies appears to be that the uterus secretes whatever 
components are necessary for the establishment of pregnancy every oestrous 
cycle and removes such secretory products if pregnancy does not occur. In 
the event of pregnancy, the corpus luteum is maintained (luteostasis) as 
are the protein components critical for embryo survival. The mechanism by 
which uterine secretory products are removed when pregnancy does not occur 
is uncertain. Uterine secretory activity is reported to decrease as 
progesterone decreases and thus the process appears to be progesterone 
dependent. Bazer and Thatcher (1977) proposed that uterine secretory
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components exit the uterus by way of the venous drainage (endocrine 
secretion) at the time of luteolysis in the non-pregnant gilt but are 
maintained intraluminally (exocrine secretion) as part of the 
establishment of pregnancy. There is some evidence that this occurs in 
the mare based on a report by Douglas and Ginther (1976) who found that 
uterine venous plasma prostaglandin F2 alpha (PGF) was reduced in pregnant 
pony mares compared with non-pregnant mares on day 14. PGF has been shown 
to have luteolytic properties (Section 3.4).
One interesting feature of the maternal recognition of pregnancy is the 
dual role of progesterone. Clearly, if a pregnancy is to be established 
and continue successfully, the corpus luteum must continue to secrete 
progesterone, but the irony is that progesterone also prepares the uterus 
for its role in luteolysis.
3.3 Equine Uteroferrin (acid phosphatase)
In 1972 , Murray et al. demonstrated the presence of a bisic glycoprotein 
with a purple coloration in porcine uterine secretions. Since then, the 
protein has become known as uteroferrin. In 1974, Schlosnagle et al. 
showed that uteroferrin had acid phosphatase activity and contained iron. 
Although uteroferrin has acid phosphatase activity, its main role is 
believed to be concerned with iron transport from mother to conceptus 
(Roberts and Bazer, 1980). Uteroferrin is in fact, one member of what may 
be a broad class of iron-containing phosphatases with unusual spectral 
properties which result from a novel type of di-iron active site (See 
Roberts and Bazer, 1984). As both the horse and pig have the same type of 
diffuse epitheliochorial placentation, it was suggested that both species 
may possess similar maternal-embryonic transfer systems for support of the 
conceptus.
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In 1979, Zavy e t al. chromatographed equine uterine luminal proteins 
and revealed 5 major fractions of approximate molecular weight 7,275,000 
(I); 275,000 (II); 170,000 (III), 56,000 (IV) and 15,000 (V). It was 
found that peaks I, IV and V, when expressed as a percentage of the total 
protein, were significantly affected by day of the oestrous cycle whereas 
peaks II and III were not. Acid phospatase activity was found in 
fractions III and IV and was also significantly affected by day of the 
oestrous cycle. The enzyme had maximum activity in the late luteal phase 
which declined after luteolysis. In 1982, Zavy et al. further analysed 
the protein milieu of cyclic pony mares by two-dimensional polyacrylamide 
gel electrophoresis and found that a number of unique proteins, apparently 
of non-serum origin, appeared by the mid-luteal phase but disappeared by 
day 20 of the oestrous cycle. Furthermore, these proteins were maintained 
until at least day 20 of pregnancy. One of these pregnancy-associated 
proteins had a low molecular weight of 35,000 and was basic with an 
isoelectric point of 9.7. Characterisation of this polypeptide revealed 
that its properties were very similar to those of the porcine 
glycoprotein, uteroferrin, it had similar molecular weight, identical 
co-migration in two-dimensional electrophoresis systems (Zavy et al., 
1982) and a similar Km (Michaelis-Menton constant) for acid phosphatase 
activity (McDowell et al., 1982). The proteins also cross-react immuno- 
logically and appear to be induced by progesterone (Zavy et al., 1978; 
Zavy et al. , 1982). The equine uterine luminal protein in question has 
thus been called equine uteroferrin and it is believed to have the same 
physiological role as porcine uteroferrin, iron transport across the 
placenta to the developing embryo. The acid phosphatase enzymic activity 
of uteroferrin is easily monitored and has subsequently been used as an 
indicator of proteins synthesized and secreted by the progestational 
uterus. Equine uteroferrin has been found to increase in uterine
flushings during the luteal phase of the oestrous cycle, reaching a peak 
on day 14 in ponies and day 16 to 18 in horses (Sharp, 1980). After this 
pivotal stage in non-pregnant mares, uteroferrin decreases until acid 
phosphatase activity is no longer detected at day 20. In pregnant mares, 
however, the acid phosphatase activity of uteroferrin continues to 
increase until at least day 20, (Sharp, 1980). Experiments using explants 
of porcine endometrium have shown that porcine uteroferrin is synthesized 
by endometrial tissue (Basha et al., 1978). It was further reported that 
porcine uteroferrin was synthesized maximally in mid-pregnancy around day 
60 [of a 115 day gestation] in the pig. Porcine uteroferrin production 
from late pregnancy endometrium (day 105) was, however, very low. The 
secretion of equine uteroferrin throughout gestation is thought to mirror 
the secretion pattern of porcine uteroferrin although this awaits 
clarification.
In 1987, McDowell et al. investigated the effects of progesterone and 
oestradiol on the secretion of equine uterine proteins. Exogenous 
progesterone was found to increase the total protein content of uterine 
secretions and also to increase the secretion of uterine specific 
proteins, as monitored by uteroferrin. Endometrial explants were used in 
this work suggesting that equine endometrial tissue secretes uteroferrin. 
In addition, it was demonstrated that oestrogen acts synergistically with 
progesterone to increase both total protein and uteroferrin in uterine 
secretions of mares.
3.4 Conceptus Secretory Products with Particular Reference to a Potential 
Antiluteolysin
Conceptuses produce a number of factors which may play a vital role in the 
establishment and maintenance of pregnancy, e.g steroids, prostaglandins 
and proteins. The continued secretion of progesterone is clearly
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important in this context and thus its source of production, the corpus 
luteum, must be protected from any luteolytic activity. It has been noted 
that progesterone is particularly important in the induction of 
endometrial development and the secretion of endometrial histotroph 
(uterine secretion/milk) which appears essential in the nourishment of 
conceptuses having epitheliochorial fusion-type implantation (Schlafke and 
Enders, 1975).
The regression of corpus luteum function and the decrease in progesterone 
secretion have been related to an increase in uterine prostaglandin 
F2alpha (PGF) synthesis and/or secretion (Zavy et al., 1978; Vernon et 
al. , 1981), increased uterine venous PGF (Douglas and Ginther, 1976) and 
increased 15-keto-13,14-dihydro-PGF2alpha otherwise known as prostaglandin 
F2alpha metabolite (PGFM) (Neely et al., 1979). Furthermore, it seems that 
the maternal recognition of pregnancy involves primarily a mechanism that 
prevents luteolysis by preventing PGF synthesis or secretion. Non­
pregnant mares during luteolysis (days 14 to 16) have been found to have 
higher concentrations of PGF in their uterine fluid and uterine venous 
plasma than did pregnant mares at the analogous stage of pregnancy.
In order to avert the luteolytic process, the embryo must be present 
during a critical period of the luteal phase. Hershman and Douglas (1979) 
demonstrated that flushing embryos from the uterus on day 14 resulted in a 
return to oestrous for the majority of mares, whereas flushing embryos 
from the uterus on day 16 resulted in corpus luteum maintenance. The 
requirement for the presence of the embryo coincides with the time of PGF 
secretion and expected luteolysis and it has been suggested that this time 
(day 14 to 16) should be referred to as the critical period for the 
maternal recognition of pregnancy. Further evidence for this was
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presented by Vernon et al. (1979) who found that the time of maximal PGF 
secretion coincides with the time of maximum PGF binding by luteal cell 
membrane receptors. It was also reported that the ability of corpora 
lutea from pregnant mares to bind PGF was equivalent to that of corpora 
lutea from non-pregnant mares in oestrous. This suggest that corpus 
luteum maintenance in pregnancy is better explained by reduced PGF 
secretion than by altered PGF receptor function.
In 1981, Vernon et al. observed the apparent paradox of increased in vitro 
PGF production from endometrium of pregnant mares. In physiological 
terms, however, this was not surprising as the endometrium had been 
optimally primed for PGF secretion by virtue of its long exposure to 
progesterone, Berglund et al. (1982) investigated this phenomenon further 
and found that the co-culture of pregnant endometrium with conceptus 
membranes reduced PGF production. This inhibitory effect of conceptus 
membranes suggests the possibility that embryonic factors may be 
inhibiting PGF synthesis and/or release. These findings were corroborated 
by Sharp and McDowell (1985) who also reported that Banamine was able to 
block increased PGF production from endometrium in vitro proving that 
increased PGF concentrations reflected synthesis and release of the 
prostaglandin.
The nature of the signal from conceptus to the uterine endometrium 
inhibiting prostaglandin F2alpha synthesis has not yet been elucidated. 
Zavy et al.(1979b) reported that the horse conceptus produces substantial 
amounts of oestrogens between days 8 and 20 pregnancy. Other workers have 
shown prolonged corpus luteum maintenance in mares treated with various 
oestrogens during dioestrus (Bery and Ginther, 1978). These findings are 
however controversial as others have found no such effects of oestrogen in 
mares. In 1983, Fazleabas and McDowell showed that day 12 to 14 equine
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conceptuses incubated in vitro secrete a unique array of at least five 
proteins ranging in molecular weight from about 50,000 to greater than 
400,000. Conceptus membranes incubated on day 15 or later, displayed 
entirely different pattern of proteins, and proteins of yolk sac origin 
such as transferrin and alpha-foetoprotein were dominant. In addition, 
after day 15 the chorioallantois produced an array of acidic proteins with 
the 2 dominant groups having estimated molecular weights of 28,000 and 
less than 15,000 and pis of about 6.4 and less than 4, respectively. Day 
14 conceptuses secreted either protein pattern or aspects of both, 
indicating that this particular day was the pivotal point As the critical 
period for the maternal recognition of pregnancy coincides with this 
pivotal day, it is suggested that the "early" proteins may be involved in 
the pregnancy recognition mechanisms (Sharp and McDowell, 1985).
In 1986, McDowell characterised proteins produced by cultured equine 
conceptuses and endometrium by 2 dimensional polyacrylamide gel 
electrophoresis (2-D PAGE) and fluorography of culture medium. Prior to 
day 14, there were two groups of isoelectric variants with molecular 
weights of 50,000 and 20,000 (approx.). After day 14, serum-like proteins 
were evident as reported by Fazleabas and McDowell (1983). Furthermore, 
it was found that the addition of high molecular weight conceptus 
secretory products (greater than 14,000) and low molecular weight 
secretory products (less than 14,000) decreased endometrial PGF 
production. In addition, endometrium from pregnant mares produced 
proteins similar to those produced by endometrium from diestrous mares. 
The maternal recognition of equine pregnancy has been suggested to be a 
process in which "the uterus is programmed to produce a given array of 
proteins that is not altered by the recognition and establishment of 
pregnancy. Rather, pregnancy permits the continued secretion of luteal
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progesterone by a process of luteo-stasis which, in turn, allows the 
secretion of uterine specific proteins in a pattern that is pre-ordained" 
(Sharp and McDowell, 1985).
3.4.1 Oxytocin and the Maternal Recognition of Pregnancy
Oxytocin has been shown to have a role in luteolysis in both the cow 
(Fields et al., 1983) and the sheep (Wathes and Swann, 1982). As early as 
1959, Arsmtrong and Hansel demonstrated that exogenous oxytocin could 
shorten the luteal phase of the oestrous cycle in the cow and that the 
luteolytic effect was mediated via the release of PGF. Very little work 
of this nature has been carried out in the mare.
In 1985, Betteridge et al. demonstrated that oxytocin stimulates the 
release of PGF around the time of luteolysis in the mare which suggests 
that oxytocin plays a role in luteolysis. It was suggested that the 
increasing response to oxytocin was due to the action of progesterone 
since progesterone priming of an ovariectomized mare for 14 days resulted 
in induction of responsiveness to oxytocin. It has recently been 
demonstrated, however, that the decline in the response to oxytocin seen 
after day 16 may not be due to the decrease in progesterone concentrations 
(Goff et al., 1987). It has been suggested that the increase in oestrogen 
concentration that occurs before ovulation may be involved in turning off 
the response to oxytocin, but this awaits clarification. Goff proposes 
that during the oestrous cycle decreasing progesterone and increasing 
oestradiol quickly inhibit the response to oxytocin. In the pregnant 
mare, it is thought that the release of PGF in response to oxytocin is 
reduced. Furthermore, Goff et al. (1987) found that in non-pregnant mares 
there was an increasing response to oxytocin between days 11 and 13 post­
ovulation but during pregnancy this increase was abolished. On this 
basis, Goff suggests that the maternal recognition of pregnancy occurs
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between days 11 and 13 and not between days 14 and 16 as suggested by 
Hershman and Douglas (1979). One theory regarding the mechanism involved, 
is that as increasing plasma oestrogen concentrations correspond to 
decreased responsiveness to oxytocin, then oestrogen produced by the 
embryo may maintain the corpus luteum in this fashion (Goff et al., 
1987).
3.5 Oestrogen and Early Equine Pregnancy
Oestrogen production from the equine conceptus rises during the period 
between days 12 and 20 after ovulation, but may begin as early as day 6 
(Paulo and Tischner, 1985). The possible luteostatic function of 
oestrogens has already been discussed but there are further features of 
these hormones worthy of mention in this context. Zavy et al. (1984) 
found that changes in concentration of oestrone and 17 beta-oestradiol 
occurring within the uterine environment were not discernable in plasma 
obtained from the peripheral circulation during this period. It was 
suggested that this may be due to the action of the sulfotransferase 
enzyme found in the endometrium. Mares have appreciable amounts of this 
enzyme between days 18 and 36 of pregnancy (Heap et al., 1982). Such an 
activation system could sulphate oestrogens before leaving the uterine 
environment so that they would appear in the peripheral circulation in 
their conjugated form. Perry et al. (1976) suggest that in the pig, 
oestrogens of conceptus origin are sulphated by the endometrium and 
transported to the ovary where it exerts luteostatic activity. It is 
possible that a similar mechanism exists in the horse. An increase in 
total oestrogens (conjugated plus unconjugated) has been shown to occur in 
the peripheral circulation of the mare by day 35 of pregnancy. Oestrone 
sulphate is one of these conjugated oestrogens, and its detection in mares 
is used as a pregnancy test (Parkes et al., 1977) [Section 3.11,1]. Both
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oestrone and oestradiol are produced by the conceptus membranes (Heap et 
al« , 1982; Zavy e t al. , 1984). Oestrone and oestradiol concentrations 
have been measured in the yolk sac during early pregnancy (Zavy et al.,
1984). Both oestrogens increased between days 12 and 14 of pregnancy 
which mirrors a similar increase seen in uterine fluid and conceptus 
membrane incubations (Zavy et al. , 1979), On days 12, 14 and 16, both 
oestrogens were comparable in concentration but by day 18, oestrone became 
predominant. A similar switch over also occurred in uterine fluid. Zavy 
suggests that oestradiol may be converted to oestrone and this may occur 
due to oestrogenic stimulation of the endometrium by the conceptus, 
resulting in increased 17-beta-hydroxysteroid dehydrogenase activity 
which catalyses the reaction. Such a mechanism does exist in the equine 
endometrium (Flood and Marrable, 1975). As oestrone sulphate increases 
during early equine pregnancy,it is suggested that the shift from 
oestradiol to oestrone may be the first step in preparation for the 
sulphation process.
In addition to having a potential role in the maternal recognition of 
pregnancy, hormones of conceptus origin may regulate secretion from the 
endometrium which have nutritional importance to the developing conceptus. 
This was illustrated by Zavy et al. (1982) who reported an increase in 
glucose, fructose, ascorbic acid and glucose phosphate isomerase activity 
within the uterine fluid of the mare during the early stages of pregnancy. 
Oestrogens secreted by the conceptus may be involved in regulating 
carbohydrate and amino acid flux from the maternal system into the uterine 
lumen and conceptus (Zavy et al., 1984). A mechanism such as this would 
assure nourishment of the conceptus during its 37 day pre-implantation 
period.
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3.6 The Synthesis and Biological Functions of Equine Chorionic
Gonadotrophin (eCG) 
eCG (formerly known as pregnant mare serum gonadotrophin) is pregnancy 
specific and found in the mares bloodstream during the first half of 
pregnancy (Allen, 1969b). More precisely, it is first detectable in serum 
between days 35 and 41 of gestation, rises to a maximum concentration at 
about day 60 and this is followed by a steady decrease in concentration to 
become undetectable between days 100 and 150 (Cole and Hart, 1930; Allen 
1969c).
eCG is produced by uterine structures, the endometrial cups. 
Endometrial cups were first described by Schauder (1912) and consist of a 
series of small ulcer-like, endometrial outgrowths in the pregnant horn of 
the uterus (Amoroso, 1952) forming in a circle around the developing 
foetal sac. The cups are initially present as small pale raised areas in 
the endometrium at day 38-40, then steadily grow for 30-40 days taking 
on their distinct saucer like shape due to continuing growth at the 
periphery and degeneration of the central regions of each structure. Allen 
(1970) has observed that after about day 80 they become increasingly pale 
and begin to release a sticky secretion which adheres to the surface of 
the overlying allantochorion. This exocrine phase-heralds the start of a 
steady degeneration which finally results in the necrotic cup tissue and 
admixed exocrine coagulum being sloughed from the surface of the 
endometrium between days 120 and 150. This sloughed material sits upon the 
surface of the foetal membranes where, as a consequence of gravity and 
other physical forces, it sinks towards the centre of the conceptus and 
so gives rise to the pedunculated chorioallantoic pouches described by 
Clegg et al. (1954).
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eCG is a major component of endometrial cup secretions. This unique 
glycoprotein (mol.wt 70,000) consists of two non-identical subunits and 
its carbohydrate component is large, relative to that of other 
glycoprotein hormones, as it approaches 45% by weight (Moore and Ward, 
1980). The molecule occurs in different forms depending on whether it is 
isolated from serum or from endometrial cups: the circulating form of the 
molecule appears to be larger, contain more carbohydrate and have 
different amino-terminal residues from that isolated from endometrial cups 
(Aggarwal et al. , 1980). In addition, a number of authors have reported 
that the biological activity of eCG in the mare is similar to that of 
luteinizing hormone (LH) (Squires and Ginther, 1975; Moore and Ward,
1980). In 1979, Licht et al. reported that in other mammals, eCG has both 
LH and follicle-stimulating hormone (FSH) activity. Removal of sialic acid 
from eCG caused an increase in LH activity (Manning et al., 1987).
Other equids, including donkey (Bell et al., 1967) and zebra (King, 1965), 
also secrete a gonadotrophin during early pregnancy. In 1980, Aggarwal 
et al. isolated donkey chorionic gonadotrophin (dCG) from the serum of 
pregnant donkeys using the same methodology as that used for the isolation 
of eCG. The levels of dCG in pregnant donkeys are lower than the levels 
of eCG in pregnant mare sera (Allen, 1975b). Chemically, dCG was found to 
be similar to eCG in fractionation behaviour and glycoprotein nature. The 
donkey hormone was found, however, to have significantly less carbohydrate 
(31%) than had eCG (45%) and several differences were found in a 
comparison of amino-acid compositions. Unlike eCG, which has a 
considerable amount of FSH-like activity, dCG was found to have primarily 
LH-like biological activity, similar to hCG (Louvet et al., 1976). Stewart 
et al. (1977) found that hybrid mule and hinny conceptuses produce eCG
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with an FSH:LH ratio approximately midway between those of the horse and 
donkey. It is a mixture of both eCG and dCG. Immunologically, dCG was 
found to significantly cross react in a homologous radioimmunoassay for 
eCG. '
All CG values referred to in the following sections were calculated using 
a common immunoassay of eCG’s regardless of the type of pregnancy under 
investigation.
3.7 The Endometrial Cup Reaction
The total lack of any direct physical connection between the cups and the 
overlying allantochorionic membrane initially led to the idea that the 
cups were maternal in origin representing some form of decidual response 
to the presence of the developing conceptus in the uterus (Clegg et al., 
1954; Allen, 1970).
In 1972, Allen and Moor established that specialised equine trophoblast 
cells recovered at a specific stage of gestation can produce large 
quantities of eCG in vitro. Only allantochorionic girdle cells were found 
to have this potential for eCG synthesis and these cells were found to 
exhibit the same distinctive morphological features characteristic of 
normal endometrial cup cells. Furthermore, Allen found that these 
trophoblastic cells secreted eCG over at least 180 days in vitro, whereas 
in vivo, eCG is secreted for only 80 days. The endometrial cups are 
therefore of foetal origin.
By day 36 after ovulation, the equine trophoblast is clearly divided into 
its invasive and non-invasive components. Where the enlarging allantoic 
and regressing yolk sac mambranes meet, a pale annulate band is formed 
that surrounds the conceptus (Allen, 1982). This chorionic girdle
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separates from the foetal membranes and invades the underlying maternal 
endometrium between days 36 and 38. Once in the endometrial stroma, the 
cells quickly lose their pseudopodia, enlarge and start secreting eCG, 
The cells remain clumped together to form the endometrial cups (Allen et 
al. , 1973). The cups can thus be described as highly specialized
gonadotrophin-secreting foetal trophoblast cells which retain no physical 
connection with the remainder of the conceptus.
Throughout the entire lifespan of the cells, increasing numbers of 
lymphocytes and to a lesser extent, plasma cells and eosinophils 
accumulate in the endometrial stroma around the cups. Lymphocytes begin 
to aggregate immediately after the cups begins to develop and aggregation 
increases during the next 60-80 days resulting in a band of cells which 
appear to wall off the cup tissue from the surrounding normal endometrium. 
The numbers of lymphocytes in those aggregates have been shown to vary 
considerably between individual animals and to be related to the size of 
the endometrial cups, i.e. fewer lymphocytes are attracted to larger, 
broader cups than to smaller, more isolated structures. When the cups 
begin to degenerate, around day 80-90, the lymphocytes begin to invade the 
cup tissue and destroy the large cup cells (Allen, 1982).
3.7.1 Endometrial Cup Development and Foetal Survival in Intra-, Inter- 
and Extraspecific Equine Pregnancies
Female equids have the unique capacity to carry to term a variety of 
inter- and extraspecific pregnancies that differ markedly in genotypic and 
phenotypic characteristics from the surrogate mother (Allen, 1982; Kydd 
e t al. , 1985; Summers et al. , 1987). The available data on 
endometrial cup development and foetal survival has recently been 
tabulated (Allen et al., 1987) and this is shown in Table 3.1.
73
Table 3.1
Endometrial cup development and fetal survival in intra-, inter- and extra­
specific equine pregnancies
Fetal
genotype
Mare
genotype
Fetakmaternal 
karyotype (2n = )
Endometrial cup 
development and 
lifespan*
Outcome of 
pregnancy
Intraspecific mating 
Horse 
Donkey 
Grant’s zebra
Horse 
Donkey 
Grant's zebra
64:64
62:62
46:46
4 - 4 - 4 -  L  
4- L 
4- L
Term
Term
Term
Interspecific mating 
Mule Horse 63:64 + S Term
Hinny Donkey 63:62 4* 4- 4- 4* L Term
Extraspecific embryo transfer 
Przewalski's 
horse Horse 66:64 4* 4* L Term
Horse Donkey 64:62 4- 4- 4- -1- L Term
Horse Mule 64:63 4 - 4 - 4 -  L Term
Donkcv Mule 62:63 4- L Term
Grant’s zebra Donkey 46:62 4- S Term
Grant’s zebra Horse 46:64 ±  VS Term
Donkey Horse 62:64 — 80% abort at
Day 80 05
’ Endometrial cups persist for: L = >60 days; S = 15-30 days; VS = <10 days.
(Allen et al. > 1987)
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A common feature of all successful intra-, inter- and extra-species 
pregnancies is invasion of foetal chorionic girdle cells into the 
endometrium at day 36 to 38, Endometrial cups exhibit two variables when 
the types of pregnancy are compared.
a) The amount of cup tissue that develops.
b) The lifespan of the cups:- this may reflect the intensity and success 
of the maternal leucocyte reaction in hastening the death of the cups 
(Allen et al., 1987).
It is evident from Table 3.1 that endometrial cup development and life span 
ranges from large and relatively long-lived cups in mares carrying horse 
conceptuses and donkeys carrying hinny and horse conceptuses to very small 
and transient cups in mares carrying zebra conceptuses. Allen et al. 
(1987) conclude that the paternal genome has a marked influence on the 
growth of the progenitor chorionic girdle and hence, on the amount of 
endometrial cup tissue that develops after invasion; regardless of changes 
in uterine environment resulting from embryo transfer, a much broader and 
more active chorionic girdle develops on the conceptus when a horse is the 
sire than when a donkey or Grant's zebra is the sire. It seems however 
that any conceptus that gives rise to any degree of endometrial cup 
development in the maternal uterus, has a chance-of implanting normally 
and proceeding normally to term.
3.7.2 The Immunological Implications of the Endometrial Cup Reaction 
Studies of the donkey-in-horse pregnancy as a model of foetal death has 
led to a greater understanding of the foeto-maternal immunological 
interactions in early gestation which protect the antigenically foreign 
foetus from potentially lethal maternal immune responses. It has been 
suggested that the invasion of chorionic girdle cells into the endometrium
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to form endometrial cups provides a vital and temporally important 
antigenic stimulus to the mother that results in her becoming tolerant of 
any foreign foetal antigens that may subsequently be expressed at the 
foeto-maternal interface (Allen et al., 1987).
Antczak et al. (1987) have developed monoclonal antibodies which can 
distinguish between the invasive and non-invasive trophoblast. In this 
study, it was found that the expression of antigens by the invasive 
trophoblast was gradually lost during the development of the chorionic 
girdle. The modulation of these molecules may be indicative of a 
functional role related to cell-cell interactions (Antczak e t al., 
1987). In total, it appears that both paternally-derived alloantigens and 
trophoblast-specific molecules (Section 2.7.6) are presented for maternal 
immune recognition by the development of the endometrial cups and also 
that both types of antigens are concerned in eliciting the humoral and 
cell-mediated responses observed (Allen et al., 1987).
3.8 Equine Chorionic Gonadotrophin: A Pregnancy Specific Immunosuppressive 
Hormone
Another way in which endometrial cup development might suppress the 
maternal response to antigens expressed by the trophoblast during 
placentation is by the action of the principal secretory product of the 
cups: eCG. It is possible that the presence of eCG at high concentrations 
on the invasive trophoblast and in circulation may give a high negative 
charge to both trophoblast cells and maternal lymphocytes resulting in 
mutual repulsion between them. Such a mechanism has been described for 
hCG (Kirby, 1968).
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Further support for this theory is the presence of the hormone at the time 
when the main foetal stimulus to the mother is greatest, i.e. during 
placentation it is secreted directly into the uterine lumen between the 
trophoblast and endometrial epithelium as an exocrine endometrial cup 
secretion.
eCG is also found in the lymphatic and blood circulation. Preliminary in 
vitro studies suggest that eCG may suppress lymphocyte proliferation in 
response to both the mitogen Con.A and the one way mixed lymphocyte 
reaction (Kydd and Allen - personal communication). It has been 
speculated, however, that this may be due to an immunosuppressive 
contaminant (cf EPF in human chorionic gonadotrophin preparations) (Rolfe 
et al. , 1983). This is an area awaiting further clarification. Evidence 
of an immunosuppressive role of eCG in vivo is, however, not clear cut as 
eCG administration to a mare carrying a donkey conceptus offered no 
protection for the conceptus.
It is thus proposed that eCG alters the immunological activity of maternal 
lymphocytes in the blood and its presence in the uterine lumen contributes 
to the fibrinoid layer which coats the trophoblast cells thus masking the 
foetal antigens from maternal recognition. Preliminary in vitro studies 
on eCG suggest that it may have an immunosuppressive effect, particularly 
as a local effect at the maternal-foetal interface.
3.9 The Immunoprotection of Equine Pregnancy after Endometrial Cup 
Degeneration
The endometrial cup reaction lasts for less than 100 days, i.e. the cups 
have degenerated and eCG has disappeared from the circulation by mid­
gestation, It is thought that other proteins take over the immuno- 
protective role of eCG during the second half of gestation. The most
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likely source of these factors is the placenta which produces very large 
quantities of both phenolic and ring-B unsaturated oestrogens from day 90 
onwards of gestation.
Progesterone has been shown to have immunomodulatory properties by both 
in vivo and in vitro techniques (Clemens et al, 1979; Stites and
Siiteri, 1983) and thus this may play a significant role in the later 
stages of equine pregnancy. Progesterone and its 5 alpha-pregnane 
derivatives are secreted by the equine placenta from day 90 onwards 
(Raeside & Liptrap, 1975; Pashen & Allen, 1979). It is thus proposed 
that the immunoprotection of the equine foetus in the latter stages of 
pregnancy may be due to the local production of large quantities of 
progestogens and oestrogens.
3.10 Mare Pregnancy Protein 1 (MPP-1): a Pregnancy Specific Protein 
MPP-1 was discovered by Gidley-Baird et al. in 1983. Allen (1979) had 
already shown by his work on luteal maintenance in the mare that by day 
16 after ovulation the conceptus has exerted its first influence on 
maternal utero-ovarian function and this provided the impetus for an 
investigation into whether other pregnancy specific proteins existed in 
the horse and if one or more was measurable during pregnancy before the 
appearance of eCG.
Using an anti-pregnant mare antiserum adsorbed with stallion serum, 
Gidley-Baird et al. (1983) demonstrated two precipitates in two-
dimensional crossed immunoelectrophoresis using serum from pregnant mares 
as the antigen. One of these precipitated in the beta-1 region andthe 
other in the alpha-2 region. By tandem-crossed immunoelectrophoresis, 
Gidley-Baird et al. (1983) showed identity between eCG and the alpha-2 
mobile protein. In addition, it was found that the antiserum completely
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inhibited the action of eCG in hypophysectomised mice. The beta-1 mobile 
protein was found in all of the pregnant mares tested and was detectable 
in the earliest samples taken at day 30. This protein designated mare 
pregnancy protein-1 (MPP-1) was not detected in stallions, geldings or 
non-pregnant mares and thus like eCG, may be pregnancy specific.
3.11 Pregnancy Testing in Mares
3.11.1 Serum Hormone Tests
a) Equine Chorionic Gonadotrophin (eCG)
eCG can be detected in the mare's blood by 42 days after conception. The 
use of eCG as a pregnancy test has hot, however, been 100% successful, 
and more thoroughbred mares show detectable levels of eCG than actually 
give birth. The reason for this is that once the chorionic girdle cells 
have invaded the uterine stroma to form endometrial cups at around day 38, 
subsequent loss of the pregnancy, by whatever means, does not alter the 
normal sequence of development and regression of the endometrial cups 
(Allen, 1969b). High concentrations of eCG will thus appear in the blood 
for many weeks resulting in a pseudopregnancy. The other disadvantage of 
measuring serum eCG as an indicator of pregnancy is its late appearance. 
Serum eCG levels are, however, routinely measured in order to offer 
assurance that the mare has conceived and reached the stage when the 
endometrial cups have formed and begun producing gonadotrophin.
b) Progesterone
After ovulation, the corpus luteum produces progesterone and serum levels 
increase to greater than 2 ng/ml in two to three days. In non-pregnant 
mares in oestrous, the progesterone level drops sharply to less than 1 
ng/ml when luteolysis occurs around day 16. In pregnant mares, the corpus 
luteum is maintained and levels remain elevated. Progesterone assays
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can be used to detect elevated levels of the hormone during pregnancy that 
is from 18 to 25 days after ovulation. A proportion of oestrous cycles, 
however, are followed by a persistent corpus luteum (Stabenfeldt et al., 
1974). Indeed, Allen et al. (1974) reported that during a breeding 
season, 93% of 362 non-pregnant, non-cycling thoroughbred mares had this 
condition. As a functional corpus luteum may keep serum progesterone levels 
high for up to 90 days a confirmatory pregnancy test is required.
The major information obtained from a progesterone assay is thus whether 
or not the corpus luteum has been maintained, which might be indicative of 
a pregnancy.
c) Oestrone Sulphate (ES)
Oestrone sulphate is a conjugated steroid hormone which, in pregnant 
animals, is secreted primarily by the conceptus membranes (Heap et al., 
1982; Zavy et al. , 1984; Kasman et al. , 1987) [Section 3.5]. Serum ES 
concentrations have been shown to increase within a few weeks post­
breeding in pregnant mares and to increase very sharply after 60 days to 
reach levels greater than 30,000 pg/ml at 80 days. Thereafter, these high 
levels were maintained throughout pregnancy (Sist et al., 1987). The mean 
ES serum concentrations in non-pregnant mares was approximately 750 pg/ml. 
Serum oestrone sulphate can thus be used as a reliable diagnosis of 
pregnancy and foetal viability from day 60 onwards. Concentrations of ES 
in milk can also be used for the diagnosis of pregnancy but the levels are 
lower than in serum and the test is only reliable after day 90 of 
gestation (Sist et al., 1987).
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3.11.2 Pregnancy Diagnosis by Manual Examination and Other Techniques 
Rectal palpation can be used to diagnose pregnancy, sometimes as early as 
day 19. A more reliable diagnosis by this technique, however, can be 
made at day 40 (Rossdale and Ricketts, 1974). In recent years, 
transrectal ultrasonography has made possible the detection of equine 
pregnancy by week two after ovulation with 98% accuracy (Chevalier and 
Palmer, 1982; Ginther, 1986; Woods et al., 1987).
3.12 Immunosuppression in Species with Epitheliochorial Placentation
Research to date into immunosuppressive mechanisms associated with the 
equine epitheliochorial placenta has been limited to a preliminary study 
on the cells which accumulate around the endometrial cups. As described 
in section 3.7.4, a population of cells with a suppressor function has 
indeed been identified (Kydd and Allen, 1986). Pregnancy associated 
immunosuppression has, however, been more widely investigated in other 
species exhibiting epitheliochorial placentation. A major motivation for 
such work has been due to the high rate of early embryonic mortality in 
domestic animals. In horses, early embryonic loss has recently been 
determined by ultrasound examinations of mated mares; it was found that 
25.7% of conceptuses observed on day 11 were lost by day 25 (Ginther,
1985). In pigs, approximately 30% of the eggs fertilised at breeding are 
lost due to embryonic mortality and a high proportion of these are lost 
during the first 25 days of pregnancy (Pomeroy, 1960). In cattle, there 
is an embryonic mortality rate of 40% (Thatcher et al., 1985). Clearly, if 
these animals could be immunologically manipulated in early pregnancy so 
that the pregnancy success rate could be improved, then the financial 
input into farming and stud-breeding could be considerably curtailed.
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This economic incentive has led to much research into the immunological 
maintenance of early bovine pregnancy. Bovine, ovine and porcine research 
in this area has generally been focussed on immunosuppression associated 
with uterine flushings in early pregnancy and with potentially immuno­
suppressive products of the conceptus in short term culture. In addition, 
preliminary work is in progress on uterine suppressor cells in the pig as 
well as in the horse (Croy et al., 1987).
3.12.1 Immunosuppression and Uterine Flushings
In 1977, Roberts demonstrated a dose-dependent inhibition of phyto- 
haemagglutinin (PHA) stimulated blastogenesis in uterine flushings from a 
day 18 pregnant cow, whereas uterine flushings from a day 16 unmated cow 
and a day 13 pregnant cow were not inhibitory. More recent studies, 
however, report an inhibition of PHA stimulated lymphocyte blastogenesis 
by uterine flushings from both pregnant and non-pregnant cows (Segerson 
et al«, 1984; Fisher et al. , 1985). Similarly, uterine flushings from 
pregnant and non-pregnant ewes inhibited PHA stimulated blastogenesis and 
the MLR in a dose-dependent manner (Segerson, 1981). An immunosuppressive 
activity of porcine uterine flushings (pregnant and pseudo-pregnant) has 
been attributed to two progesterone-induced acidic proteins known as
porcine acidic proteins (pAP) (Murray et al^ . , 1978; Allen et al. ,
1981; Knight e£ al,, 1973). Despite the above reports of
immunosuppressive activity in uterine flushings, Fisher et al. (1985) 
were unable to show immunosuppression in bovine uterine vein serum and plasma. 
This suggests that the immunosuppressive substance(s) in the uterine lumen 
does not enter the uterine vein or, if present there, is diluted 
so that it cannot be detected under assay conditions. Similarly, serum 
taken from pregnant sheep has been shown not to inhibit the MLR or
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PHA-stimulated blastogenesis (Miyasaka and McCullough, 1981; Segerson,
1981).
The report that the immunosuppressive porcine acidic proteins were induced 
by progesterone (Knight et al., 1973) led to speculation that the immuno­
suppressive activity in uterine flushings of other species may be 
associated with progesterone. Segerson (1981) found that the increase in 
ovine uterine flushing immunosuppression correlated with a rise in 
progesterone. Murray and Chenault (1982) demonstrated that progesterone 
itself is not immunosuppressive to bovine lymphoblastogenesis and 
consequently suggested that progesterone may influence immune function 
indirectly rather than directly by inducing the synthesis of immuno­
modulatory proteins or glycoproteins. In 1985, Sherblom e t al. 
investigated the relationship between serum progesterone and immuno­
suppression in cows. Serum samples were taken from progesterone-oestrogen 
treated ovariectomised cows and from control ovariectomised cows. The 
average progesterone level in treated animals rose from 1 ng/ml (day 0) to 
plateau at 5 ng/ml (days 12 to 36). Immunosuppression was observed in 
serum samples in which the circulating progesterone concentration was in 
the normal physiological range (4 to 6 ng/ml). Lymphocyte proliferation 
appeared to be a function of rising progesterone concentrations because as 
the progesterone level reached a plateau, immunosuppressive activity 
returned to control levels. Furthermore, a significant difference in the 
degree of immunosuppression between the treated and non-treated animals 
occurred when PHA was used as the mitogen but not when pokeweed mitogen 
was used. This phenomenon suggests that the observed immunosuppression 
was directed against T rather than B lymphocytes. In the same report, 
sialic acid and sialyl transferase activity was measured during bovine 
pregnancy and a close correlation was found with progesterone levels, i.e.
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all three factors reached peak levels at the same time (day 12). Immuno­
suppressive activity, however, was found to peak at day 8. Sherblom 
et al. (1985) suggest that progesterone may stimulate the synthesis of 
glycoproteins which are immunosuppressive and sialyl transferase may be a 
marker for a late phase in the process.
The identity of immunosuppressive substance(s) in sheep and cow uterine 
flushings has not been elucidated but available data indicates that they 
are >3,500 Mol.wt in the sheep (Segerson, 1981) and >1,000 Mol.wt in the 
cow (Fisher et al., 1985) determined by sample dialysis. Small molecules 
such as prostaglandin E and progesterone are thus eliminated as potential 
candidates for the immunosuppressive function. One possibility, however, 
is alpha-foetoprotein (68,000 Mol.wt). Roberts (1977) and Fisher et al. 
(1985) found that uterine flushings from pregnant cows inhibit lymphocyte 
stimulation in a manner similar to that reported for alpha-foetoprotein. 
In 1982, Butler et al. detected two 'pregnancy specific' proteins by 
immunoelectrophoresis using antisera developed to homogenates of bovine 
extraembryonic membranes. These proteins were present in extracts of 
bovine placental membrane from foetuses aged 25 to 270 days. One of the 
proteins had a similar molecular weight and isoelectric point to alpha- 
foetoprotein and also yielded a reaction of identity with bovine alpha- 
foetoprotein by immunodiffusion. The other protein, designated by Butler 
as 'protein B', has not been identified but appears to be pregnancy 
specific. Janzen et al. (1982) detected an alpha-foetoprotein in the 
bovine uterine lumen by RIA at days 14 to 22 of pregnancy. In 1984, 
Segerson et al. partially characterised uterine luminal secretions from 
pregnant and non-pregnant cows. Polyacrylamide gel electrophoresis (PAGE) 
and sodium dodecyl sulphate-PAGE revealed that bovine day 17 samples 
consisted of three uterine specific cathode migrating bands that were
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composed of several proteins/polypeptides, each with a molecular weight of 
less than 48,000. Segerson observed that the percentage composition of 
two of all three bands was greater in the pregnant than in the non­
pregnant state. In addition, there have been reports of pregnancy 
specific proteins in the cow. Laster (1977) reported a 50,000 to 60,000 
Mol.wt pregnancy-specific protein present by 15 days post-mating. Bartol 
et al. (1981) found four proteins present in uterine flushings by day 19 
of pregnancy but absent on day 19 of the oestrous cycle. Segerson et al.
(1984) conclude from these data that the greater immunosuppressive 
activity of uterine protein secretions for pregnant and for non-pregnant 
cows within day 17 uterine flushings may be due to a greater quantity of 
uterine specific protein(s), the appearance of pregnancy specific 
protein(s) or an activation, synergism etc. of these macromolecules. The 
suppressive factor(s) for non-pregnant cows is presumably of endometrial 
origin and of endometrial and(or) conceptus origin for pregnant cows.
3.12.2 Immunosuppression and Conceptus Products
In 1983, French and Northey demonstrated that media from cultured 18 day 
old bovine embryos inhibited PHA-induced incorporation of thymidine into 
bovine lymphocytes. They found that the substance had a molecular weight 
of between 500 and 10,000, it was only produced by_live cells, it was not 
toxic to lymphocytes, acts in a partially reversible manner and shows some 
species specificity. This work was further developed by Fisher et al.
(1985) indicating that the Mr was between 500 to 1,000. The embryo 
culture medium (ECM) decreased tritiated uridine incorporation by 
proliferating bovine lymphocytes suggesting that the ECM was inhibiting 
RNA synthesis. The effect on uridine incorporation was, however, less 
than the effect on tritiated thymidine incorporation indicating that RNA 
synthesis inhibition was secondary to decreased blastogenesis.
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Furthermore, ECM added 20 to 30 hours after PHA was as suppressive as if 
added at the time of addition of PHA. This latter phenomenon suggested 
that ECM was not simply interfering with the binding of PHA to the cell 
surface or binding to PHA itself, making it unavailable for interaction 
with the cell surface. A similar immunosuppressive mechanism may also 
exist in the sheep. Extracts of day 25 sheep conceptus membranes have been 
shown to inhibit mitogen-stimulated blastogenesis and the activity was 
reported to reside in the <10,000 molecular weight fraction (Staples et 
al,, 1983). In 1982, Masters et al. reported that preattachment ovine and 
porcine conceptuses in culture secrete a high molecular weight (>660,000) 
acidic glycoprotein (HMWGP) which is relatively resistent to proteolysis. 
In 1987, Murray et al. reported that HMWGP purified from incubation medium 
of preimplantation elongating ovine (day 16 and 17) and porcine (day 16) 
conceptuses was immunosuppressive. HMWGP inhibited tritiated thymidine 
incorporation into lymphocytes stimulated by PHA and also the two way MLR 
in a dose dependent manner. It is of interest that both the pig and sheep 
conceptuses secrete chemically-similar glycoproteins shown to be immuno­
suppressive. Murray et al. (unpublished) have also identified a similar 
glycoprotein in the incubation medium of day 17 bovine conceptuses which 
also has immunosuppressive activity. Murray et al. (1987) conclude that 
the secretion of a biochemically related glycoprotein may represent a 
common mechanism whereby the conceptuses of ungulates influence maternal 
immune reactivity within the uterus. In addition, mouse embryos and 
embryonal carcinoma appear to secrete similar HMWGP’s (Muramatsu et al., 
1979) to the one reported by Murray et al. (1987).
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3.13 Platelets and Pregnancy
The rational behind the input of platelet studies into this project is 
twofold. Firstly, it has recently been suggested that the maternal 
recognition of pregnancy in humans and laboratory animals is associated 
with a transitory thrombocytopenia. Secondly, a number of pregnancy 
associated proteins play a role in the inhibition of platelet aggregation, 
particularly during the later stages of pregnancy.
3.13.1 Platelets and the Maternal Recognition of Pregnancy 
The establishment of a successful pregnancy has been shown to be heavily 
dependent on a signal from the embryo which results in the prolonged 
maintenance of the corpus luteum. Changes in levels of pregnancy- 
associated proteins and hormones during this period are used to diagnose 
pregnancy. Prior to this, however, the embryo has been effecting changes 
in the maternal physiology for days. The earliest changes reported are a 
change in the properties of circulating maternal lymphocytes and a 
significant thrombocytopenia. The latter is defined as a significant 
reduction in the absolute numbers of platelets below the normal level. 
O'Neill (1985a) demonstrated that an early pregnancy-associated 
thrombocytopeniawas reported to occur as an initial maternal response to 
conception in humans and mice, both animals with haemochorial 
placentation. This thrombocytopenia occurs within 6 hours of 
fertilisation and is maintained for the first few weeks of pregnancy. 
Platelet numbers are reduced due to increased activation and consumption 
demonstrated by an enhanced platelet factor III activity during the 
thrombocytopenia period.
Platelet activation occurs only in the presence of a viable embryo and the
extent of the activation can be correlated with the number of embryos
present in the reproductive tract. The platelet activation is presumably
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caused by a soluble factor produced by the embryo, O ’Neill (1985a, b) 
further demonstrated that this thrombocytopenia was not an immunological 
reaction to antigenically alien embryos since syngeneic matings and 
transfer of parthenogenetically activated eggs produced the same result. 
The factor responsible for the thrombocytopenia has been partially 
purified and shown to have similar chemical, biochemical and physiological 
properties to the potent platelet activating factor l-0-alkyl-2-acetyl- 
sn-glyceryl-3-phosphocholine (O’Neill, 1985c). Consequently, it has been 
called 'embryo derived platelet activating factor’ (EDPAF).
O'Neill et al. (1985, 1987) looked at EDPAF and early pregnancy associated 
thrombocytopenia as a means of monitoring embryonic viability in women 
undergoing embryo transfer. Evidence was produced demonstrating that only 
those embryos producing EDPAF in vitro caused early pregnancy associated 
thrombocytopenia (EPAT) after embryo transfer and only patients displaying 
EPAT had a successful transfer. In addition, it has been shown in rodents 
that the inhibition of the activity of EDPAF by specific antagonists 
prevents implantation which further exemplifies the crucial role of this 
factor in the establishment of pregnancy (Spinks and O’Neill, 1987).
The only other very early embryonic signal so far described is an ’ovum 
factor' which induces the generation of early pregnancy factor (EPF) 
activity in maternal serum during the preimplantation stage of pregnancy 
(Morton et al., 1980; Cavanagh et al., 1982) (Section 2.7.6.1c). In 
1985(c), O'Neill noted circumstantial evidence for similarities between 
'ovum factor’ and EDPAF. One example of this is that the partial 
characterisation of ’ovum factor’ has shown it to be a low molecular 
weight molecule(s) with a strong tendency to associate with carrier 
proteins (Cavanagh et al., 1982) and in these physical characteristics, it 
is similar to PAF (Synder, 1985). Platelets play a central role in many
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immune responses and thus may have a role in modulating the maternal 
immune response in pregnancy. This modulatory role has been demonstrated 
in that the removal of maternal platelets with anti-platelet antisera 
results in an inhibition of implantation (Gasic and Gasic, 1970) and that 
factors released by platelets promote blastocyst outgrowth (O'Neill 
et al. , 1985). Cavanagh et al. (1982) demonstrated that the injection of 
oestrous mice with culture fluid from fertilised eggs resulted in EPF 
activity and that the factor responsible was the partly characterised 
'ovum factor'. In 1986, Orozco et al. found that when synthetic PAF was 
injected into mature female mice during dioestrus, proestrus or oestrus, 
it also induced the expression of EPF activity detectable in the sera of 
the animals within one hour of injection. Neither ovum factor nor PAF are 
active in the rosette inhibition test (RIT) but is believed that they act 
as a primary signal, inducing and interacting with secondary factors which 
act to generate the RIT-active EPF species from preexisting inactive 
precursors (Clarke and Wilson, 1985). The above studies indicate that the 
ovum factor responsible for the induction of EPF-activity in the 
periimplantation stage of pregnancy may be the same as the EDPAF which is 
responsible for the altered maternal platelet physiology at this time. 
There has been no research into EPAT in animals with epitheliochorial 
placentation. The detection of EPF activity in this species indicates, 
however, that a similar mechanism may exist.
3.13.2 Pregnancy and Platelet Aggregation
In the placenta, particularly the haemochorial, there is much pooling of 
blood in the placental blood sinuses and thus coagulation may be expected 
to occur. As the occurrence of widespread placental thrombosis is rare, 
it seems likely that the placenta protects itself by a platelet anti­
aggregatory mechanism. It is well known that the walls of many blood
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vessels contain prostacyclin which is a very potent platelet anti­
aggregatory agent and the structure of the placenta indicates that its 
platelet anti-aggregatory properties may be attributed to its 
vascularity.
In 1977, Myatt and Elder found that human placental extracts inhibited 
ADP-induced platelet aggregation. The inhibition was prostacyclin-like, 
as the inhibitor was labile at 37 °C and neutralised by the prostacyclin 
synthetase inhibitor, tranylcypromine. In 1982, however, Dembele-Duchesne 
et al. presented evidence that prostacyclin was not the active inhibitory 
agent in placental extracts when they failed to detect 6 keto- 
prostaglandin Fjalpha, the major stable metabolite of prostaglandin in 
either extracts or in the medium when placental microsomes were incubated 
with arachidonic acid. Hutton et al. (1980) added further weight to this 
claim when they reported that placental extracts specifically inhibited 
platelet aggregation induced by ADP, whereas umbilical artery-derived 
prostacyclin inhibited a number of proaggregatory agents. In addition, 
Hutton et al. (1980) found that the aggregatory activity of the ADP was 
removed after incubation of ADP with the placental extracts, i.e. the 
extracts were degrading the ADP. This degrading activity was found to be 
considerably higher in the placenta than in the myometrium, umbilical cord 
or foetal membranes. The effect of the extracts was mimicked by purified 
human placental alkaline phosphatase but the heat lability of the anti­
aggregatory activity suggested another enzyme. In 1987, O ’Brien et al. 
confirmed that human placental extracts are capable of inhibiting 
specifically ADP-induced platelet aggregation by approximately half. 
Furthermore, it was found that platelets fail to undergo complete 
aggregation but, in fact, disaggregate after an initial response. In this 
recent investigation, the ADP-ase activity of the placental extracts was
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shown not to be affected by pH whereas heat stable alkaline phosphatase 
has maximum activity at pH 9.0; this effectively eliminated the enzyme as 
a potential anti-aggregatory candidate. O ’Brien et al. (1987) also found 
that there was a deficiency of the inhibitor in some pregnancies with 
abrupt to placentae and intrauterine growth retardation. In 1984, Maki et 
al. described an anti-aggregatory placental protein with different 
properties to those reported above. The inhibitor was high in molecular 
weight (450,000) and inhibited platelet aggregation induced by ADP, 
collagen and adrenalin but not ristocetin. Furthermore, the inhibitor was 
stable at room temperature for 5 days and devoid of phosphatase activity. 
It appears from the above reports that unimpeded retroplacental blood flow 
may depend upon the local inhibition of platelet aggregation.
Platelet aggregation inhibitors and anti-coagulants work together in 
protecting the foetus from a hazardous thrombosis. Uszynski (1979) 
reported a placental dialysable peptide inhibitor of both thrombin and 
urokinase. In 1984, Maki et al. described a coagulation inhibitor which 
was not dialysable, having a molecular weight of 45,000 and had no anti- 
-urokinase activity. Recent work on human pregnancy associated proteins 
has revealed that at least 2 of them may have roles as anti-coagulants, 
namely PP5 [placental protein 5] (Soma et al., 1985) and PAPP-A [pregnancy 
associated plasma protein-A] (Bischof et al., 1982). Both of these 
proteins have an affinity for the heterogenous sulphated 
glycosaminoglycan heparin which is itself a potent anti-coagulant. This 
property has proved useful in the isolation and purification of the 
proteins. To date, there is no available data on the inhibition of equine 
and bovine platelet aggregation by placenta derived inhibitors and also on 
pregnancy associated anti-coagulants.
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CHAPTER -4-
MATERIALS AND METHODS
4.1 Samples
Blood serum samples were taken from equids throughout pregnancy by Dr W R 
Allen at the Equine Fertility Unit, 307 Huntington Road, Cambridge, The 
types of pregnancy were as follows:
(a) Normal Horse Pregnancy
(b) Transferred Horse Pregnancy
(c) Normal Donkey Pregnancy
(d) Transferred Donkey Pregnancy
(e) Hybrid Donkey-in-Horse Pregnancy
The transferred pregnancies were established by the surgical implantation 
of a fertilised egg (washed from the uterus of a donor mare) into the 
uterus of a recipient mare. Equine placental samples, taken during the 
course of various operations on horses at various stages of pregnancy, 
and uterine flushings were also obtained from the Equine Fertility Unit,
Blood serum samples from 13 performance horses before and after mating were 
obtained from RIA UK (Sunderland). Samples were taken from day 0 to day 
12 where day 1 referred to the day when the mare was sired by a stallion. 
Both successful and unsuccessful pregnancies were investigated blind, 
pregnancy being determined by an ultra-sonic scan at day 90.
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Equine and bovine term and aborted placental material was obtained 
from two sources:
Dr L Wood at the Ministry of Agriculture, Fisheries and Food, Central 
Veterinary Laboratory, New Haw, Weybridge, Surrey
Dr C J Green, Veterinary Surgery, 129a Newbold Lane, Broomhill, 
Sheffield.
Fresh horse blood for lymphocyte and platelet studies was obtained from 
two sources:
Dr P Dixon, Churchfield Veterinary Centre, 29 Sackville Street, Barnsley 
Dr C J Green, Veterinary Surgery, 129a Newbold Lane, Broomhill, 
Sheffield.
Fresh bovine blood for platelet studies was obtained from Woolley Brothers 
Abattoir, Mosborough, Sheffield, under the supervision of Mr P Hutchinson.
4.2 Protein assay
Protein was determined quantitatively using the method of Ohnishi and Barr 
(1978). This simplified method of protein determination combines the 
method of Lowry et al. (1951) with the Biuret method and results in a more 
stable colour complex. This enables many samples to be developed at the 
same time and enhances reproducibility. A further advantage of this 
method is that the reagent can be stored at room temperature for several 
months.
To 0.8 ml of the sample, 3.2 ml of BS7 reagent [Appendix II] was added. 
The solutions were mixed and left for 10 min at room temperature. After 
this period, 0.1 ml of Folih and Ciocalteau phenol reagent was added and 
quickly mixed. Samples were incubated for a further 20 min at room
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temperature to allow the colour to stabilize and were then read at 600 nm 
against a blank made up from treating 0,8 ml of water in the same way as 
the sample.
A calibration curve was produced using bovine serum albumin (BSA, fraction 
V) dissolved in sodium acetate buffer (0,1 M; pH 4.8) [Appendix I], 0.8 ml 
of each standard (0-1000 ug/ml) was treated in the same way as the sample. 
All standards and samples were determined in duplicate.
4.3 Development of Antisera against Proteins in Horse Pregnant and
Non-Pregnant Serum
4.3.1 Immunization
Samples used were early pregnancy serum (6 weeks) obtained from Dr W R 
Allen and virgin mare serum obtained from Dr L Wood. Two New Zealand 
white rabbits were immunized, one with early pregnancy serum and the 
other with virgin mare serum. The immunization procedure was as follows:
Equine blood serum was emulsified in an equal volume of Freunds complete 
adjuvent and 1 ml of the emulsion was injected subcutaneously at four 
sites along the neck and back of the animal. Following this primary 
immunization, the first booster was given 3-4 weeks later. Further 
boosters were given routinely at 2-3 week intervals.
4.3.2 Bleeding
Approximately 10 days after the second and subsequent booster, 25-30 ml of 
blood were taken from a marginal ear vein. The rabbit was wrapped in a 
towel with its head protruding. The ear was wiped with xylene to induce 
vasodilation. The margin of the ear was streaked with Vaseline to prevent
94
the spreading of blood and a longitudinal cut (approx. 2 mm) was made in 
the vein with a sharp sterile scalpel blade. The blood was collected by 
gravity drip into a plastic universal container.
4.3.3 Preparation of Antiserum from Whole Blood
Blood was allowed to clot by standing at room temperature for 
approximately 2 h. The clot was then carefully separated from the vessel 
wall (ringed) and allowed to retract at 4°C overnight. Blood serum was 
then removed using a Pasteur pipette and centrifuged at 1000 x g for 15 
min The remaining clear supernatant was the antiserum.
As repeated freezing and thawing is known to cause protein denaturation 
and eventual loss of antibody activity, the antiserum was frozen in 3,0 ml 
aliquots at -20°C.
4.4 Immunological Screening of Antisera
4.4.1 Two-Dimensional Crossed Immunoelectrophoresis
Two-dimensional crossed immunoelectrophoresis (Weeke, 1973) was used to 
screen antisera for the presence of antibodies against known and unknown 
serum proteins.
1% agarose (Sigma - Type II medium EEO) was made up in tris-barbitone 
buffer (pH 8.6) [Appendix II]. The 1% agarose solution was heated to 90°C 
in a steamer to give a clear molten agarose gel. The gel was then placed 
in a water bath regulated 60°C to prevent it solidifying (agarose gel 
becomes solid at temperatures < 56°C), Molten agarose was poured on to 8 
x 8 cm glass plates (10 ml agarose per plate). Once the gel had set, 
sample wells were punched along one side of the plate (3 wells per plate). 
One of the samples (serum antigens) was mixed with tracker dye 
(bromophenol blue) and 1 |il of each sample was applied to each well. The
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samples were electrophoresed usingan LKB 2217 Multiphor, until the 
bromophenol blue spot had traversed the plate. The current used for 3 
plates was 20 mA (constant current) and the time taken to complete the 
first dimension was about 2,5 h. After this period, the first dimension 
gel was divided into three strips so that each strip contained a sample 
well and the separated components of the sample. Each strip of gel 
(approx. 2.5 x 8.0 cm) was transferred to the cathodic end of a clean 
glass plate by sliding the strip of gel carefully off the plate onto 
another using a clean razor blade. The glass plates were placed on a 
horizontal surface and 7 ml of antibody-containing gel was poured onto 
the remainder of the plate. Volumes of antisera used were generally 100 
HI or 150 HI per 7 ml of agarose. Once the gel had set, the plates were 
transferred to the Multiphor tanks and the gel was connected with the 
buffer by means of filter paper wicks (5 pieces thick). The separated 
components of the initial sample were electrophoresed at 20 mA constant 
current (3 plates) into the antibody containing gel. This second 
dimension was allowed to run overnight (16-20 h). Throughout the entire 
process, the gels were kept cool by means of a water circulator (LKB 2209 
Multi Temp) at 10-20°C, Once the second dimension was complete, the peaks 
could be visualised by lateral illumination but in most cases the plates 
were stained. On completion of the second dimension, the plates were 
pressed, soaked in 0.1M NaCl for 2 x 1 h, stained with 0.05% Coomassie in 
acetic acid: methanol:water (50:40:10) for 10 min and then destained in 
acetic acid:methanol:water (10:20:70) for 30 min. The plates were then 
dried in a stream of warm air.
Samples of blood serum taken from ponies and mares at various stages of 
pregnancy including before and after mating were electrophoresed against 
rabbit antisera raised against pregnant horse serum (anti-pregnant horse
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serum) and compared with virgin serum samples run against the same 
antiserum. In addition, the same samples of equine serum were run against 
rabbit antiserum raised against virgin horse serum (anti-virgin horse 
serum) and compared with the above. Pregnant donkey serum was also 
electrophoresed against the anti-pregnant horse antiserum to investigate 
the degree of between species cross-reactivity. Serum samples taken from 
a donkey-in-horse pregnancy was also electrophoresed against the same 
antisera. Placental extracts were electrophoresed against the anti­
pregnant horse antiserum in order to investigate the origin of observed 
pregnancy-associated proteins.
4.4.2 Tandem Crossed Immunoelectrophoresis
Tandem crossed immunoelectrophoresis (Kroll, 1973) was used to investigate 
the identity of proteins in different samples as visualised by two- 
dimensional crossed immunoelectrophoresis. Two circular application wells 
were punched out in the same track in the first dimensional agarose 
electrophoresis gel with an intercentre distance of 8 mm. The samples to 
be compared were each placed in one of the application wells. Two- 
dimensional crossed immunoelectrophoresis was then performed as previously 
described. The fusion of precipitin lines in the final pattern is 
indicative of protein identity between the two samples.
4.5 Adsorbed Antisera
Antiserum raised against pregnant horse serum was adsorbed with virgin 
horse serum to remove these specificities not related to equine pregnancy. 
This was achieved by treating the antiserum with virgin horse serum 
covalently linked to Sephacryl S-300 prepared by the borohydride reduction 
method as follows:
97
(a) Oxidation of the Gel
15 ml (settled volume) of Sephacryl S-300 in a 50 ml plastic 
centrifuge tube (volume measured after allowing to settle 
overnight) was washed thoroughly with 2 1 of distilled
water. Washing was achieved by topping up the centrifuge 
tube with distilled water and thus suspending the gel followed 
by gentle centrifugation. The supernatant was discarded and 
the process repeated. The washed gel was resuspended in 50 ml 
of 5mM/l sodium m-periodate in 0.1 M sodium acetate buffer pH
5.0. The reaction was carried out with end-over-end mixing for 
1 h at room temperature. The excess periodate was reacted by 
the addition of 5 ml 10% (v/v) glycerol with further end-over- 
end mixing for 1 h. The gel was washed thouroughly with 0.1 M 
sodium bicarbonate as described above. The oxidised Sephacryl 
S-300 was using for coupling to protein.
(b) Coupling of Virgin Horse Serum to the Oxidised Gel
The protein content of virgin horse serum was determined by the 
Ohnishi-Barr method. The serum sample was diluted in 0.1 M 
sodium bicarbonate to a protein concentration of 5-8 mg per ml 
of gel (approx. 1 in 4 to 1 in 5 dilution). 15 ml (settled gel 
volume) of oxidised Sephacryl S-300 was resuspended in 20 ml of 
the dilute serum in 0.1 M NaHC03 pH 9.0. This suspension was 
mixed by end-over-end rotation overnight at room temperature. 
After the reaction, the uncoupled protein solution was recovered 
from the gel by thoroughly washing with 2 1 of phosphate
buffer pH 7.4. The volume of each wash was recorded and samples 
taken of each for protein determination. The amount of protein 
bound to the gel could then be calculated.
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(c) Borohydride Reduction
The reacted Sephacryl S-300 was resuspended in 0,5 M phosphate- 
buffered saline pH 7.4 and allowed to settle for 30 rain. The
supernatant was removed and kept for protein determination. The 
gel was then washed with an equal volume of phosphate-buffered 
saline to remove the majority of unbound protein and thus this 
supernatant was also kept for a protein determination. The
solid phase was then resuspended in 500 mg of sodium borohydride 
in a final volume of 100 ml and reacted with occasional stirring 
for 30 min at room temperature. After this period, the solid 
phase was washed alternately in 0.25 M citrate buffer (pH 4.0) 
and 0.25 M Tris-HCl (pH 8.5), approximately four times with 
each buffer. All washes were kept for a check on the removal 
of further unbound protein. Finally the gel was resuspended 
in phosphate-buffered saline,
4.6 Specificity Test of Adsorbed Antisera
Adsorbtion was considered complete if no precipitin lines were formed when 
virgin horse serum was used as the antigen and electrophoresed against the 
adsorbed antisera. ~
A more rapid test of specificity was also adopted utilising the technique
of counter-immunoelectrophoresis on glass plates or microscope slides. 1% 
agarose gel (High EEO) was poured onto the glass surface and allowed to 
set. Pairs of 4 pi wells were punched in the gel 1.5 cm apart, one well 
being situated towards the cathodic end of the plate and one towards the 
anodic end. Antigen was placed in the cathodic wells and adsorbed 
antisera was placed in the anodic wells. The plates were transferred to
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Multiphor tanks and the gel was connected with the buffer by means of 
filter paper wicks (5 pieces thick). The samples were electrophoresed at 
20 mA constant current for 2.5 h using barbitone buffer (pH 8.6).
During electrophoresis the antigens move towards the anode in the normal 
fashion. The immunoglobulins, however, move towards the cathode because 
IgG has a slight positive charge at pH 8.6. and also due to the electro- 
endosmotic effect of the agarose on electrophoresis (Agarose- High EEO). 
Electro-endosmosis in agarose occurs due to the presence of ionisable 
groups in the gel that become negatively charged on electrophoresis. 
Agarose contains sulphonic acid groups which are responsible for this 
negative charge. The natural tendency of the negative charges is to move 
towards the anode, but this is impossible since the medium is stationary. 
To counter the force generated, a movement of positively protonated water 
molecules (H30+) occurs towards the cathode. Subsequently, the 
electrically neutral gamma-globulin fraction of serum moves towards the 
cathode.
4.7 Precipitin Line Immunization
This is a technique of producing monospecific or oligospecific antisera 
against protein(s) visualised as a precipitin line in an agarose gel after 
two-dimensional crossed imunoelectrophoresis, i.e. specific antigen- 
antibody complexes in the gel are used as immunogen (Kroll, 1981).
A two-dimensional crossed immunoelectrophoretic run was completed and the 
peaks were viewed by lateral illumination. After identification of a peak 
of interest, the agarose gel was blotted with filter paper under a slight 
pressure to remove non-precipitated antigens and to reduce the agarose gel 
to a thin but not completely dry sheet. The specific precipitin line was 
cut out of the gel by means of a Linocutter. Strips of agarose gel
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containing the precipitin line of interest were washed in 5 1 of 0.1 M NaCl 
overnight to remove unprecipitated protein (antigen). The precipitin 
lines were then placed in a centrifuge tube with fresh 0.1 M NaCl and 
centrifuged at 15,000 g for 10 min to ensure that all non-precipitated 
antigen and weakly associated antigens had been removed from the agarose. 
The washed agarose gel strips containing the immunocomplex were 
solubilised by suspension in 1 ml of 6 M KI. The solubilisation process 
was aided by sonication of the sample in an ice bath. After complete 
solubilisation, 0.5 ml of the solution was mixed with an equal volume of 
Freunds complete adjuvent and emulsified. The initial 1 ml suspension 
contained approximately 2.5 cm of the initial precipitin line. To ensure 
enough immunogen was immunized, 1,0 ml of the emulsion was injected 
subcutaneously. The immunization protocol was as previously described 
(Section 4.3.1).
4.8 Heparin Affinity Chromatography
Heparin is a naturally occurring sulphated heterogenous glycosaminoglycan 
and since its discovery by McLean in 1916, much evidence has accumulated 
which demonstrates that heparin functions as a powerful anticoagulant. 
Twenty percent of the total number of circulating proteins in human plasma 
have an affinity for heparin, which can be demonstrated by investigating 
those plasma proteins which bind to immobilised heparin in heparin 
affinity chromatography (Teisner et al., 1983). Furthermore, two human 
pregnancy associated proteins appear to have an affinity for heparin, 
namely PAPP-A (pregnancy associated plasma protein-A) and PP-5 (placental 
protein-5) [Section 3.15].
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4.8.1 Chromatographic Procedure
Two types of affinity media were used, namely heparin-sepharose and 
heparin-ultrogel. A 10 cm column was packed with the heparin solid phase. 
The affinity media was washed with 10 column volumes of distilled water. 
Distilled water was used both to wash and to elute unbound protein from 
the column so that fractions collected from the column could subsequently 
be concentrated by lyophilization and the resulting concentrate 
investigated by immunoelectrophoresis. High salt concentrations would 
otherwise interfere with subsequent immunoelectrophoresis. The flow rate 
of the column was adjusted to 12 ml/h and 3 ml fractions were collected. 
The eluate level on the column was lowered to the surface of the affinity 
medium, the pump switched off and 1 ml of pregnant equine serum was 
carefully applied on to the affinity medium using a Pasteur pipette. The 
pump was switched on until the sample had just entered the affinity media 
when 2 ml of distilled water was applied to the column. The column was 
then filled with distilled water and the pump and fraction collector 
switched on.
The absorbance of each fraction eluting from the column was measured at 
256 nm against a distilled water blank to test for protein. All the 
fractions with measurable optical densities were collected and numbered. 
The column was washed until no further protein was detected.
Proteins bound to the heparin-Sepharose and heparin Ultrogel were eluted
at the same flow rate with a linear salt gradient ranging from 0.2 M NaCl
to 1.0 M NaCl in distilled water. As before, elution was monitored at
each salt concentration at 256 nm against the appropriate blank. All
absorbance measurements were taken using the LKB Ultrospec
spectrophotometer. Once all the originally bound protein had been eluted
from the column, all the samples with an absorbance reading above 0,600
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were freeze dried after the pooling and dialysis of homogenous protein 
peaks. The samples were redissolved in one tenth of the original volume 
and run as the antigen source in two-dimensional crossed immuno­
electrophoresis. The affinity column was regenerated by thoroughly 
washing with distilled water.
4.9 Lymphocyte Blastogenesis
4.9.1 Preparation of Placental/Uterine Extracts
All placental and uterine extracts were homogenised in phosphate buffered 
saline (PBS) containing a small amount of the protease inhibitor- 
phenylmethylsulphonyl fluoride [PMSF]. 10 mg of PMSF was dissolved in 
1 ml of ethanol to give a saturated solution of PMSF. 100 Ml of this PMSF
solution was added to 100 ml of PBS.
Samples of placental and uterine tissue were taken from fresh equine and 
bovine placentae as a consequence of the termination of a pregnancy, 
post-mortem or after normal delivery. The tissue was chopped up as 
finely as possible using sharp surgical scissors and a razor blade and 
added to the PBS with PMSF to give about 100 mg of wet tissue per ml of 
solution. The solutions were then homogenised using an electric 
homogeniser while maintaining the samples at low temperature in an ice 
bath. After homogenisation the samples were centrifuged at 2,000 g for 
30 min to remove all debris. For use in lymphocyte blastogenesis studies, 
these samples were still found to contain too much sediment for filter 
sterilisation and were thus centrifuged at 18,000 g for 30 min. The 
resulting supernatant was dialysed against 0.05 M PBS for 24 h. After 
dialysis the samples were centrifuged again at 18,000 g to remove any
precipitated protein. The protein content of each sample was then
determined by the method of Ohnishi-Barr (Section 4.2) and all samples
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were diluted to the same protein concentration using sterile PBS. All 
samples used in lymphocyte cultures were filter sterilised through 0.45 
micron Millipore membranes before use. Doubling dilutions were prepared 
in sterile PBS.
4.9.2 The Two-Way Allogeneic Mixed Lymphocyte Reaction (MLR)
(a) Isolation of peripheral blood lymphocytes from the blood of a horse 
Whole blood was obtained by venepuncture from two non-inbred horses. Blood 
was taken from the jugular vein of each horse into 10 ml Vacutainers each 
containing 200 units of lithium heparin as anticoagulant. Lymphocytes 
and mononuclear cells were then separated from the whole blood by the 
method of Boyum (1968). Each blood sample was diluted with two volumes 
of Dulbecco's modification of Eagles medium containing 20 mM/1 HEPES 
(DMEM). Alternatively, the blood was allowed to sediment under gravity for 
40 min at room temperature and the lymphocyte rich plasma drawn off and 
diluted with two volumes of DMEM. 9 ml of lymphopaque, specific gravity 
1.084 [Appendix I] was aseptically dispensed into sterile 25 ml universal 
containers (8 per horse). 15 ml of diluted blood or plasma was carefully 
layered on to the lymphopaque in each universal using a 5 ml adjustable 
pipette, previously cleaned with ethanol fitted with a sterile tip. The 
samples were then centrifuged at 300 x g (calculated at the interface of 
the serum and lymphopaque) for 30 min at room temperature. Within the 
sterile surroundings of a laminar air flow cabinet the clear supernatant 
was removed (using a sterile plastic tip) down to the opaque band of 
white cells at the lymphopaque interface. The band of white cells was 
removed from every gradient and placed into separate universal containers 
for each horse.
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Approximately 25 ml of DMEM was added to each cell sample and the cells 
were resuspended by gentle inversion. The cells were then centrifuged at 
150 x g for 15 min and the supernatants discarded. The cells, visualised 
as a small pellet at the bottom of the universal, were resuspended in 1 ml 
of DMEM by slowly circulating the DMEM above the pellet using a sterile 
disposable pipette tip attached to a 1 ml adjustable pipette. The whole 
washing procedure was repeated a further twice and the cells were finally 
suspended in 1 ml of DMEM containing 0,04 M NaHC03, 10% controlled 
process serum replacement-2, 2 mM/1 glutamine, 200 ml of 5000 iu/ml 
penicillin and 5000 pg/ml streptomycin. This supplemented DMEM was 
referred to as DMEM+,
(b) Estimation of viable cell numbers
An estimation of the number of viable cells isolated from each horse was 
determined using the trypan blue exclusion method. 25 ul of cell 
suspension was transferred into a disposable plastic tube with 25 ul of 
trypan blue (0.2% in physiological saline). The cells were left at room 
temperature for a 10 min incubation period and then small aliquots of the 
suspension were introduced into a double chamber improved Neubauer 
haemocytometer. Using a light microscope and a x40 objective, the number 
of viable cells were counted. The plasma membrane of a viable cell does 
not permit the entry of non-electrolyte dye substances and thus the 
unstained cells were counted as viable, i.e. non-viable cells stain blue. 
Cell numbers were estimated utilizing the following formulae:
4No of cells counted x 25 x 10
No of cells/ml = -----------------------------------------
No of trip le ruled squares used in count
The samples used for the cell count were discarded and the remaining cells
diluted to a final concentration of 1 x 10^ cells/ml in DMEM+ or
2 x 106 cells/ml in DMEM+ depending on the number of viable cells.
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(c) Setting up mixed lymphocyte cultures
Cell cultures were prepared from a stock cell suspension of 1 x 10^ 
cells/ml and were incubated in a 96 well microtitre plates (Falcon 
Laboratories). 200 Ml of a cell suspension from one donor horse was added 
to 6 microtitre plate wells (2 x 10^ cells per well). Each of the next 6
wells contained 2 x 10^ cells from the second donor horse. These
represented control cultures. Equal volumes of the cell suspensions 
obtained for the 2 individual donor horses were then mixed together and 
200 Ml of this lymphocyte culture (2 x 10^ lymphocytes per well) was added
to the remaining wells. Control cultures contained 50 Ml of DMEM and
experimental cultures contained 50 Ml of sample. All samples were 
incorporated into the assay in triplicate wells.
The peripheral wells of the plate were not used as sample wells but were 
filled with 200 Ml of DMEM with bicarbonate in order to maintain the 
humidity around the cultures. The plates were then incubated for 5 days 
at 100% humidity at 37°C in 5% CO2 in air in a Hereaus CO2 incubator.
(d) Pulsing of cells with tritiated thymidine (^H-Tdr)
After 5 days of culture, 1 j. Ci of ^H-Tdr (90 Ci/mM) in a total volume of 
25 jjI (diluted in DMEM) was added to each well except three zero hour 
control wells containing mixed lymphocyte cultures. The cultures were 
pulsed under sterile conditions and than incubated for a further 24 h. The 
zero hour controls were pulsed 24 h later just prior to harvesting.
(e) Termination and harvesting of cultures
After this final 24 h incubation period, the cells were harvested onto 
glass fibre filter paper, either manually using 5% trichloroacetic acid 
(TCA) containing 30 mM/1 pyrophosphate, or by the use of a Skatron semi­
automated cell harvester.
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For the manual termination of the cell cultures, the contents of each well 
were aspirated into plastic disposable tubes on ice. A 200 Ml volume of 
trypsinising solution (0.05% trypsin, 0.02% EDTA in physiological saline) 
was then added to each well in order to free the adherent cells. After a 
30 min incubation period at room temperature, the wells were once again 
aspirated into the appropriate cell suspensions on ice. 1 ml of ice cold 
5% TCA containing 30 mM pyrophosphate was added to each cell suspension 
and incubated at either room temperature for 1 h or 4°C overnight, in 
order to precipitate the DNA. The DNA precipitate was isolated by 
filtration of the cell suspension through glass fibre filter paper using a 
Millipore sintered glass filter assembly attached to a vacuum line. Prior 
to filtration, the filters were soaked in TCA, placed into the vacuum 
filter holder after which 5 ml of ice cold TCA was dispensed onto it. 
Each sample in turn was vortex mixed and tipped into the filter holder 
containing the TCA. The tube was washed with 2 x 1 ml volumes of TCA, the 
contents being dispensed into the filter holder each time. The vacuum was 
applied and the filter allowed to drain after which 2 x 5 ml volumes of 
TCA were added to the filter holder followed by 5 ml of ice cold ethanol. 
Once the filter had drained, the vacuum pump was switched off and the 
filter papers transferred to scintillation vials and allowed to dry for a 
minimum of 30 min. The extent of ^H-Tdr incorporation into the DNA of 
each culture was assessed by liquid scintillation counting using an LKB 
Rackbeta 1212 for a 10 min period. The scintillation fluid was either 
cocktail 'O' scintillant (0.3% PP0, 0.01% P0P0P in toluene) or 'Optiphase 
Hisafe ’,
A majority of the cell harvesting was performed using the Skatron semi­
automatic cell harvester. All samples were harvested onto glass fibre 
filter paper. The filter paper was allowed to dry overnight and then
107
punched out into plastic disposable vials. 3 ml of scintillant was added 
to each vial and the vials were counted for 10 min in a LKB Beta-Counter 
as described above.
4.9.3 The Mitogenic Stimulation Assay (MSA)
Peripheral blood lymphocytes (PBL’s) were isolated from whole blood as 
previously described (Section 5.9.2a). The cell suspension was diluted 
with DMEM+ to a concentration of 1 x 10^ cells/ml. 100 yl of cell 
suspension was added to each well (1 x 10^ cells/well) in addition to 
50 jjL of mitogen, 50 |il of sample and 50 jjL of DMEM+. The control 
cultures contained DMEM in place of the sample and the background 
stimulation was assessed by incubating cells in the absence of mitogen, 
i.e. 100 Ml cell suspension, 100 Ml DMEM and 50 Ml DMEM+. Zero hour 
controls were also set up by pulsing 3 wells just prior to harvesting. 
These control wells contained cells and mitogen but no sample. This 
procedure also serves as an assessment of contamination due to 
unincorporated ^H-Tdr. The mitogen used in this work was concanavalin A 
(Con.A) at a final concentration of 2 Mg/ml.
The plates were incubated for 72 h at 100% humidity, 37°C in 5% CO2 in air. 
6 h prior to termination, the cultures were pulsed with ^H-Tdr (1 uCi) and 
on termination were harvested using a Skatron semi-automatic cell harvester 
and counted as described above.
4.9.4 Cytotoxicity Test
The cytotoxicity test is used as a safeguard against sample toxicity being 
mistaken for immunosuppression in the MLR and the MSA, Cultures of 
lymphocytes from one donor (2 x 10^ cells/well) were incubated with each 
sample over a 6 day period. Each culture was set up in triplicate. The 
cells were counted every 24 h using the Trypan Blue exclusion method
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(Section 4.9.2b). No more than 2 extracts were taken from any one culture 
in order to avoid a reduction in cell numbers obscuring the results. The 
number of viable cells was recorded as a percentage of the total numbers 
of cells in each well and a significant decrease in this percentage was 
indicative of sample toxicity.
4.9.5 Conditioned Medium
Conditioned medium is the supernatant from an MLR and contains lymphokines 
and other factors produced by stimulated lymphocytes. MLR cultures were 
incubated over a 6 day period in a 96 well microtitre plate as previously 
described. At the end of the incubation period, the cultures were 
aspirated, pooled and centrifuged to sediment the cells. The cell free 
supernatant was removed and hence referred to as conditioned medium. In 
both the MLR and MSA, 50 pi of conditioned medium was added to each 
culture containing immunosuppressive samples in order to investigate 
whether the immunosuppression could be reversed by the secreted lymphocyte 
factors. The number of cells per well had to remain the same and thus the 
original dilution of the cells was adjusted to account for this. In the 
MLR, the cell suspension was diluted to a concentration of 2 x 10^ 
cells/150 pi (1.34 x 10^ cells/ml) and consequently 150 pi of this
suspension was added to each well. In the MSA, the cell suspension was
diluted to 1 x 10^ cells/150 pi (2 x 10^ cells/ml) and 50 pi of this
suspension was added to each well. The volumes of the other additives
were therefore as previously described.
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4.9.6 Delayed Addition of Samples
This is a means of finding out whether a sample with a known immuno­
suppressive activity inhibits the activation stage of lymphocyte 
proliferation or a later stage. Samples were added to MLR and MSA
cultures after various incubation times, i.e. 24, 48, 72, 96 h for the MLR
and after 24, 36, 48 and 72 h for the MSA.
4.10 Equine Hormone Assays
A number of samples used in the lymphocyte culture work were assayed for 
equine chorionic gonadotrophin (eCG) and progesterone. These assays were 
carried out by members of the research team at the Equine Fertility Unit, 
in Cambridge. A double antibody (sandwich) type of enzyme linked immuno­
sorbent assay (ELISA) was used for both hormones. Progesterone was 
assayed using a kit obtained from Hoechst U.K. Limited. The eCG ELISA was
developed at the Equine Fertility Unit and the details of this assay are
as follows.
4.10.1 ELISA Assay for eCG (PMSG)
All buffers used in this assay are listed in Appendix III. The basic
components of the assay were an unlabelled antibody (anti-eCG), a labelled 
antibody (anti-eCG conjugated to alkaline phosphatase via a lysine link) 
and a standard, the 2nd International Standard-serum gonadotrophin,
A Nunc immuno-plate was coated with purified polyclonal anti-eCG at a 
concentration of 5 jjg/ml; 120 pi was added to each well. The plate was
incubated at 37°C for 16 h in a closed box. After this period, the plate
was washed with 4 x 200 jil of wash buffer and glaze. A range of standards 
was prepared from the original standard serum gonadotrophin in standard 
buffer (0; 0.5; 1.0; 5.0; 10.0; 50.0; 100.0; 200,0 iu/ml). All standards 
and samples were diluted 1:50 with dilution buffer. 20 |il of sample or
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standard were added to appropriate wells and 100 |il of dilution buffer was 
added to every well after which the plate was incubated for 1 h at 37°C. 
The wells were washed with 4 x 200 pi of assay wash buffer to remove 
unbound eCG, After draining, 100 pi of labelled anti-eCG (polyclonal) was 
added to each well and this was followed by a further 1 h incubation 
period. The wells were washed and drained as before, this time removing 
any unbound labelled anti-eCG, and 100 pi of substrate was added to each 
well. After a further 20 min incubation period, 100 pi of amplifier was 
added to each well and the plate was left until the colour development in 
the 200 iu/ml standard gave an optical density reading between 1.5 and
2.0. The colour development was stopped with 100 ml of 0.4 M sulphuric 
acid and the plate was read and calibrated using a Titertek uniskan 
spectrophotometer with a computer link. The lowest detectable amount 
using this assay was 0.5 iu/ml and its working range was from 3 to 
200 iu/ml.
4.11 Platelet Aggregation Studies
4.11.1 Preparation of Placental Extracts
As described previously for lymphocyte work (Section 4.9.1).
4.11.2 Equine Blood Sample Collection and Preparation
Whole blood was obtained by jugular venepuncture into 4.5 ml vacutainers 
containing 0.105 M sodium citrate as anticoagulant. The ratio of blood to 
anticoagulant was 9:1. The vacuntainer was gently inverted to prevent 
separation of the blood, after which it was centrifuged at 50 x g for 10 
min at room temperature. After centrifugation, there was approximately 1 
ml of plasma per 10 ml of cell suspension. This plasma has a high
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platelet content and is thus referred to as platelet-rich plasma (PRP). 
The PRP was carefully removed using a plastic transfer pipette and 
expelled into a plastic tube.
A second method for preparation of PRP was investigated. Blood was stood 
at room temperature for approximately 10 min. When the erythrocytes had 
sedimented leaving about 1 ml of plasma at the top of the tube, the plasma
was removed as PRP. Once the PRP had been removed, the remaining blood
was centrifuged at 1,500 x g for 10 min. The plasma left had no or very
small number of platelets and was retained as platelet poor plasma (PPP).
PRP and PPP preparation was carried out as soon as possible after sample 
collection (within 30 min).
A marked feature of horse blood is the natural clumping of erythrocytes 
leading to the separation of cells and plasma within minutes. Since the 
sedimentation rate of horse blood is very rapid and resuspension by 
inversion does not always provide an even distribution of platelets 
because of spontaneous aggregation, the platelet number in the PRP can 
vary (White et al., 1975). Furthermore, the number of platelets in horse 
PRP is, on the average, lower than the number in human PRP and thus the 
magnitude of platelet responses is lower (White et al., 1975).
4.11.3 Human and Bovine Blood Sample Collection and Preparation
Human and bovine erythrocytes do not sediment as quickly as equine 
erythrocytes therefore a higher centrifugation speed is required for the 
preparation of PRP. Whole blood was centrifuged at 250 x g for 10 min.
4.11.4 Platelet Aggregation Studies
After preparation, PRP was equilibrated at 37°C for 15 min. Platelet
aggregation studies were carried out using collagen and ADP as agonists.
Aggregation was assessed using a platelet aggregometer (ADG Instruments
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Ltd - Model 1002). The aggregometer measures the turbidity of the PRP 
which is continually stirred in a cuvette. Changes in optical density are 
constantly assessed as a means of detecting the effects of aggregating 
agents. When platelets aggregate the optical density decreases and when 
the aggregates disperse the optical density increases.
300 |il of PRP was incubated with 60 ^1 of 0.85% saline in an aggregation 
cuvette for 3 min, 40 jj.l of agonist was added and the aggregation 
recorded by means of a chart recorder (Kip-Zonen) connected to the 
platelet aggregometer. Maximum deflection of the recording pen was 
pre-set with platelet-rich and platelet-poor plasma. Thus, as platelets 
aggregated and fell out of the light path, transmission increased and was 
recorded as an upward swing of the pen. To assess the inhibitory effect 
of the placental extracts, the saline was replaced by a sample. The 
platelet aggregation response was recorded for approximately 5 min.
4.11.5 Collagenase Assay
One agonist used to induce platelet aggregation was collagen. The 
inhibition of collagen induced platelet aggregation by a sample may be due 
to the breakdown of collagen by collagenase.
The substrate for collagenase in the assay was p-phenylazo- 
benzyloxycarbonyl-Pro-Leu-Gly-Pro-Arg, Collagenase splits the hydrophilic 
substrate specifically between leucine and glycine resulting in a coloured 
lipophilic fragment and a non-coloured tripeptide. The change in optical 
density of the fragment at 320 nm per unit time is a measure of the enzyme 
activity.
PZ-Pro-Leu-Gly-Pro-Arg collagenase pz-Pro-Leu + Gly-Pro-Arg
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2.0 ml of substrate solution (Appendix II) was added to 0.4 ml of calcium 
chloride solution (0.1 M) in a test tube and allowed to stand for 5 min at 
25°C. After this period, 0.1 ml of sample (placental extract) or standard 
(collagenase) was added, mixed and incubated for exactly 15 min at 25°C.
0.5 ml of incubation mixture was then quickly transferred to prepared test 
tubes filled with 1.0 ml citric acid solution (25 mM; pH 3.5) and 5.0 ml 
ethylacetate. The test tubes were shaken for 15 sec and the ethylacetate 
phase was transferred by pipette into test tubes containing 300 mg of 
anhydrous Na2S04. These test tubes were shaken and the contents 
transferred into plastic cuvettes, after which the change in absorbance 
was measured. The ’volume activity’ and ’specific activity' of the enzyme 
can be calculated using the following formulae
2.5 x 5 x E
Volume activity (U/m l sample)
21 x 0.1 x 0.5 x 15
Volume activity
Specific activity (U/m g protein)
Concentration
( E= E sample -  E blank; E= Extension (absorbance))
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CHAPTER -5-
IMMUNOCHEMICAL STUDIES OF EQUINE PREGNANCY
5.1 Introduction
Published data on the presence of serum pregnancy specific/associated 
proteins in the horse is limited. The most widely reported protein is 
equine chorionic gonadotrophin (eCG), first detectable in the maternal 
circulation at day 42 of gestation (Allen and Moor, 1972), In addition, a 
single report describes another pregnancy specific protein designated mare 
pregnancy protein-1 (MPP-1), detectable in the earliest sample 
investigated which was day 30 of gestation (Gidley-Baird et al., 1983). 
Furthermore, serum based pregnancy tests have been shown only to be 
reliable after day 60 of gestation when elevated levels of the conceptus 
derived steroid, oestrone sulphate, can be detected (Sist et al., 1987). 
Prior to this time, serum pregnancy tests are only tentative indicators of 
pregnancy - elevated progesterone levels are used to confirm a continued 
activity of the corpus luteum (days 18-25) and elevated eCG levels are 
used to confirm conception (days 42-90).
The rationale behind this section of work was to investigate the presence 
of other pregnancy specific or pregnancy-associated serum proteins which 
may be detectable in the peripheral circulation during early gestation. 
Subsequently, it was hoped to evaluate the use of one or more of these 
factors in the detection of equine pregnancy prior to day 60 of gestation. 
This Chapter describes the detection of a new pregnancy specific serum 
protein which is present prior to day 30 of gestation. The first half of 
the Chapter deals primarily with the detection of the new protein, its
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quantitation and investigates the potential use of this protein as an 
indicator of pregnancy. The source and purification of the protein are 
dealt with in the latter half of the Chapter.
5.2 The Detection of a New Pregnancy-Specific Protein in the Horse 
by Two-Dimensional Crossed Immunoelectrophoresis
Rabbits immunized with both pregnant and non-pregnant horse serum
developed antibody tit res measurable in immunoprecipitation techniques. 
Two-dimensional crossed immunoelectrophoresis of equine serum obtained 
from pregnant or non-pregnant animals, run against rabbit anti-pregnant 
horse antisera resulted in the formation of many precipitin lines.
Serum samples were taken from two mated horses (HI, H2) at different times
from day 2 to day 12 after mating where day 0 represented the day that the
mare was sired by a stallion. Pregnancy was investigated in both animals
by an ultrasound scan carried out at day 90 after mating. Pregnancy was
confirmed in one whereas the second horse (H2) failed to become pregnant.
Serum samples were also taken from a third horse (H3), which was
subsequently revealed to be pregnant by succesful outcome of the
pregnancy, at later gestational ages ranging from day 21 to day 239. Serum
samples from all the above animals were electrophoresed against rabbit
anti-pregnant horse antisera. Examination of the immunoelectrophoretic
plates (Figs 5.1, 5.2, 5.3) revealed a precipitin line representing a
protein which appeared to be associated with the pregnant state of the
horse (Compare H2 Fig.5.2 with HI and H3 Fig.5.1 and 5.3). The protein had
beta2~electrophoretic mobility and was first detected in the peripheral
blood serum at day 6 in a pregnant horse (Fig.5.IB). This protein was not
present in serum from the horse that failed to become pregnant after
mating (H2) (Fig.5.2), in serum from a gelding (H4) (Fig.5.4A), in
serum from a virgin mare (H5) (Fig,5.4B) or in serum from a mare that
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BFig.5.1 Two-dimensional crossed immunoelectrophoresis of serum taken from a 
pregnant mare (HI) at intervals during the first 10 days after mating. 
[a= 32~hors.PP, b= y2-hors.P, antisera= rabbit anti-pregnant horse]
A (day 3), B (day 6), C (day 9), D (day 10).
Beta2“hors. PP is first detectable at day 6. Pregnancy was confirmed 
by ultrasound scan at 90 days.
s= a9-macroglobulin
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Fig.5.2 Two-dimensional crossed immunoelectrophoresis of serum taken from 
a mare (H2) (after mating) which failed to become pregnant; serum 
samples were taken at intervals during the first 10 days.
[antisera= rabbit anti-pregnant horse]
A (day 2), B (day 6), C (day 7), D (day 10).
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Fig. 5.3 Two-dimensional crossed immunoelectrophoresis of serum from a 
pregnant mare (H3) at day 21 at intervals during gestation.
[a= $2-hors.PP, b = y 2-hors.P, antisera= rabbit anti-pregnant horse] 
A (day 21), B (day 83), C (day 147), D (day 239).
Pregnancy was confirmed by successful outcome.
s= a9-macroglobulin
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Fig. 5.4 Two-dimensional crossed immunoelectrophoresis of gelding (H4) (A), 
virgin horse serum (H5) (B) and non-pregnant horse serum from a 
previously pregnant mare (H6) (C) against rabbit anti-pregnant 
horse antiserum.
Only gamrr^-hors.P (b) is present.
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hadpreviously been pregnant (H6) (Fig.5.4C). A second protein with 
gamma2~electrophoretic mobility that was present in gelding (H4) serum and 
in serum from both of the non-pregnant mares (H5, H6) (Fig.5.4A, B,C) was 
also present in serum taken from pregnant mares (HI, H3) (Figs 5.1, 5.3). 
This protein appeared to be iramunologically related to the pregnancy 
specific protein of beta2~electrophoretic mobility in that the precipitin 
lines of the proteins showed continuity (See eg, Fig 5.3). In addition, 
serum from a number of other pregnant mares was pooled and 
electrophoresed against rabbit anti-pregnant horse antiserum. The two 
precipitates were continuous indicating the presence of identical 
antigenic determinents in the compared samples (Fig.5.5).
The two proteins were termed beta2-hors. pregnancy protein (3 2“hors.PP)and 
gamma 2-hors. protein (Y2~hors.P) ipespec tively. Two-dimensional crossed 
immunoelectrophoresis of pregnant mare serum against rabbit anti-virgin 
horse antiserum revealed the presence only of the 32~hors.PP recipitate 
(Fig.5.6). Tandem crossed immunoelectrophoresis of virgin horse serum and 
pregnant horse serum against rabbit anti-pregnant horse antisera, revealed 
the fusion of the Y2“hors. P precipitin lines from the two samples 
indicating an identity between the postulated Y2~hors.P in pregnant and 
non-pregnant horses (Fig.5.7)^
To summarise, a protein with beta2-electrophoretic mobility is described, 
which appears in the serum of mares specifically during pregna.ncy. The 
protein is first detected at day 6 post-covering and is immunologically 
related to another protein present in the non-pregnant mare.
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Fig. 5.5 Two-dimensional crossed immunoelectrophoresis of pooled serum from 
a number of pregnant mares. The equine pregnancy protein 
precipitates have fused together.
[antiserum= rabbit anti-pregnant horse]
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bFig.5.6 Two-dimensional crossed immunoelectrophoresis of pregnant horse 
serum (H3) against rabbit anti-virgin horse serum.
Only gamn^-hors.P (b) is present.
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Fig.5.7 Tandem crossed immunoelectrophoresis of virgin horse serum and 
pregnant horse serum against rabbit anti-pregnant horse antisera. 
The y^-hors.P precipitates have fused together.
(VHS= virgin horse serum; PHS= pregnant horse serum)
124
5.3 Identification of Equine Chorionic Gonadotrophin (eCG)
As eCG is the most widely reported pregnancy specific protein, a possible 
identity between eCG and 3 2"h°ts.PP was investigated, although this seemed 
unlikely in view of the source of eCG and the early appearance of 
3 2~hors•
eCG was obtained from two commercial sources, Sigma and Intervet. The 
hormone was electrophoresed against rabbit anti-pregnant horse antiserum. 
Both hormone preparations revealed a peak in the alpha2 area of the gel 
(Fig.5.8A, B) as described by Gidley-Baird et al. (1983). A number of 
contaminating proteins were, however, also present particularly in the 
Sigma preparation (Fig.5.8A). Pregnant mare serum was also 
electrophoresed against rabbit anti-eCG (Equine Fertility Unit, Cambridge) 
and a similar precipitin line was observed (Fig.5.8C). Neither 3 2~hors.PP 
or Y2-hors.P was revealed in any of the above immunoelectrophoretic runs. 
Therefore, since neither eCG preparations contain material identifiable 
immunologically as either 3 2“hors.PP or Y2“h°rs*I> an^ as anti-eCG failed 
to precipitate either of these 2 proteins in pregnant mare serum known to 
contain 82"“hors.PP (H3), it was concluded that 3 2~hors.PP and Y 2“hors.P 
are proteins distinct from eCG.
5.4 Semi-Quantitation of 6 ?-hors,PP Levels during Pregnancy
In order to determine the relative changes in concentration of 3 2~hors.PP
throughout pregnancy the area under the protein precipitin line was
compared to the area under a common protein precipitate present on each
plate. The common protein selected was the protease inhibitor alpha2“
macroglobulin, the concentration of which does not vary during pregnancy
(Carlson et al., 1986). This protein also produced a clearly identifiable
precipitate on all immunoelectrophoresis plates. When fresh serum is used
in two-dimensional crossed immunoelectrophoresis, alpha2_macroglobulin
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Fig.5.8 Two-dimensional crossed immunoelectrophoresis of two preparations 
of eCG, from the suppliers Sigma (A) and Intervet (B), against 
rabbit anti-pregnant horse antiserum and also of pregnant mare 
(H3) serum (eCG phase) against rabbit anti-eCG (C). [X=eCG]
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sometimes forms two precipitates in the second dimensio'n, each with 
identical electrophoretic mobility in the first dimension (Dott et al., 
1985). In such cases, the upper peak was used as the standard as only the 
lower peak varies in height.
The orientation of specific precipitin peaks on an immunoelectrophoretic 
plate is variable. Consequently, the positioning of a base line for the 
determination and comparison of areas on the same plate is difficult. To 
overcome this problem, the base line was drawn in the two most plausible 
positions and the peak areas calculated for each position. The two chosen 
base line positions were firstly, each peak with its own base line and 
secondly, a common base line for all protein precipitates. Once the peak 
areas and ratios were determined for both base line positions, the average 
areas were calculated. This procedure was repeated with different anti­
pregnant mare antisera and the results compared (Table 5.1). This 
experiment was carried out with serum samples from two pregnant horses, 
namely HI (day 3-10) and H3 (day 21-239). The peak areas shown in Table
5.1 suggest that there is an increase in secretion of $2”hors.PP f°r at 
least the first 21 days of gestation. From day 83 onwards, however, 
82~hors.PP levels decline suggesting that peak levels of the protein are 
produced at some stage between days 21 and 83. Such a secretion pattern 
suggests that the function of such a protein is of prime importance during 
early pregnancy, for example in human pregnancy certain immunomodulatory 
proteins are present at a higher concentration during early pregnancy 
than later in gestation. Furthermore, when implantation occurs in the 
horse at day 37, 32~hors.PP levels are elevated, which suggests that the 
protein may have a biological function during this process.
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5.5 R9-hors.PP as an Indicator of Pregnancy
Sequential serum samples were taken from 16 horses for up to 3 weeks after 
mating with a stallion. Pregnancy was determined either at 90 days by 
ultrasonic scan (N=13) or by successful outcome (N=3). Eleven horses were 
found to be pregnant by these criteria. Serum samples from all horses 
were run in two-dimensional crossed immunoelectrophoresis against rabbit 
anti- pregnant horse antiserum. At this stage, it was unknown which 
horses were pregnant and which were not, the immunoelectrophoresis was 
performed blindly. In addition, serum samples from 14 mares known not to 
be pregnant were also run against the same antiserum in the imrauno- 
electrophoretic system described. f^-hors.PP was detected in 10 of the 11 
mares which were later confirmed to be pregnant. Two of the five mares 
that were covered by a stallion and did not develop a successful pregnancy 
transiently showed the presence of the protein. In one of these two 
horses (H7), the protein was detectable at day 5 only but not in the 
samples taken on the following four days. In the other horse (H8) 
8 2-hors.PP was detected on day 10, the last sample obtained. In horses 
where pregnancy was confirmed,82-hors.PP appeared in all subsequent 
samples investigated. The protein was not detected in any of the samples 
taken from the 14 mares known not to be pregnant. When the significance of 
these results was assessed by the Chi-squared test using a 2 x 2 
contingency table, it was found that the use of 82~hors.PP as an indicator 
of pregnancy was clinically significant at the 10% level (Table 5,1a).
It is possible that the transient appearance of 62“hors.PP in 
circulation of those mated horses which subsequently proved not to be 
pregnant may represent a situation analogous to the state of biochemical 
pregnancy described in the human (Miller et al., 1980). Indeed, it has 
been reported that similar fertilization rates occur in both normal and
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Table 5.1a
Actual
Test
Pregnant Non-pregnant
8.25 3.75
2.75 1.25
X = 4 . 7 5  with 1 degree of freedom
This is significant at the 10% level. P<0.10
Key
2Contigency table for Chi test in order to determine the significance of 
32 -hors.PP detection as a pregnancy test.
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barren mares but significantly different • . day 14 pregnancy rates (Ball 
et al., 1985).
5.6 The Detection of Serum gp-hors.PP during a Donkey and Donkey-in-Horse 
Pregnancy
Once the presence of 82-hors.PP in the circulation of pregnant horses had 
been confirmed, it was of interest to investigate whether or not the 
protein was present during pregnancy in closely related species within the 
same Genus.
A series of 10 serum samples were taken from one pregnant donkey at 
different stages of gestation from day 32 to day 252. Two-dimensional 
crossed immunoelectrophoresis of each serum sample against anti-pregnant 
horse antiserum resulted in the formation of many precipitin line peaks 
demonstrating a high degree of cross-reactivity between horse and donkey 
serum proteins. Only on one occasion did a precipitate appear in the 
beta-2 area of the gel, which resembledB2~hors,PP (Fig.5.9A). That this 
could not be repeated on subsequent runs with the same sample suggests 
that the precipitate could have been an artifact. B2“hors.PP did not, 
therefore, appear to be present in the serum from that particular pregnant 
donkey or it was not detectable within the limits of sensitivity imposed 
by the detection technique.
10 serum samples were taken from a donkey-in-horse pregnancy, and clearly 
showed the existence of 82“h°rs*PP after running each sample in the 
immunoelectrophoretic system described against rabbit anti-pregnant horse 
antiserum (Fig.5.9B).
These preliminary findings suggest that $2-hors.PP may be species specific. 
If this is the case then its presence in a donkey-in-horse pregnancy may 
be indicative of a maternal origin of the protein.
130
cFig.5.9 Two-dimensional crossed immunoelectrophoresis of serum from 
a donkey pregnancy [A], a donkey-in-horse pregnancy [B] 
and a normal horse pregnancy (H10) [ C ].
[a= $2 ~hors.PP, b= Y 2 ~hors.P, antiserum= rabbit anti-pregnant 
horse].
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5.7 The Source of 3?-hors.PP
It is widely accepted that before day 14 after ovulation the equine 
conceptus produces some signal enabling the continued survival of the 
corpus luteum (Hershman and Douglas, 1979). Evidence suggests that 
oestrogens produced from the conceptus reduce the sensitivity of the 
uterus to oxytocin resulting in a decrease in the secretion of the 
luteolytic agent prostaglandin F2alpha which enables the continued 
functioning of the corpus luteum (Goff et al., 1987). Conceptus derived 
factors may, however, have other localised effects on the uterus possibly 
resulting in the secretion of further early pregnancy factors, such as 
3 2”hors.PP and MPP-1 from maternal tissue. The presence of the protein in 
a donkey-in-horse pregnancy and its apparent absence in a donkey pregnancy 
may be taken as preliminary evidence for a maternal source of 82-hors.PP. 
More concrete evidence for this theory was required and this led to an 
investigation of the factors present in uterine flushings and endometrial 
extracts.
5.7.1 Immunoelectrophoresis of Horse Uterine Flushings
Approximately 4 litres of Dulbecco’s modification of Eagles medium (DMEM) 
was flushed through the uterus of a horse (H9) that had been sired by a 
stallion 6 days previous. The flushings were collected in measuring 
cylinders (2 litre volume) and allowed to stand for approximately 15 min. 
to allow any fertilised eggs or tissue present, to sediment. The DMEM 
was aspirated from the measuring cylinders leaving approximately 100 ml of 
liquid at the bottom of the cylinders. The fertilised egg was then 
located by the microscopical examination of the uterine flushings after 
which it was used in embryo transfer work at the Equine Fertility Unit in 
Cambridge.
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The remaining uterine flushings were pooled, extensively dialysed against 
PBS, concentrated by a factor of 10 by freeze drying and dialysed again. 
The resulting uterine flushing concentrate was electrophoresed against 
rabbit anti-pregnant horse antiserum in immunoelectrophoresis. After 
staining, a precipitin line was visible in the beta2 area of the gel, 
indicating that 82-hors.PP was present. The peak was, however, very faint 
and could not be seen by photography. It is likely that the proteins 
were present in very low concentration in the flushings but as these were 
reconstituted in a small volume (approx. 200 ul), it was not possible to 
concentrate them further. It is also possible that the freeze drying 
process decreased the antigenicity of the proteins. The flushings used in 
this study were obtained from one horse (H9). Serum samples were not 
taken from this individual around the time of flushing and thus the 
possible presence of82-hors.PP in the serum could not be investigated. For 
future investigations of this nature, flushings from a number of pregnant 
horses should be pooled and concentrated to give an enriched flushing 
concentrate. The above results indicate that32~hors.PP may be of uterine 
origin although this requires further clarification,
5.7.2 The Immunoelectrophoresis of Horse Placental/Uterine Extracts
from Tissues Taken during the eCG Phase of Pregnancy 
(day 60 and day 80)
In order to try and identify the tissue responsible for 82-hors.PP 
secretion, a number of placental/endometrial extracts were electrophoresed 
in the system described.
Implantation and the establishment of the equine placenta are 
characterised by the invasion of the maternal endometrium by trophoblast 
cells which develop into the endometrial cups. In order to investigate a
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possible physiological role of ^-hors.PP during the establishment of 
placentation, the endometrial/placental extracts to be immuno- 
electrophoresed were taken during the eCG phase of pregnancy.
Placental and uterine tissues were obtained from a 60 day (after mating) 
pregnant mare (HI1) post-mortem. Additional placental tissue samples were 
taken from a second horse (H12) whose pregnancy was terminated at day 80 
(after mating). After preparation of the homogenates, all samples were 
diluted to a protein concentrations of 0.6 mg/ml. A summary of the tissue 
source and day of gestation of these homogenates is shown in Table 5.2. 
All samples were electrophoresed in two-dimensional crossed immuno­
electrophoresis against rabbit anti-pregnant horse antiserum. Serum taken 
from the eCG phase of gestation of a pregnant mare (day 83) was 
electrophoresed simultaneously as a positive control.
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Table 5.2
Source of Homogenate Day of Gestation
(0.6 mg/ml) (after mating)
Pregnant horn endometrium Day 60
Endometrial cup homogenate Day 60
Non-pregnant horn endometrium Day 60
Pregnant horn allantochorion with Day 80
endometrial cup secretion
Pregnant horn allantochorion with Day 80
no visible cup secretion
Non-pregnant horn allantochorion Day 80
Placental/uterine extracts taken from two pregnant mares (Hll: day 60 
H12: day 80)and used in two-dimensional crossed immunoelectrophoresis
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Using this methodology, 82”hors .PP could not be identified in any of the 
samples taken either at day 60 or day 80. At day 60, no eCG was detected 
in the non-pregnant horn endometrium (Fig.5.10D). Both pregnant horn 
endometrium (Fig.5.10B) and endometrial cup homogenate (Fig.5.10C) 
produced virtually identical patterns after immunoeletrophoresis, both 
showing the presence of eCG. All three samples revealed a second 
predominant peak in the alphas area of the gel in the position of 
albumin.
At day 80, no eCG was detected in the non-pregnant horn allantochorion 
(Fig.5.12D). Two different anti-pregnant horse antisera were used in the 
immunoelectrophoresis of the day 80 samples. Both pregnant horn 
allantochorion with endometrial cup secretion and the same tissue without 
visible cup secretion, showed the presence of eCG particularly with 
antiserum 1 (Fig.5.11B, C). The electrophoretic mobility of eCG did show 
some variation which may be attributed to a variable glycosylation of the 
molecule. The carbohydrate component of eCG is large, approaching 45% by 
weight (Moore et al. , 1980). In addition, it is reported that the 
molecule occurs in different forms, indeed the circulating form of the 
molecule is more highly glycosylated than that isolated from endometrial 
cups (Aggarwal et al., 1980). In addition to eCG and albumin, day 80 
pregnant horn allantochorion with cup secretion produced a number of other 
precipitin line peaks post-immunoelectrophoresis with both antisera. 
Antiserum 1 resulted in a further 4 peaks in addition to eCG and albumin 
(Fig.5.11B). Antiserum 2 revealed a total of 10 precipitin line peaks, six 
of which were very sharp and clear (Fig.5.12B). However, none could be 
identified as $2~hors.PP. These results contrast sharply with pregnant 
horn allantochorion with no endometrial cup secretion which gave one clear 
precipitin line identified as albumin and perhaps another peak of
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Fig. 5.10 Two-dimensional crossed immunoelectrophoresis of horse placental 
and uterine extracts taken at day 60 of gestation.
[a= $2 -hors-pP ’ b= Y2-h°rs-P> X- eCG, antiserum= rabbit anti- 
-pregnant horse]
A: Day 83 pregnant horse serum (Control)
B : Pregnant horn endometrium
C: Endometrial cup homogenate
D: Non-pregnant horn endometrium
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Fig.5.11 Two-dimensional crossed immunoelectrophoresis of horse 
allantochorion extracts taken at day 80 of gestation - 
rabbit anti-pregnant horse antiserum 1.
[a= $2 -hors.PP, b= Y 2 “hors.P, X= eCG]
A: Day 114 pregnant horse serum (Control)
B : Pregnant horn rich with endometrial cup secretion 
C: Pregnant horn - little endometrial cup secretion.
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Fig. 5.12 Two-dimensional crossed immunoelectrophoresis of horse 
allantochorion extracts taken at day 80 of gestation - 
rabbit anti-pregnant horse antiserum 2.
[a= $2“hors.PP, b= Yg-hors.P, X= eCG]
A: Day 83 pregnant horse serum (Control)
B : Pregnant horn rich with endometrial cup secretion 
C: Pregnant horn - little endometrial cup secretion 
D: Non-pregnant horn allantochorion
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unknown identity (Figs.5.11C, 5.12C). Similarly, only one peak could be 
seen in the position of albumin when non-pregnant horn allantochorion was 
immunoelectrophoresed (Fig.5.12D).
These results suggest that eCG may be one of a number of factors produced 
by the endometrial cups. That many of these factors are detected by an 
antiserum raised against the serum of a pregnant mare may, however 
indicate that the sample was contaminated with serum protein. Indeed, one 
of the peaks corresponds to the position of a 2-macroglobulin and another 
to that of IgM.
With respect to 32~hors.PP, it was not possible to investigate the 
presence of the protein in the serum of the animals from which the tissue 
was taken as the appropriate serum samples could not be obtained from the 
Equine Fertility Unit.
In conclusion, it appears that B2~hors.PP is either not present or is not 
produced in high enough concentrations to be detected in any of the eCG 
phase tissue extracts investigated. Furthermore, the tissue homogenates 
were prepared without any extensive washing of the tissue (Section 4.9.1) 
and thus it is unlikely that the protein was leached out of the tissue 
during extract preparation. Two lines of evidence indicate, however, that 
32“hors.PP is °f uterine origin. Firstly, the protein is present in 
maternal serum taken from a donkey-in-horse pregnancy and does not appear 
to be present during a donkey pregnancy. Secondly, f^-'hors.PP has been 
detected in uterine flushings taken from a horse (H9) 6 days after mating 
with a stallion. The uterine origin of $2“hors.PP, however, still 
requires furtherinvestigation. Additional evidence may be obtained by 
immunoeletrophoresing uterine extracts taken earlier during pregnancy,
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i.e. before the eCG phase. Such endometrial tissue can, however, only be 
taken as a consequence of a post-mortem examination and is thus difficult 
to obtain.
5.8 The Partial Purification of 67-hors.PP
Approximately 20% of total circulating proteins in human plasma have been 
observed to bind to a immobilised heparin, the majority of which can be 
eluted by increasing the salt concentration to 0.45 M NaCl (Teisner 
et al., 1983). These authors suggest that heparin affinity
chromatography may be an effective procedure for the isolation and 
purification of each interacting protein. Heparin affinity has already 
been used in the isolation and purification of two human pregnancy 
associated proteins (PAPP-A and PP-5) (Teisner et al., 1983; Salem et al., 
1980) and thus may be useful in the purification of equine pregnancy 
associated proteins. In the same report, Teisner et al. showed that the 
interaction of proteins with heparin in two dimensional crossed immuno­
electrophoresis can be used to predict the outcome of heparin affinity 
chromatography. Consequently, in order to investigate whether $2-hors.PP 
interacted with heparin, pregnant mare serum was immunoelectrophoresed 
using heparin in the first dimension gel.
5.8.1 Investigation of an Interaction between Heparin and the Horse 
Proteins ($?-hors.PP and Y?-hors.P)
A stock solution of 300 U/ml heparin was prepared. Different amounts of 
this were mixed with molten agarose prior to pouring and gels containing 
21, 30 and 60 units of heparin per ml gel were poured in the usual way. 
Pregnant mare serum was electrophoresed in the first dimension in each gel 
and subsequently run against rabbit anti-pregnant horse antisera in the 
second dimension. In addition, a control immunoeletrophoresis plate was 
run with no heparin in the first dimension gel.
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32-hors.PP and Y2”hors.P were identified in all gels. The electrophoretic
mobility of the proteins was unaltered in the first dimension but the
peaks appeared to increase in height in the second dimension as the
concentration of heparin increased in the first dimension gel (Fig. 5.13). 
This was confirmed by measuring the area under $2“hors.PP and y2“^ors‘^  
and comparing them to the area under the a2~roacroglobulin peak as 
described in Section 5.4 (Table 5.3). ct2-macroglobulin has been shown not 
to interact with heparin (Teisner et al., 1983). The peak areas outlined 
in Table 5.3 suggest that there is an increase in the relative peak areas 
for both 32_hors.PP and Y2“hors.P as the concentration of heparin in the 
first dimension increases.
In conclusion, heparin has no effect on the electrophoretic mobility of 
B2"hors.PP and Y2”h°rs«P the first dimension. The presence of heparin 
in the first dimension gel, however, increased the size of the 32“*hors.PP 
and Y2~hors.P second dimension peaks indicating that there was an 
interaction between heparin and the equine proteins. As peak height is 
directly proportional to antigen concentration, it is possible that the 
binding of heparin to the proteins results in an increase in the number of 
available epitopes.
5.8.2 Partial Purification of 3?-hors.PP by Heparin Affinity Chromatography
The above data illustrates that there is some interaction between heparin 
and 32~hors.PP. In order to partially purify 32“hors.PP, l.O.mlof pooled 
pregnant mare serum was passed through 5 ml of washed heparin Ultrogel. 
Once all of the unbound protein had been washed from the column by washing 
with distilled water (Fig.5.14a), the bound protein was eluted from the 
column using a stepped salt gradient of 0.2 M, 0.4 M, 0,6 M, 1.0 M NaCl 
(Fig.5.14b). The most concentrated fractions from each peak were pooled,
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Fig.5.13 Two-dimensional crossed immunoelectrophoresis of pregnant 
mare serum with heparin incorporated into the first 
dimension gel.
A (Control), B (21 U/ml gel), C (30 U/ml gel), D (60 U/ml gel) 
[a= 39~hors.PP, b= Yo-hors.P]
, 7•'i 1 I.
I f (A. ~ 1 f  ^
As *
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Table 5.3
Heparin in First 
Dimension Gel
32 Ratio Y 2 Ratio 
x + 6n-l of 2 positions of base line
0 (Control) 7.23+0.47 36.34±9.13
21 u/ml 6.94+1.97 40.97±0.98
30 u/ml 7.82+1.63 45.74+0.58
60 u/ml 11.00+5.97 106.72±1.77
The effect of heparin in the first dimension gel on the size of the 
32~hors.PP and Y2~hors.P second dimension peaks.
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dialysed and concentrated by freeze drying. Each pooled peak, the wash 
and the original sample were then electrophoresed in two-dimensional 
crossed immunoelectrophoresis against rabbit anti-pregnant horse 
antiserum. The results showed that B2“hors.PP and Y2“hors.P appeared to 
be eluted from the column with 0.2 M NaCl (Fig.5.15), However, when this 
experiment was repeated and 2 ml of pooled mare serum was passed through a 
10 ml column of heparin Ultrogel these two pregnancy proteins were not 
retained in the column but were slightly retarded in the wash.
One cause of the apparent variable heparin affinity of the proteins could 
be the salt concentration of the original sample - physiological saline is 
0.15 M with respect to NaCl and this approaches closely the molarity at 
which the proteins were first eluted. To investigate whether reduction of 
the salt concentration of serum enhanced the heparin binding capacity of 
the proteins, a 2 ml sample of serum from a pregnant mare was dialysed 
against 5 1 of distilled water. 1 ml of this dialysed sample was passed 
through 5 ml of heparin Ultrogel and 3 ml fractions collected. The wash 
and fractions eluted with 0.2 M NaCl were dialysed, freeze dried and 
redissolved in 300 ul of distilled water and immunoelectrophoresed as 
before. (32“‘h°rs • PP an(* Y2”h°rs*P appeared to be present in the 0.2 M 
eluent. Assuming that the observed precipitin lines were $2“hors.PP and 
Y2~hors.P, this experiment indicates that the salt concentration has 
some effect on the heparin binding capacity of the two proteins. 
Furthermore, the close biochemical relationship of B2~hors.PP an(  ^
Y2“hors.P is emphasized by the fact that they are always eluted together 
in an affinity experiment such as this.
The use of a weak heparin affinity for the partial purification of
proteins has proved problematic for other researchers (Teisner et al.,
1983). It has been reported that if a protein comes through a heparin
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Fig.li. 14(a) Elution profile - serum sample from pregnant mare passed through hepar: 
ultrogel column (peaks represent non-bound p ro te in ).
CM
©-lOIDCvjS
CO
C\J
OCUJCQ<cocU_
bX)
•rHPt,
WU08Z-3DNVVWSVY147
.5.14(b) Elution profile - serum sample from a pregnant mare passed through heparin 
ultrogel column (peaks represent bound protein).
Fig.5.
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%
/ \ 1 a
i Two-dimensional crossed immunoelectrophoresis of 0.2 M 
eluent obtained from the heparin affinity chromatography 
of a pooled serum sample from a number of pregnant mares 
[a= 32-hors.PP, b= Y2 ~hors.P]
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affinity column in the void volume, then an interaction with heparin is by 
no means ruled out (Teisner et al., 1983). In the same report, Teisner 
postulates that affinity may be affected by column dimensions and some 
proteins may only be slightly retarded in the void volume, e.g. complement 
factors.
It appears from the above that heparin affinity chromatography could be 
used to partially purify 32-hors.PP. The variable heparin affinity of the 
protein, however, requires further investigation so that the purification 
conditions can be optimised.
5.8.3 Development of an Oligospecific Antiserum for 3?-hors«PP
An oligospecific antiserum for f3 2“h°rs.PP and Y 2"hors.P would be useful in 
the identification of the proteins in various tissues and also in their 
immuno-purification. Precipitin line immunization and the adsorbing of 
antisera raised against serum from a pregnant mare with virgin horse serum 
were two techniques used to try and obtain such an antiserum.
5.8.3.1 Precipitin Line Immunization
This technique requires the removal of precipitin lines from an agarose 
gel after two-dimensional crossed immunoelec trophoresis . Consequently, 
attempts were made to increase the clarity of the peaks by using different 
quality agarose. Special precautions concerning the choice of gel quality 
are necessary when analyzing proteins with known heparin interactions 
because the sulphate groups of agarose have protein binding properties 
similar to those in commercial heparins (Laurell and McKay, 1981). Such 
proteins can only be analysed reliably by precipitation techniques if 
highly purified agarose with a sulphate content of less than 0.01% is 
used. Pregnant mare serum was electrophoresed in two-dimensional crossed 
immunoelectrophoresis using a low sulphate containing agarose (Sigma-Type
149
VIII) for both dimensions.- The resulting peaks, however, were very large 
and diffuse which suggests that the sulphate groups in the agarose play an 
important role in the precipitation process (Fig.5.16). When the 
experiment was repeated using low sulphate containing agarose for the 
first dimension and normal agarose for the second, to aid precipitation, 
the peaks were of a better size but the equine pregnancy proteins could 
not be identified. Subsequently, normal agarose (Type II) was used for 
the identification and removal of precipitin lines for immunization.
Pregnant mare serum was immunoelectrophoresed against rabbit anti-pregnant 
horse antiserum. The $2“hors.PP and Y2-hors.P precipitin lines were 
removed from the gel and solubilized as described in Section 4.7. A New 
Zealand white rabbit was immunized with the 32-hors.PP and Y2~hors.P 
antigen-antibody complex following the protocol outlined in Section 4.3.1. 
A total of 6 precipitin lines were solubilized in 1 ml of KI and thus 3 
precipitin line equivalents (32“hors.PP and Y2~hors.P) were used for the 
primary immunization and subsequent booster immunizations. After the 
second booster immunization and after each subsequent booster, the rabbit 
was bled and antiserum obtained (Section 4.3.2). Pregnant mare serum 
known to contain 32“hors.PP andY2~hors.P was immunoelectrophoresed against 
various concentrations of each preparation of the antiserum. Despite 
repeated immunoelectrophoretic runs, no precipitin lines were observed, 
and there was no evidence of an oligospecific antiserum against 
32-hors.PP and Y2“hors.P.
The most likely reason for this is that the amount of protein immunized 
may have been too low to induce antibody production. Another possibility 
is that as antigen-antibody complex was immunized instead of antigen, the
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Fig. 5.16 Two-dimensional crossed immunoelectrophoresis of pregnant 
mare (H3) serum in two types of agarose gel.
A: Type II
B: Type VIII [low sulphate content]
ar/t*\
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epitopes of the antigen may have been masked by the antibody component of 
the complex*
5.8.3.2 Adsorbing Antisera with Virgin Horse Serum
Complete adsorbtion of rabbit anti-pregnant horse antiserum was 
unsuccessful. Antisera passed through Sephacryl S-300 linked to virgin 
horse serum was used in two dimensional crossed immunoelectrophoresis 
using virgin and pregnant serum as the antigen source. Precipitates in 
the alpha^ region of the plate were, however, formed in both cases. 
However, in view of the close immunological relationship of 32-hors.PP and 
Y2“*hors.P, the removal of specificities to one of the proteins by 
adsorption of the antisera would probably remove specificities to the 
other. Consequently, the above results were not unexpected.
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CHAPTER -6-
INVESTIGATIONS INTO THE BIOLOGICAL ACTIVITIES ASSOCIATED WITH 
PLACENTAL AND ENDOMETRIAL TISSUES OF THE HORSE
6.1 Introduction
Local immunosuppressive mechanisms are thought to play a critical role in 
the immunoprotection of the mammalian foetal allograft (Clark et al., 
1987; Chaouat, 1987), Research in this area has, however, largely 
focussed on mammals with haemochorial placentation particularly the human 
and mouse. Conversely, analogous research in mammals with 
epitheliochorial placentation has been very limited. The establishment of 
the equine epitheliochorial placenta is of particular interest in view of 
the endometrial cup reaction unique to the genus Equus. During this 
period, the foetal stimulus to the mother is maximal (Allen et al., 1986) 
and it is thought that local immunosuppressive mechanisms may play an 
important role in the protection of the equine foetus (Antczak and Allen,
1984). There is evidence to show that at least one population of T cells 
attracted to the endometrial cups have suppressor rather than cytotoxic 
activity (Kydd and Allen, 1986). Furthermore, preliminary in vitro 
studies suggest that the principal secretory component of the cups, equine 
chorionic gonadotrophin (eCG), may suppress lymphocyte proliferation (Kydd 
and Allen, unpublished). The effects of extracts of equine placental and 
uterine tissues on lymphocyte proliferation and the inhibitory mechanisms 
of the factors on this proliferation have not previously been reported. A 
major objective of this section of work was to evaluate the inhibitory 
effects of specific maternal and foetal tissues on lymphocyte 
proliferation.
The in vitro tests used to assess lymphocyte proliferation were the 
allogeneic two way mixed lymphocyte reaction (MLR) and the mitogen 
stimulation assay (MSA) using Concanavalin A (Con.A) as the mitogen. In 
both assays, lymphoproliferation was assessed by measuring the uptake of 
^H-Tdr into the DNA of the proliferating lymphocytes (Section 6.3). The 
inhibitory effect of a sample on lymphocyte proliferation was taken as 
evidence of an immunosuppressive effect. The MLR is considered to be 
a better test for immunosuppressive activity in that the assay conditions 
approximate those that occur during in vivo lymphocyte stimulation and 
proliferation. In this assay, two populations of cells are stimulated to 
proliferate by foreign MHC class II antigens on the cells surface of the 
opposite population. In the context of pregnancy, the MLR can be used as 
a model of maternal cell mediated immunity. The suppression of the MLR by 
placental extracts can be described as an in vitro model of the graft 
-versus-host reaction.
The first part of this Chapter deals with the effect of the lectin Con.A 
on equine lymphocytes. This is followed by the major section dealing with 
the effects of eCG phase maternal and foetal tissues on lymphocyte 
proliferation. Finally the inhibitory activity of term placental tissue 
is investigated and the results compared to activities of analogous 
tissues taken earlier in gestation (eCG phase).
6.2 The Mitogenic Stimulation of Equine Lymphocytes with Concanavalin A 
(Con.A)
All mitogen stimulation assays (MSA's) used in this work were set up using 
the lectin Con,A as the response of equine lymphocytes to 
phytohaemaglutinin (PHA) has been reported to be very variable (Lazary et 
al., 1973a).
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Con.A is a mitogenic lectin with a specificity for the sugars aD-Mannose, 
ot—D-*Glucose and D-Fructose, As a consequence of their carbohydrate 
specificity, a number of lectins can activate from 30 to 60% of cells and 
are thus often referred to as polyclonal activators. No information is 
currently available regarding the mechanism of action of Con.A. It is 
reported, however, that antibodies against the sheep red blood cell 
receptor (CD2 antigen) block cell proliferation in response to PHA but not 
in response to Con.A (O'Flynn et al., 1985). This demonstrates that the 
two lectins mediate their effects on the cell via different cell surface 
receptors.
Equine lymphocyte cultures at a concentration of 1 x 10^ cells/ml were 
incubated with different concentrations of Con.A ranging from 0 to 16 
ug/ml culture fluid. To determine the optimum mitogenic concentration of 
Con,A, tritiated thymidine incorporation by triplicate cultures (expressed 
as mean counts per minute) was plotted against the final concentration of 
Con,A in each culture. This procedure was carried out with lymphocytes 
from two different horses and both sets of results are shown in Fig.6.1. 
The maximum response was achieved with a mitogen (Con.A) concentration of 
2 ug/ml culture fluid and this concentration was selected for further 
mitogen stimulation studies. In both horses, the sensitivity of the 
lymphocytes appeared to be the same although the magnitude of response 
varied. Increasing concentrations of Con.A from 0 to 2 ug/ml resulted in 
an increase in lymphocyte proliferation as measured by tritiated thymidine 
uptake. As the concentration of Con.A was increased beyond 2 ug/ml, the 
degree of lymphocyte proliferation decreased until no proliferation 
occurred at concentrations of 8-12 ug/ml.
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Concanavalin A. (ug/ml culture flu id)
F ig .6.1 The effect of different concentrations of Con.A on equine lymphocyte 
proliferation; determination of maximum mitogenic concentration. 
Results are expressed as means ± standard error of each calibration. 
(n=2)
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There are no published data on the dose-response relationships of equine 
lymphocytes to Con,A. However, this appears to be similar to the observed 
effect of mitogens on human lymphocyte proliferation, only in the later 
case, the decline in the proliferative response at high mitogen 
concentrations is more gradual and tends to tail off so that there is 
always some response (Pockley and Bolton, personal communication). High 
concentrations of the mitogen were shown not to be cytotoxic. It is 
thought that as more mitogen is added to a cell culture, the more mitogen 
will become bound to the cell surface. Consequently, it is possible that 
this will interfere with the production and/or interaction of the 
cytokines with the cell surface.
The sensitivity of mammalian lymphocytes to Con.A under optimal conditions 
has been reported to vary between 10,000 and 200,000 CPM/culture 
(Kristensen et al., 1982).
6.3 Assessing the Inhibitory Activity of Biological Samples on Lymphocyte 
Proliferation: Control Cultures
The incorporation of ^H-Tdr into the DNA of the control cultures (those 
containing no tissue extract) of mitogenically and allogeneically stimulated 
lymphocytes was taken as 100%. Incorporation into cultures incubated 
with tissue samples was compared with these values. Each such 
experiment was carried out in triplicate. Non-specific (background) 
stimulation of the lymphocytes, as assessed by the uptake of ^n-Tdr into 
unstimulated lymphocytes either in the absence of Con,A (MSA) or in 
lymphocytes from one donor (MLR), was generally less than 20% of this 
control value for the mixed lymphocyte reaction and less than 5% for the 
Con.A stimulated lymphocytes when the final concentration of Con.A was 2.0 
pg/ml. In a few instances, non-specific stimulation was as high as 60%, 
particularly in the MLR, where the cell numbers in each culture were twice
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that of the MSA cultures. It has been reported, however, that freshly 
prepared lymphocytes are not necessarily in the Gg phase of the cell cycle 
(resting) but may already have reached a later phase already committed to 
proliferation due to an unknown endogenous stimulus (Kristensen et al., 
1982). Consequently these cells will have a high thymidine uptake until 
the cycle has passed, or might maintain a high activity as a consequence 
of further cell proliferation (Bodeker et al., 1980; Kristensen et al., 
1982).
Significance levels referred to in the text were calculated using 
Student’s t test.
6.3.1 Assessing the Cytotoxic Effects of Samples Incorporated into 
Lymphocyte Cultures 
All placental and endometrial extracts used in this research were 
incubated with 2 x 10® cell for 6 days. After this period, the viability 
of the lymphocytes was assessed by using the Trypan Blue exclusion method. 
The percentage of viable cells in all treated cultures was not 
significantly different to that in control cultures suggesting that the 
samples were not cytotoxic to the lymphocytes.
6.4 The Inhibitory Effect of eCG on Lymphocyte Proliferation as Assessed 
by the MLR and MSA
A majority of placental samples used in this study were taken during the 
eCG phase of equine pregnancy and thus some samples were expected 
to contain measurable amounts of this hormone. As preliminary in vitro 
studies suggested that eCG may have an immunosuppressive effect (Kydd and 
Allen, unpublished), it was deemed appropriate to confirm and further 
investigate these findings.
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eCG obtained from ’Intervet1 was extensively dialysed to remove the sugar 
stabiliser. Con.A-stimulated equine lymphocytes and mixed lymphocyte 
cultures were incubated with concentrations of 0-40 iu/ml eCG throughout 
the entire culture period.
In the MLR, a dose-dependent inhibition of lymphocyte proliferation was 
observed (Fig.6.2). A significant inhibition occurred between 5 and 
10 iu/ml (P<0.10). Increasing eCG concentrations beyond 10 iu/ml resulted 
in a plateau with no further increase in inhibitory activity and this 
maximal inhibition was less than 100%.
In the MSA, a dose-dependent inhibition of lymphocyte proliferation 
occurred between eCG concentrations of 10 and 40 iu/ml (Fig.6.3). The 
difference in the inhibitory effect of eCG at each of these concentrations 
was found to be significant (P<0.02), Furthermore, maximal eCG 
concentrations tested were found not to induce 100% inhibition.
eCG is documented as containing 45% carbohydrate consisting of 14.3% 
hexose, 20.6% hexosamine and 10.2% sialic acid (Schams and Papkoff, 1972). 
Moreover, Con.A has a specificity for the hexoses a-D-mannose and 
a-D-glucose as well as D-fructose. It is possible therefore that eCG may 
inhibit the MSA by binding to the Con.A and thus preventing an interaction 
between the mitogen and the cell surface.
The inhibitory effect of eCG in the two way MLR is indicative of an 
immunosuppressive effect of the hormone preparation. That eCG did not 
induce 100% inhibition in either the MLR or MSA suggests that the hormone 
does not inhibit the proliferation of all cell populations in culture. 
Furthermore, the inhibitory effects of eCG at 40 iu/ml in both the MLR and
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F ig .6.2 The effect of eCG, related to hormone activity, on the inhibition of H-thymidine 
uptake by mixed lymphocyte cultures. C.P.M. in control cultures = 56,500. 
Results are expressed as means ± standard error, (n=2).
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F ig .6.3 The effect of eCG, related to hormone activity, on the inhibition of H-thymidine 
uptake by Con.A stimulated lymphocytes. C.P.M. in control cultures = 170,000. 
Results are expressed as means ± standard error, (n=2).
MSA were not significantly different (P>0.10). This suggests that eCG was 
not binding to the Con.A in the MSA and could be inhibiting 
lymphoproliferation in both assays via similar mechanisms.
The above data confirms the earlier findings of Kydd and Allen 
(unpublished) and may be indicative of an immunosuppressive role of the 
hormone. During placentation, eCG is secreted directly into the uterine 
lumen between the trophoblast and endometrial epithelium as an exocrine 
endometrial cup secretion suggesting that any immunomodulatory role would 
be local.
6.5 The Effect of Maternal/Foetal Tissues, Taken during the eCG Phase 
of Pregnancy, on Lymphocyte Proliferation
Samples of tissue were obtained from two pregnant mares at days 60 
(Hll)and 80 (H12) of gestation. These particular days represent key 
stages of the endometrial cup reaction, i.e. at day 60, the endometrial 
cups are healthy, active and maximal amounts of eCG are found in the 
maternal circulation. At day 80, serum eCG levels have fallen and the 
cups are starting to degenerate. The ability of all tissue extracts to 
inhibit lymphocyte proliferation was assessed and the apparent immuno­
modulatory activity of the tissues and their importance in local immuno­
suppression during the endometrial cup reaction was evaluated.
6.5.1 eCG and Progesterone Concentrations of Endometrial and Placental 
Tissue Extracts Taken at 60 Days of Gestation 
A horse, 60 days pregnant, was sacrificed and the uterus removed. Maternal 
and foetal tissue extracts, prepared as described in Section 4.9.1, were 
diluted to 0.6 mg protein per ml and assayed for eCG and progesterone by 
ELISA (Table 6.1). eCG is produced by the endometrial cups and 
consequently the endometrial cup homogenate contained more eCG than the
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Table 6.1
SAMPLE (0.6 mg/ml) eCG (iu/ml) Progesterone (ng/ml)
PREGNANT HORN 
ENDOMETRIUM
n/d 0.1
NON-PREGNANT HORN 
ENDOMETRIUM
n/d 0.5
PREGNANT HORN 
ALLANT0CH0RI0N
15.0 30.0
NON-PREGNANT HORN 
ALLANT0CH0RI0N
n/d 16.6
ENDOMETRIAL CUP 
HOMOGENATE
70.5 0.8
AMNION 4.6 0.7
eCG and progesterone concentrations of day 60 placental and endometrial 
extracts as determined by ELISA. Values are means of duplicates, working 
range of eCG assay: 3-200 iu/ml, recommended range of standards for 
progesterone assay: 1-10 ng/ml. (n/d = not detectable).
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other samples, in this case 70.5 iu/ml. Pregnant horn allantochorion also 
contained detectable levels of eCG at 15.0 iu/ml. No eCG was detected in 
the pregnant horn endometrium as the cups are only beginning to secrete 
into the surrounding tissues at day 60 and the tissue itself was not taken 
in the endometrial cup region. eCG could not be detected in non-pregnant 
horn endometrium and allantochorion as placentation and thus endometrial 
cup formation is localised in the pregnant horn. The presence of 4.6 iu/ml 
of eCG in the amnion extract can be attributed to eCG contamination which 
occurred during the dissection of the uterus within the confinement of a 
pyrex dish.
The incorporation of the above samples into an MLR or MSA would result in 
a 1 in 5 dilution of the extracts. Consequently, the incorporation of 
undiluted endometrial cup homogenate into such an assay would result in a 
final eCG concentration of 14,1 iu/ml. As discussed in Section 6.4, this 
level of eCG would result in approximately 70-75% inhibition in the MLR and 
around 20% inhibition in the MSA. The incorporation of undiluted pregnant 
horn allantochorion extract into a similar assay would result in a final 
eCG concentration of 3.0 iu/ml which would not inhibit lymphocyte 
proliferation in either assay.
The highest level of progesterone was found in the pregnant horn 
allantochorion extract (30.0 ng/ml) and a measurable level of the hormone 
was found in the non-pregnant horn allantochorion extract (16.6 ng/ml). 
Levels of the hormone in the other tissues were negligeable. Progesterone 
is produced by the equine placenta from the third month of gestation 
onwards (Allen, 1975). Furthermore, it has been demonstrated that foetal 
membranes can secrete the hormone before this time (Marsan e t a l ., 1987).
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This may explain why the hormone was detectable in the allantochorion 
extracts but not detectable in the maternal tissue or endometrial cup 
extracts.
Although the effect of progesterone on equine lymphocytes has not been 
published, Murray and Chenault (1982) found that bovine lymphocyte 
proliferation was not affected by progesterone. However, in the 
human, progesterone has been reported to inhibit human lymphocyte 
proliferation in both the MSA and MLR (Clemens et al., 1979), although at 
concentrations of between 1 and 20 'jjg/ml. It therefore seems unlikely 
that the 30 ng/ml of progesterone measured in the pregnant horn 
allantochorion would have a significant inhibitory effect on lymphocyte 
proliferation. Furthermore, the incorporation of the tissue extract into 
the lymphocyte cultures further diluted the progesterone concentration to 
6 ng/ml. Progesterone levels are in fact lower in epitheliochorial 
placentae than in haemochorial placentae (Stites and Siiteri, 1983) which 
suggests that any direct immunomodulatory role progesterone might have is 
less important in epitheliochorial placentae.
6.5.2 The Inhibition of Lymphocyte Proliferation by Endometrial Extracts
and Endometrial Cup Homogenate Taken from a Day 60 Pregnancy, as 
Assessed by the MSA and MLR
Studies of pregnancy associated immunosuppression in the horse has been 
limited to an investigation of suppressive activity associated with the 
lymphocytes that accumulate around the cups throughout their 80-100 day 
lifespan. When the cells were recovered between days 55 and 70 of 
gestation, they were found to suppress the normal mitogenic response of 
peripheral blood lymphocytes from the dam and unrelated horses (Kydd and 
Allen, 1986). In the human and mouse, however, a number of factors with 
immunomodulatory activity have been described in decidual/endometrial
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tissue (Clark et al, , 1984; Parhar and Lala, 1986; Bolton e t al. ,
1986). As pregnancy in these species is typified by the establishment of 
a haemochorial placenta, it was of interest to investigate the presence of 
analogous or similar factors in a species exhibiting epitheliochorial 
placentation (Chapter -1-). Consequently the immunomodulatory activity of 
the equine endometrium was investigated further.
In the study, three samples ware incorporated into the MSA and MLR, namely 
pregnant and non-pregnant horn endometrial extract and endometrial cup 
homogenate. Each sample induced a dose-dependent inhibition of lymphocyte 
proliferation in both assays (Figs.6.4, 6.5). In the MSA, at protein 
concentrations higher than 15 ug/ml, the non-pregnant horn endometrium was 
found to have significantly more inhibitory activity than the pregnant 
horn endometrium (P<0.05). Furthermore, no significant difference was 
found between the non-pregnant and the endometrial cup homogenate in terms 
of inhibitory activity (P>0.10).
In conclusion, the inhibitory activity of each sample in the MLR is 
indicative of immunosuppressive activity. It was uncertain, however, 
whether the inhibitory activity observed in the MSA reflected immuno­
suppressive activity or a sequestering of the mitogen by glycoproteins in 
the crude extracts. The inhibitory activity of the endometrial extracts 
was not related to eCG content suggesting that inhibitory/immuno­
suppressive activity associated with this tissue can be attributed to 
other factors.
In the MSA, only about 20% of the inhibitory activity of the undiluted 
endometrial cup homogenate may be due to the eCG concentration of 14.1 
iu/ml (Fig.6.3). The majority of the inhibitory activity in the undiluted 
sample (approx 80%) and all of the inhibitory activity in the 1 in 4
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dilution of the same sample is therefore due to other unidentified factors 
(Table 6.2). It can therefore be concluded that in the MSA, the 
inhibitory activity of the endometrial cup homogenate is not related to 
its eCG content,
6.5.3 The Inhibition of Lymphocyte Proliferation by Allantochorion 
Extracts and Endometrial Cup Homogenate Taken from a Day 60 
Pregnancy, as Assessed by the MSA and MLR
Extracts of allantochorion from the pregnant and non-pregnant horns induced 
a dose-dependent inhibition of lymphocyte proliferation in both the MLR 
and MSA (Figs.6.5, 6.6). The effects of the endometrial cup homogenate on 
the MLR and MSA were discussed in Section 6,5.2. The undiluted 
allantochorion extracts were more inhibitory in the MLR than in the MSA. 
Furthermore, in the MSA the pregnant horn allantochorion extract was not 
significantly different in its inhibitory activity to the non-pregnant 
horn allantochorion extract (P>0.10). In addition, the dose-dependent 
inhibition of the endometrial cup homogenate was virtually identical to 
that of the pregnant horn allantochorion.
These data suggest that the allantochorion samples contain immuno­
suppressive factor(s). Furthermore, the inhibitory activity was not 
related to eCG content (Table 6.2), suggesting the presence of another
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F ig .6.4 The effect of day 60 endometrial extracts, related to protein content, on the inhibition of H-thymidine 
uptake by Con.A stimulated lymphocytes. Samples used were endometrial cup homogenate (■), pregnant 
horn endometrium (O) and non-pregnant horn endometrium (• ) . C.P.M. in control cultures = 87,300. 
Results are expressed as means ± standard error, (n=4).
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F ig .6.5 The effect of day 60 placental and uterine extracts, related to protein content, on the inhibition of
H-thymidine uptake by mixed lymphocyte cultures. Samples used were endometrial cup homogenate ( • ) ,  
pregnant horn endometrium (O), pregnant horn (A) and non-pregnant allantochorion (■). C.P.M. in 
control cultures = 28,600. Results are expressed as mean incorporation into triplicate cultures (n = l).
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F ig .6.6 The effect of„day 60 allantochorion and endometrial cup homogenate, related to protein content, on the 
inhibition of H-thymidine uptake by Con.A stimulated lymphocytes. Samples used were pregnant horn 
allantochorion (• ) , non-pregnant horn allantochorion (O) and endometrial cup homogenate (■ ).
C.P.M. in control cultures = 87,300. Results are expressed as means ± standard error, (n=4).
Table 6.2
Sample Protein
ug/ml
eCG
iu/ml
Progesterone
ng/ml MSA
% inhibition 
(n=4) MLR (n=l)
PREGNANT HORN 15 n/d n/d 4.1 ± 2.5 55.7
ENDOMETRIUM 30 n/d n/d 11.1 + 4.3 49.4
60 n/d n/d 21.7 + 5.9 69.6
120 n/d n/d 55.8 + 5.1 86.6
ENDOMETRIAL CUP 15 1.762 0.020 20.5 + 6.4 0.0
HOMOGENATE 30 3.525 0.040 27.2 + 4.4 12.5
60 7.050 0.080 45.9 ± 1.9 52.6
120 14.100 0.160 70.1 + 6.5 95.7
PREGNANT HORN 15 0.375 0.750 12.3 ± 4.7 0.0
ALLANTOCHORION 30 0.750 1.500 25.2 + 6.1 4.8
60 1.500 3.000 42,5 + 8.4 18,5
120 3.000 6.000 76.5 +10.8 99.4
NON-PREGNANT HORN 15 n/d 0.415 9.4 + 3.3 0.0
ALLANTOCHORION 30 n/d 0.830 20.4 + 7.2 0.0• 60 n/d 1.660 33.7 + 6.4 78.8
120 n/d 3.320 68.7 + 8.0 99.6
Relative inhibitory potencies of day 60 samples in the MLR and MSA as 
related to protein content and including eCG and progesterone levels.
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inhibitory/immunosuppressive factor(s) associated with the allantochorion.
At day 60, the allantochorion will not extend very far into the non-✓
pregnant horn of the uterus and thus there should be little difference in 
the secretory activity of the tissues (Allen, personal communication). 
This appears to be reflected in the above data as no significant 
difference was found between the inhibitory activities of the pregnant 
horn and non-pregnant horn allantochorion extracts. The similarity 
between the inhibitory activity of the pregnant horn allantochorion and 
the endometrial cup homogenate may reflect the close biological 
relationship of the tissues, that is the endometrial cups are derived from 
modified allantochorionic cells (Allen et al., 1973). The reason for 
differing levels of inhibition between the MLR and MSA with undiluted 
samples is uncertain. This may reflect different immunosuppressive 
effects of the same factor(s) in different assays as appears to be the 
case with eCG. Alternatively, the inhibition observed in the MSA may 
reflect a sequestering of the mitogen by glycoproteins in the 
allantochorion extracts.
6.5.4 eCG and Progesterone Concentrations of Placental Tissue Extracts 
Taken at Day 80 of Gestation 
The pregnancy of a horse was terminated at 80 days gestation and specific 
tissue samples were obtained. All samples were diluted to 0.6 mg protein 
per ml and assayed for eCG and progesterone by ELISA (Table 6.3). eCG is a 
major product of the endometrial cups and thus the endometrial cup 
secretion observed in one of the allantochorion extracts produced a high 
sample eCG concentration of 251 iu/ml. The other allantochorion sample 
contained little of this secretion and this was reflected in its lower eCG 
content of 8.6 iu/ml. eCG was not present in the non-pregnant horn 
allantochorion as placentation and endometrial cup formation is localised
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Table 6.3
SAMPLE (0.6 mg/ml) eCG (iu/ml) Progesterone (ng/ml)
PREGNANT HORN 
ALLANT0CH0RI0N WITH 
ENDOMETRIAL CUP 
SECRETION (day 80)
251.0 15.7
PREGNANT HORN 
ALLANT0CH0RI0N - no 
visible secretion
(day 80)
8.6 30.0
NON-PREGNANT HORN 
ALLANT0CH0RI0N
(day 80)
n/d 26.6
AMNION (day 80) n/d 1.9
eCG and progesterone concentrations of day 80 placental extracts as 
determined by ELISA. Values are means of duplicates, working range of 
eCG assay: 3-200 iu/ml, recommended range of standards for progesterone 
assay: 1-10 ng/ml. (n/d = not detectable).
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in the pregnant horn. The lack of eCG in the amnion confirms earlier 
observations by Allen et al. (personal communication). The incorporation 
of the undiluted pregnant horn allantochorion extract, with endometrial 
cup secretion, into a lymphoproliferation assay would result in a final 
eCG concentration of 50.2 iu/ml. This concentration of eCG induces 
approximately 70-75% inhibition in both the MLR and MSA (Figs.6.2, 6.3). 
Furthermore, doubling dilutions of the sample down to a 1 in 4 dilution 
would still leave sufficient eCG (12.5 iu/ml) to cause the same degree of 
inhibition in the MLR (Table 6.4).
The progesterone concentrations of the day 80 samples were similar to 
those of the day 60 samples. The pregnant horn allantochor ion was found 
to have the highest levels of the hormone at 30 ng/ml at both stages of 
gestation. At these concentrations of the hormone, it is unlikely that 
they would exert an effect on lymphocyte proliferation (See Section 
6.5.1).
6.5.5 The Inhibition of Lymphocyte Proliferation by Day 80 Pregnant 
Horn Allantochorion as Assessed by the MSA and MLR
Pregnant horn allantochorion induced a dose dependent inhibition of ^H-Tdr 
uptake in both the MLR and MSA (Figs.6.7, 6.8 and Table 6.4). The 
inhibitory effects of allantochorion both with and without endometrial cup 
secretion were not significantly different (P>0.10) in either the MSA or 
MLR. Furthermore, the percentage inhibition values at each protein 
concentration in the MLR were found not to be significantly different from 
the analogous values in the MSA (P>0.10).
As outlined above, the extract of pregnant horn allantochorion with cup 
secretion contained enough eCG to account for all the inhibition observed 
in the MLR at each sample dilution (Table 6.4). The undiluted pregnant
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F ig .6.7 The effect of day 80 pregnant horn allantochorion, related to protein content, on the inhibition of H-thymidine 
uptake by Con.A stimulated lymphocytes. Samples used were allantochorion with visible endometrial cup 
secretion (•) and allantochorion with no obvious secretion (O). C.P.M. in control cultures = 112,600.
Results are expressed as means ± standard error, (n=4).
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F ig .6.8 The effect of day 80 pregnant horn allantochorion, related to protein content, on the inhibition of H-thymidine 
uptake by mixed lymphocyte cultures. Samples were allantochorion with visible endometrial cup secretion ( • )  
and allantochorion with no obvious secretion (O). C.P.M. in control cultures = 156,700.
Results are expressed as means ± standard error, (n=3).
TABLE 6.4
Sample Protein
ug/ml
eCG
iu/ml
Progesterone
ng/ml
% inhibition 
MSA (n=4) MLR (n=3)
PREGNANT HORN 15 6.2750 0.3925 26.4+11.1 23.0+10.0
ALLANTOCHORION WITH 30 12.5500 0.7850 45.7+ 7.0 36.9+ 5.8
ENDOMETRIAL CUP 60 25.1000 1.5700 75.8+ 3.6 66.6+ 8.3
SECRETION 120 50.2000 3.1400 96.8+ 0.9 92.7+ 1.8
PREGNANT HORN 15 0.2150 0.7500 23.8+ 9.4 28.9+13.5
ALLANTOCHORION - no 30 0.4300 1.5000 58.7+15.7 34.2+ 4.7
visible secretion 60 0.8600 3.0000 77.6+11.2 67.6+11.5
120 1.7200 6.0000 92.6+ 4.8 89.8+ 4.9
NON PREGNANT 15 n/d 0.6650 33.3+ 3.5 54.2+12.2
HORN 30 n/d 1.3330 23.7+ 2.4 45.6+ 9,2
ALLANTOCHORION 60 n/d 2.6600 81.2+ 5.7 84.8+ 4.0
120 n/d 5.3200 94.5+ 2.2 87.6+ 5.6
AMNION 15 n/d 0.0475 17.4+ 7.5 9.8+ 9.7
30 n/d 0.0950 53.4+ 9.0 51.8+14.3
60 n/d 0.1900 83.1+ 3.9 68.7+10.7
. 120 n/d 0.3800 97.7± 1.5 97.4+ 0.6
Relative inhibitory potencies of day 80 samples in the MLR and MSA as
related to protein content and including eCG and progesterone 
concentrations (n/d= not detectable).
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horn allantochorion extract without cup secretion, however, contained too 
little eCG (1,72 iu/ml final concentration) to account for any of the 
observed inhibition. This indicates that the ability of the pregnant 
horn allantochorion extract to suppress lymphocyte proliferation is 
independent of eCG content. The presence of additional inhibitory factors 
to eCG would be expected to result in an additive inhibitory effect. That 
this does not occur suggests that the inhibitory factors in both samples 
are the same and that eCG is not the factor responsible. It appears 
therefore that the commercial preparations of eCG tested in the MLR and 
MSA (Section 6.4) may contain an inhibitory/immunosuppressive contaminant 
and that the hormone itself may not inhibit lymphocyte proliferation.
The MSA data further confirms a non-inhibitory effect of eCG. In the MSA, 
the undiluted allantochorion extract with cup secretion contained enough 
eCG (50.2 iu/ml) to account for most of the observed inhibition (Fig. 6.3, 
Table 6.4). The undiluted sample of pregnant horn allantochorion without 
cup secretion, however, contained too little eCG (1.7 iu/ml) to account 
for any observed inhibition. That the two samples were equivalent in 
suppressive activity illustrates that no additive effect was occurring 
between eCG and any other inhibitory factor(s), which suggests that eCG 
may not inhibit lymphocyte proliferation. Furthermore, as the inhibitory 
effects of the samples in the MLR and MSA were not significantly 
different, it would appear that similar inhibitory mechanisms were 
occurring in both lymphoproliferation assays. This latter point argues 
against a sequestering of the mitogen by the samples in the MSA and thus 
the inhibitory activity in this assay can be taken as evidence for immuno­
suppressive activity.
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In conclusion, evidence presented above suggests that pregnant horn 
allantochorion extract contains an immunosuppressive factor(s) which is 
independent of the presence of endometrial cup homogenate and eCG. 
Furthermore, evidence is presented which indicates the eCG does not 
inhibit lymphocyte proliferation in the MSA or MLR and is therefore not 
immunosuppressive. Indeed, it appears that the inhibitory activity of a 
commercial preparation of eCG, in the MSA and MLR (Section 6.4), may be 
due to the presence of an unknown contaminant.
6.5.6 The Inhibition of Lymphocyte Proliferation by Day 80 Non-Pregnant 
Horn Allantochorion and Amnion as Assessed by the MSA and MLR
Non-pregnant horn allantochorion and amnion induced a dose dependent 
inhibition of lymphocyte proliferation in both the MSA and MLR (Figs.6.9, 
6.10 and Table 6.4). The level of inhibition induced by non-pregnant horn 
allantochorion was comparable to that induced by pregnant horn 
allantochorion in both assays. Amnion, however, inhibited ^y-Tdr 
incorporation to a greater extent than the other tissues indicating a 
higher level of inhibitory activity as assessed by the MLR. These findings 
confirm those of Kydd and Allen (personal communication) who also found 
that amnion had a greater inhibitory effect on lymphocyte proliferation 
than other tissues. Whether the later observation was due to higher 
levels of a common immunosuppressive factor, or due to the activity of a 
different factor, is unknown. In the human and mouse, alpha foeto-protein 
(AFP) present in amniotic fluid has been reported to suppress lymphocyte 
proliferation at physiological concentrations (Tomasi, 1978; Yachin and 
Lester, 1979). In addition, PP14 is present in amniotic fluid at levels 
high enough to suppress lymphocyte proliferation (Julkunen et al., 1985;
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F ig .6.9 The effect of day 80 placental extracts, related to protein content, on the inhibition of H-thymidine uptake 
by Con.A stimulated lymphocytes. Samples were non-pregnant horn allantochorion (•) and amnion (O). 
C.P.M. in control cultures = 112,600. Results are expressed as means ± standard error, (n=4).
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Bolton et al. , 1986). It is possible therefore that an equine analogue 
to either human AFP or PP14 may have contributed to the observed 
inhibition.
6.5.7 The Relative Inhibitory Effects of Pregnant/Non-Pregnant Horn
Allantochorion and Amnion Taken from a Day 60 and Day 80 Pregnancy, 
on Lymphocyte Proliferation as Assessed by the MSA and MLR
Each of the above tissues has been shown to induce a dose-dependent 
inhibition of lymphocyte proliferation in both the MSA and MLR. When the 
% inhibition induced by each day 60 tissue extract in the MSA was compared 
to the % inhibition induced by the corresponding day 80 tissue extracts in 
the same assay, it was found that the latter day 80 extracts contained 
more inhibitory/immunosuppressive activity, on an activity per mass of 
total protein basis, than the corresponding day 60 extracts (Figs. 6.11, 
6.12, 6.13). The differences in the inhibitory activity of the pregnant 
horn allantochorion samples (day 60 and 80) were not found to be 
significantly different (P>0.10). A significant difference was, however, 
found when the non-pregnant horn allantochorion samples were compared at 
protein concentrations of 60 pg/ml and 120 pg/ml (P<0.05). In addition, 
the inhibitory activities of the amnion samples were found to be 
significantly different at sample protein concentrations of 30 pg/ml and 
above (P<0.02). Available data in the MLR also indicate that the 
inhibitory/immunosuppressive activity of day 80 extracts is higher than 
that of day 60 extracts (Table 6.5). As all samples were prepared in an 
identical manner and diluted to the same total protein concentration of 
0.6 mg/ml, it was concluded that the factors responsible for the 
inhibitory activity were present in greater quantity or more active at day 
80 of gestation than at day 60.
182
8(H oN- OCO Ioin ro ioCO oOJ T "o
o-o
.oCO
.o(0
.o'It
.S'Oo  u •*-* . as5 'O
^  . 3® eJ « T5 +-» _5 • co*3 on +i
CO3O
f-io,3
'hia
3•Hcd+->ofHPL)
l-Has+joEh
co d <u as 
t l  CDo o fc
I t sO Qj3 S.-O
1 ^ 8'3 _  co®  >0 IDH fl) ^^ tS a
3  CD
2  Q■S *£ E
§  CD 03
& < sg 3* 3 0,0 CO 
»  U  <D~  tf• >> w  ,Q ^
®  0  r*J00 M Q>
>» -2 .gas f t  •+-»-0 3  0
^  CD 
*0 0  3i3 3 “rrt *iH W *C
® l o
o ^ S- +->CD I ^  iH
Cw 17^'O'H ?o c«M WO 3 _ 
c o . 2 §
« S "CD fc-
&  -s00®.£ 1
CD > 0  CO • 0
as 3as o  D)E ^  O C0 H
3  +-» F—H3o
~ o •O U Q+■> -M ^2 3 3 I £  O O 3Eh 0 0 w
co
hi)
05lB;dn e u ip x u iitii;-H  j o  uoi^xqiqui
183
80H
o-CMO-o_oCO_oCO
b£)fS• pHo+->ouCUoH
.o.OCM
o
o(O
oin
T
”ov
ioCO
ToCM
92lB;dn euipmuCiu-H 
jo uoijiqitjui %
184 ‘
F ig .6.12 The comparative effects of day 60 (O^ and day 80 (•) non-pregnant horn allantochorion, related to
protein content, on the inhibition of H-thymidine uptake by Con.A stimulated lymphocytes. C .P.M . 
in control cultures = 87,300 and 112,000 respectively. Results are expressed as means ± standard 
error, (n=4).
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Table 6.5
Sample Protein
ug/ml
% inhibition 
MLR (day 60) MLR (day 80). 
n=l n=3
PREGNANT HORN 15 0.0 28.9 + 13.5
ALLANTOCHORION 30 4.8 34.2 + 4.7
60 18.5 67.6 + 11.5
120 99.4 89.8 + 4.9
NON-PREGNANT HORN 15 0.0 54.2 ± 12.2
ALLANTOCHORION 30 0.0 45.6 + 9.2
60 78.8 84.8 + 4.0
120 99.6 87.6 ± 5.6
Relative inhibitory potencies of allantochorion extracts in the MLR at day 
60 and 80 of gestation as related to protein content.
186
The difference between day 60 and day 80 amnion may be attributable to 
increasing levels of an equine factor similar to alpha-foeto protein (AFP) 
in the human. AFP has been reported to suppress human and murine 
lymphocyte proliferation (Tomasi, 1978; Yachin and Lester, 1979) and is 
present in the amnion in increasing concentrations during gestation (Hau, 
1986). Further support for this theory came from the finding that term 
equine amnion contained a greater level of inhibitory activity than day 80 
amnion (Section 6.7).
As it appears that eCG does not suppress lymphocyte proliferation (Section 
6.5,5.), the increase in inhibitory activity of the pregnant horn 
allantochorion cannot be explained by a change in the eCG levels of this 
hormone. Whether or not this rise in inhibitory activity bears any 
relationship to the endometrial cup reaction is, at present, uncertain.
6.6 The Inhibition of Lymphocyte Proliferation: Investigations into 
the Mode of Action of the Placental/Endometrial Factors Involved
Data discussed so far in this chapter indicate that one or more factors, 
that appear to be immunosuppressive, are associated with equine foetal and 
maternal tissues during the eCG phase of pregnancy. The identity of the 
factor(s) and their mechanism of action are, however, unknown. In the 
human and mouse, a number of immunoregulatory factors have been 
investigated, which are produced by endometrial/decidual tissue and which 
appear to block the IL-2 dependent stage of the immune response (Clark et^  
al., 1985; Tawfik et al., 1986).
Consequently, the comparative basis of this project was developed further 
by investigating the mode of action and properties of the equine 
placental/endometrial derived factors responsible for the inhibition of 
lymphocyte proliferation.
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6.6.1 The Effect of Delayed Addition of Day 80 Allantochorion and Amnion
to Mitogen Stimulated Cultures on the Inhibition of the Lymphocyte 
Proliferation
In an investigation of the mechanism by which extracts of allantochorion 
and amnion inhibit the proliferation of Con.A stimulated lymphocytes, the 
extracts were added at timed intervals after the initiation of the 
cultures. In the case of the amnion and non-pregnant horn allantochorion, 
the observed suppression of lymphoproliferation was independent of the 
time of addition up to 24 h after initiation of the cultures. The 
pregnant horn allantochorion, however, continued to suppress lymphocyte 
proliferation at a consistent level up to 36 h which was the latest 
addition of sample (Fig.6.14).
As Con.A can be removed from target lymphocytes any time after 20 h with 
no diminution of mitogenic response (Gunther et al., 1974), the results 
presented here suggest that inhibition of previously activated 
lymphocytes occurs. Furthermore, these observations suggest that the 
samples were not inhibiting lymphoproliferation simply by binding to 
Con.A. That the pregnant horn allantochorion extract had a different 
suppressive pattern in this experiment suggests that the inhibitory 
activity of the sample may occur via a different mechanism in comparison 
to the other samples and may therefore be due to a different molecule. In 
order to interpret these findings, the time scale of cellular interactions 
that occur during lymphocyte stimulation was considered. During the first 
24 h of human mitogen stimulated lymphocyte proliferation, IL-2 is 
produced by some T cell subsets and approximately 30% of the cells express 
IL-2 receptors (Cantrell and Smith, 1983; Kaye et al., 1984). In the 
absence of cell cycle progression, the IL-2 receptor density per cell 
gradually increases until a critical threshold is reached necessary for
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cell proliferation (Cantrell and Smith, 1983). This critical threshold, 
however, is related to the number of occupied receptors and thus the free 
IL-2 concentrations is also a limiting factor in clonal expansion (Kaye 
e t al. , 1984). Indeed, the rate and magnitude of clonal expansion is 
dependent on 3 variables: the free IL-2 concentration, the expression of 
IL-2 receptors and the affinity of thereceptor for IL-2 (Smith, 1984). 
Because the inhibition caused by tissue extracts occurs if added within 24 
h of initiation of the culture, it is possible that the tissue extracts 
are blocking IL-2 receptor expression, the binding of IL-2 to its receptor 
or they may be inhibiting IL-2 production. After this 24 h period, 
however, the receptor density and IL-2 concentration may be too high for 
the same concentration of sample to inhibit lymphocyte proliferation. The 
inhibition of IL-2 production has in fact been reported to occur in 
prostaglandin E2 induced immunosuppression where no immunosuppressive 
effect was observed if the sample was added 18 h after culturing T cells 
with mitogen (Chouaib et al., 1985).
6.6.2 The Effect of Conditioned Medium on the Inhibition of Lymphocyte 
Proliferation by Endometrial and Placental Samples (day 60 and 
day 80) as Assessed by the MSA and MLR
One mechanism by which tissue extracts might inhibit lymphocyte 
proliferation could be by inhibiting the generation of cytokines from the 
interacting cells. In order to test this possibility, MLR supernatant 
(conditioned medium), generated as described in Section 4.9.5, was tested 
for its ability to reverse the inhibitory effects of the samples in both 
the MLR and MSA.
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The incorporation of conditioned medium into the MSA with selected 
placental samples at 30 pg/ml final protein concentration or with a 
commercial preparation of eCG (100, 50, 25 iu/ml) was found to partially 
or in most cases totally reverse the observed level of inhibition (Table 
6.6). When the experiment was repeated using more concentrated placental/ 
endometrial samples (120 |ug/ml final protein concentration), the 
inhibition was in most instances not reversed (Table 6.7). However, the 
addition of conditioned medium to mixed lymphocyte cultures in the 
presence of placental/endometrial samples at a final concentration 
of 120 fig/ml was found only in a limited number of cases to reverse the 
observed level of inhibition. This occurred with allantochorion extract 
which reversed the inhibition by 46% and 13% in separate MLR*s.
In conclusion, data presented above suggest that the inhibition of 
lymphocyte proliferation by allantochorion extract can be reversed by 
conditioned medium in both the MSA and MLR. It appears therefore that 
factor(s) present in the allantochorion block the generation and/or 
activity of cytokines necessary for lymphocyte proliferation. The MSA 
data (Table 6.6) suggest that the amnion, endometrial cup homogenate and 
the commercial preparation of eCG also contain factor(s) with similar 
cytokine blocking activity, that is the mechanisms by which each sample 
inhibits lymphocyte proliferation appear to be similar. That the addition 
of cytokines to cells inhibited by more concentrated samples (120 ug/ml) 
had little effect on the level of inhibition, suggest that at this greater 
concentration the samples may be non-specifically binding to the lymphocytes 
and blocking cytokine-cell surface interactions.
A number of local immunosuppressive mechanisms investigated in the human 
and mouse are reported to block the IL-2 dependent stage of the immune 
response (Clark et al. , 1985; Parhar and Lala, 1986). Preliminary
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Table 6.6
SAMPLE
% inhibition of ^H-Tdr uptake
CONTROL CULTURE 
COUNTS- conditioned 
medium
+ conditioned 
medium
ENDOMETRIAL CUP 
H0M0GENATE 
(day 60)
48.6 34.6 12,796
PREGNANT HORN 
ALLANTOCHORION 
(day 60)
13.4 0.0 12,796
NON-PREGNANT HORN 
ALLANTOCHORION 
(day 80)
27.1 1.1 12,796
AMNION 
(day 80)
3.9 0.0 12,796
eCG (100 iu/ml) 40.6
83.9
12.3
65.8
17,500
12,796
eCG (50 iu/ml) 18.0
65.0
0.0
84.1
17,500
12,796
eCG (25 iu/ml) 45.0
75.0
0.0
70.0
17,500
12,796
The effect of conditioned medium on the inhibition of Con.A stimulated 
horse lymphocyte proliferation induced by equine chorionic gonadotrophin 
and placental extracts taken from a day 60 and day 80 pregnancy. Final 
protein concentration in cultures = 30 y.g/ml.
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Table 6.7
SAMPLE
% inhibition of ^H-Tdr Incorporation
CONTROL CULTURE 
COUNTS- conditioned 
medium
+ conditioned 
medium
PREGNANT HORN 
ALLANTOCHORION WITH
97.7 99.0 58,000
ENDOMETRIAL CUP 
SECRETION (day 80)
98.7 97.6 17,500
PREGNANT HORN 
ALLANTOCHORION
69.2 68.3 58,000
(day 80) 99.8 99.6 17,500
NON-PREGNANT HORN 
ALLANTOCHORION
96.3 91.9 58,000
(day 80) 50.0 5.7 17,500
AMNION (day 80)
99.8 99.7 58,000
78.6 86.5 17,500
PREGNANT HORN
ENDOMETRIUM
(day 60)
39.5 28.4 25,000
NON-PREGNANT HORN
ENDOMETRIUM
(day 60)
66.9 61.2 25,000
ENDOMETRIAL CUP
HOMOGENATE
(day 60)
57.4 64.3 25,000
PREGNANT HORN
ALLANTOCHORION
(day 60)
66.3 46.4 25,000
NON-PREGNANT HORN
ALLANTOCHORION
(day 60)
37.2 27.7 25,000
The effect of conditioned medium on the inhibition of Con.A stimulated 
horse lymphocyte proliferation induced by placental and endometrial 
extracts taken from a day 60 and day 80 pregnancy. Final protein 
concentration in cultures = 120 ug/ml.
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evidence presented here in both the delayed addition and conditioned 
medium experiments suggest that a similar mode of action may be associated 
with local immunosuppressive mechanisms occurring in the horse. Until 
this can be clarified, however, the potential inhibition of other 
cytokines must be considered, the most likely being IL-1 and interferon.
6.7 The Inhibition of Lymphocyte Proliferation by Pregnant Horn 
Allantochorion and Amnion, Taken from a Pregnancy Aborted near 
to Term, as Assessed by the MLR 
Parturition has been likened to the rejection of a previously tolerated 
graft (Siiteri and Stites, 1982). Indeed, these authors suggest that 
the endocrine changes which occur prior to parturition remove immuno- 
regulatory influences which have maintained the graft. In support of 
this, a number of immunosuppressive factors are reported to be low in the 
circulation at term, e.g. progesterone and PP14 (Siiteri and Stites, 1982; 
Bolton et al., 1983).
In order to investigate levels of immunosuppressive factors approaching 
term in equine pregnancy, pregnant horn allantochorion and amnion extracts 
taken from a placenta aborted spontaneously near to term, were 
incorporated into an MLR. Both original samples were diluted to a protein 
concentration of 0.6 mg/ml. The allantochorion only inhibited ^H-Tdr 
incorporation (48.6%) when undiluted and thus appeared to be low in 
immunosuppressive activity (Fig.6.15). The amnion, however, had an 
inhibitory effect on ^H-Tdr Incorporation when present at concentrations 
greater than 20 fig/ml culture fluid. Furthermore, the degree of observed 
inhibition was greater than that associated with day 80 amnion.
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F ig .6.15 The effect of term (gborted) allantochorion (O) and amnion (•) , related to protein content, 
on the inhibition of H-thymidine uptake by mixed lymphocyte cultures.
C.P.M. in control culutres = 156,700. Results are expressed as mean incorporation into 
triplicate cultures, (n= l) .
The low inhibitory activity of the allantochorion may be taken as evidence 
for a reduction in allantochorion associated immunoprotective mechanisms 
in preparation for parturition. As the allantochorion is the outermost 
layer of the placenta in direct contact with the uterine wall, a reduction 
in immunoprotective mechanisms associated with this tissue would lead to 
the rejection of the foeto-placental unit. As this particular pregnancy 
was spontaneously aborted, it is possible, however, that the low level' of 
inhibitory activity reflected the poor clinical state of the tissue.
The amnion is the inner most membrane of the placenta that envelopes the 
foetus directly. It would appear therefore that a reduction in immuno­
suppressive activity associated with this tissue may be less important at 
parturition. Indeed, it can be argued that such a reduction in amnion 
associated immunoprotective mechanisms would put the foetus itself at risk 
during the later stages of pregnancy. This appears to be supported by the 
high level of inhibitory activity in term amnion reported above.
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CHAPTER -7-
STUDIES OF ANTI-PLATELET AGGREGATQRY MECHANISMS IN 
THE EPITHELIOCHQRIAL PLACENTA
7.1 Introduction
In the human haemochorial placenta, the foetal villi are in direct contact 
with the maternal blood and consequently much pooling of blood occurs in 
the placental blood sinuses. In addition, it is reported that during 
pregnancy there is an increased activation of the maternal clotting system 
(Stirling et al., 1984). Despite these observations, the occurrence of a 
placental thrombosis is rare. This suggests that the placenta may protect 
itself by inhibiting platelet aggregation and/or coagulation. Indeed, a 
number of investigations have revealed that extracts of human placental 
tissue inhibit ADP induced platelet aggregation (Myatt and Elder, 1977; 
Hutton et al., 1980; O’Brien et al., 1987). In addition, a single report 
by Maki et al. (1984) described an anti-aggregatory placental protein 
which inhibited platelet aggregation induced by ADP, collagen and 
adrenalin. A number of placental associated anti-coagulants have also 
been described (Section 3.14).
In contrast to the above, there is no data available concerning analogous 
studies in species with epitheliochorial placentation. In such placentae, 
there are six layers of tissue between the maternal and foetal 
circulations. However, despite the preservation of these layers, the 
passage of nutrients across the placenta is facilitated by the 
penetration of both maternal and foetal capillaries into the epithelium 
and trophoblast where they assume adjacent positions (Ramsey, 1982).
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Furthermore, the vascularisation of the epitheliochorial placenta is 
typified by the occurrence of microvilli whose interdigitation increases 
the area of maternal-foetal contact many fold.
In the equine epitheliochorial placenta, there is no pooling of maternal 
blood. The outer surface of the chorion is, however, highly vascularised, 
that is the chorion becomes studded with thousands of tufts of short 
branched villi which enter into corresponding invaginations in the 
endometrium to form small globular structures known as microcotyledons 
(Steven and Morris, 1975).
The bovine epitheliochorial placenta is typified by its cotyledonary 
configuration, that is the villi are scattered in large clusters over the 
foetal sac. The bovine uterine mucosa exhibits localized thickenings 
independent of pregnancy known as caruncles. During pregnancy, 
proliferations of chorionic villi (cotyledons) become attached to the 
caruncles and it is through these connections that placental exchange 
occurs. The combination of caruncle and cotyledon is known as a 
placentome. The maternal caruncles become enlarged and highly 
vascularised during pregnancy in a similar way to the endometrial 
component of the equine microcotyledon. In contrast to the horse, 
however, small haematomas appear in some of the bovine placentomes. 
Hematomas are stagnant accumulations of maternal blood which lie in direct 
contact with trophoblastic villi. The trophoblast cells are reported to 
actively phagocytose the red blood cells and degrade the products of 
haemoglobin (Ramsey, 1982).
The presence of anti-aggregatory activity in the human haemochorial 
placenta has been largely associated with the pooling of maternal blood in 
the placental sinuses where it is in direct contact with trophoblast.
However, in view of the different vascular features of the equine and 
bovine placentae, the importance of analogous anti-aggregatory mechanisms 
in the epitheliochorial placenta is uncertain. Consequently, the 
following investigations were carried out to determine whether or not 
anti-aggregatory mechanisms are associated with term equine and bovine 
epitheliochorial placentae.
7.2 The Inhibition of Platelet Aggregation by Equine Term Placental 
Extracts
Extracts of amnion and allantochorion, taken from a normal term placenta, 
were added to equine platelets in the presence of collagen and ADP. Both 
undiluted extracts were used at the same final protein concentration of
52.5 lig/ml. It was found that equine allantochorion inhibited platelet 
aggregation induced by collagen but not platelet aggregation induced by 
ADP. Doubling dilutions of the sample showed the same anti-aggregatory 
effect down to a 1 in 16 dilution (Fig.7.1). Term amnion had no effect on 
platelet aggregation at even the highest concentration investigated.
High concentrations of collagenase in a sample will prevent collagen 
induced platelet aggregation by degeneration of the collagen. The 
allantochorion extract was assayed for collagenase and levels of the 
enzyme were found to be below the working range of the assay. The sample 
did not therefore contain enough collagenase to degrade sufficient 
collagen under the conditions of the experiment.
In conclusion, it appears that equine term allantochorion contains a 
factor(s) capable of inhibiting platelet aggregation induced by collagen 
but not aggregation induced by ADP. This contrasts with reports of human 
placental extracts, most of which inhibit ADP induced aggregation but not
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Fig. 7.1
Inhibition of collagen induced equine platelet aggregation by term
placental allantochorian:-
A(Sample+ADP), B(Sample+Collagen), C(Sample[l:2 diln’]+Collagen), 
D(Control for C), E(Sample[1:8 diln1]+Collagen), F(Control for E) .
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collagen induced aggregation. Only in one case was a factor isolated from 
the human placenta which inhibited both ADP and collagen induced platelet 
aggregation (Maki et al., 1984).
On the addition of collagen to a suspension of platelets, there is a short 
delay followed by the secretion of ADP which induces the platelets to 
aggregate. As the equine sample had no effect on ADP induced platelet 
aggregation, it must be either blocking the activity or binding of 
collagen to the platelets or it may be interfering with one of the 
reactions occurring inside the platelet leading to ADP secretion. In 
brief, this series of reactions leading to secretion involves the release 
of arachinodic acid from the platelet membrane which is quickly converted 
into endoperoxides. These , in turn, are converted into thromboxane A2 
which is the stimulus for ADP secretion. It is interesting that most 
factors isolated from the human placenta do not interfere with these early 
events of platelet aggregation but appear to degrade the ADP (O'Brien 
et al., 1987). With respect to the equine placenta, it is possible, 
however, that the highly vascular nature of the allantochorion may 
necessitate an inhibitor of collagen induced platelet aggregation due to 
high levels of collagen in the membrane.
7.3 The inhibition of Platelet Aggregation by Bovine Placentome Extract
An extract of bovine placentome taken from a normal term placenta was
added to bovine platelets in the presence of collagen and ADP. The final
protein concentration of the extract when added to the platelets was
52.5 Jig/ml. On addition of the extract to platelet rich plasma, there was
a small amount of aggregation followed by an apparent dissociation. When
ADP was added to this mixture, there was no response and thus the extract
had inhibited ADP induced platelet aggregation (Fig.7.2). It is possible
that this activity may be due to a phosphatase activity, indeed such a
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Fig. 7.2
Inhibition of ADP induced bovine platelet aggregation by bovine 
placentome homogenate:-
A(Sample+Platelet Rich Plasma), B(A.+ADP), C(Control for A. and B.).
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mechanism has been described in the human placenta (Hutton et al., 1980). 
The placentome extract (2 ml) was, however, dialysed against 5 1 of 
distilled water (overnight) before incorporation into the experiment. As 
it is reported that extensive dialysis results in the loss of zinc atoms 
from alkaline phosphatase necessary for enzymatic activity (McComb et al., 
1979), it is unlikely that this enzyme is responsible for the anti­
aggregatory activity associated with the sample. This awaits further 
clarification.
When collagen was added to the bovine platelets incubated with placentome 
extract, aggregation occurred as normal. This contrasts with the effect 
of equine allantochorion which inhibited collagen induced aggregation but 
had no effect on ADP induced aggregation.
An additional study was carried out on the effect of equine and bovine 
placental extracts on human platelet aggregation induced by ADP and 
collagen. Platelet aggregation was found to occur as normal suggesting 
that the anti- aggregatory factors described are species specific. 
Moreover, the lack of inhibition when ADP stimulated human platelets 
were incubated with bovine placentome extract indicates that it is even 
less likely that a phosphatase activity in the sample was responsible for 
the inhibition of bovine lymphocyte aggregation.
In conclusion, it appears that both the equine and bovine epitheliochorial 
placentae exhibit anti-platelet aggregatory activity. The bovine activity 
is more akin to that described in the human placenta. It appears, 
however, that the bovine factor(s) responsible may not be degrading the 
ADP as is the case with the human inhibitory factors. Whether or not the 
presence of haematomas in bovine placentomes and placental sinuses in the 
human placenta have any bearing on the inhibition of the ADP agonist is at
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present uncertain. The equine anti-aggregatory factor is unique in that 
it specifically inhibits collagen induced platelet aggregation. That 
platelet anti-aggregatory activity is found in placentae as diverse as the 
haemochorial and epitheliochorial types suggest that placenta anti­
aggregatory factors are of critical importance in the prevention of a 
hazardous thrombosis in mammals.
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CHAPTER -8-
FINAL DISCUSSION
Early embryonic and foetal loss in the mare, most of which occurs before 
day 12 after ovulation (Forde et al., 1987), has proved to be a serious 
economic loss to the horse breeding industry. Moreover, the serum tests 
used for the actual detection of pregnancy are not reliable until the 
detection of oestrone sulphate produced by the foeto-placental unit from 
day 60 onwards. From days 18-25, maternal progesterone levels are 
elevated during pregnancy due to the continued activity of the corpus 
luteum. In the non-pregnant mare, luteolysis occurs at day 16 and 
consequently levels drop. A proportion of oestrous cycles are, however, 
followed by a persistent corpus luteum which continues to secrete 
progesterone, resulting in a pseudo-pregnant state (Stabenfeldt et al., 
1984). Indeed, in one study, 93% of 362 non-pregnant mares during the breeding 
season were reported to have elevated plasma progesterone levels (Allen 
et al. , 1974). Consequently, elevated progesterone levels can only be 
used as a tentative indicator of pregnancy. Similarly, eCG detectable in 
the maternal plasma at 42 days post-conception is only indicative of the 
presence of functional endometrial cups. This was demonstrated by Allen 
and Moor (1972) who found that once the chorionic girdle cells invade the 
uterine stroma to form endometrial cups at around day 37 (implantation), 
the subsequent loss of the pregnancy did not alter the normal sequence of 
development and regression of the endometrial cups. Although other 
techniques are available for pregnancy diagnosis such as rectal palpation 
and ultrasound echography, little information is obtained regarding the
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physical state of the foetus. Consequently, it would appear that there is 
a need for a non-invasive method of detecting pregnancy before day 60 
which also allows foetal well being to be monitored.
Evidence is presented in this thesis for the presence of a protein with 
82~electrophoretic mobility which appears in the peripheral circulation of 
the horse specifically during pregnancy. The pregnancy specific protein 
designated 82”^ors*^^ was first detectable at day 6 after mating and than 
increased for at least the first 21 days of pregnancy. Levels of the 
protein appeared to be elevated between days 21 and 83, that is during 
implantation, after which it decreased throughout gestation. The assay 
system used, two-dimensional crossed immunoelectrophoresis, lacks the high 
sensitivity of some immunoassay systems and the failure to demonstrate 
this protein in the serum of non-pregnant mares may be a consequence of 
the lower limit of sensitivity imposed by the assay. Consequently, it is 
possible that 62-h°rs*P*) may present in the non-pregnant state at low 
levels and elevated during pregnancy^
That 32-hors.PP was transiently present in the serum of 2 pregnant mares
that failed to become pregnant, suggests that the protein may be produced
in response to a biochemical pregnancy as described in the human (Miller
et al., 1980). Indeed, it has been reported that there are similar
fertilization rates in normal and barren mares but significantly different
day 14 pregnancy rates (Ball et al., 1985). The problem of early foetal
loss in the mare throws into question the utility of $2-hors.PP as a
pregnancy test, particularly during the first month of gestation. The
possible link of 62“hors.PP with biochemical pregnancy, however, indicates
that monitoring of the protein may be useful in assessing foetal well
being. It is conceivable that the monitoring of 62”hors.PP levels in
this way may enable the early detection of pseudopregnancy as defined by
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elevated levels of progesterone and/or eCG in the absence of 2“hors.PP. 
Consequently the mares could be artificially induced to return to oestrous 
and appropriate arrangements made for another mating.
It has been reported that much foetal loss occurs around the time of 
implantation at day 37 (Whyte and Allen, 1985). In addition, Woods et al. 
(1987) reported that the pregnancy loss rate is significantly less after 
implantation than before. The presence of elevated levels of 82"*hors.PP 
after implantation suggests that the risk of foetal loss may be 
sufficiently low to justify the development of a routine non-invasive 
pregnancy test earlier in gestation than day 60 when elevated levels of 
oestrone sulphate are detectable.
Data presented in this thesis suggests that 32“hors.PP is detectable in a 
serum of a donkey-in-horse pregnancy but not detectable in a normal donkey 
pregnancy. These findings coupled with the detection of 32~hors.PP in 
uterine flushings suggest that the protein has a maternal origin. It is 
possible therefore that the reported early equine conceptus derived 
factors (Hershman and Douglas, 1979) may have a localised effect on the 
uterus resulting in the secretion of further early pregnancy factors, one 
of which may be 32~hors.PP.
To date, only two other equine pregnancy specific serum proteins have been 
reported in the literature: equine chorionic gonadotrophin (Cole and 
Hart, 1930) and mare pregnancy protein-1 (Gidley-Baird et al., 1983).
An identity between 32-hors.PP and equine chorionic gonadotrophin (eCG) 
was excluded as antisera to eCG did not precipitate 32-hors.PP and 
purified eCG did not contain material which was immunologically similar to 
82-hors.PP. Furthermore, 32~hors.PP was detected in the serum before the 
development of the endometrial cups which secrete eCG.
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A comparison o f 82-hors.PP with published data about mare pregnancy 
protein-1 (MPP-1) revealed some common factors between the proteins. 
Firstly, MPP-1 is reported to have beta^-electrophoretic mobility and was 
detected using a similar imraunoelectrophoretic system to that described 
here. Secondly, MPP-1 was present in the earliest serum sample 
investigated taken at day 30 of gestation and thus may be detectable at an 
earlier stage of pregnancy. It is possible that MPP-1 and 32-hors.PP are 
identical proteins, although the slightly differing electrophoretic 
mobilities may suggest either different proteins or differing forms such 
as degree of glycosylation of the same protein.
There are, however, two factors which mitigate against such an identity. 
Firstly, 32-hors.PP is immunologically related to a protein found in the 
serum of non-pregnant mares. This protein was found to have gamma2 
electrophoretic mobility and has been designated as gamma2 horse protein 
(Y2-hors.P). The relationship of the two proteins was apparent from a 
continuity of the protein precipitin lines formed in two-dimensional 
crossed immunoelectrophoresis. No similar protein related to MPP-1 was 
described by Gidley-Baird et al. (1983). Secondly, the antisera developed 
by Gidley-Baird et al.(1983) against pregnant mare serum was adsorbed with 
stallion serumt Data presented in this thesis demonstrate that such an 
adsorption process removes antibody specificity to 82-hors.PP and this has 
been attributed to the close immunological relationship between 82-hors.PP 
and a protein present in the non-pregnant horse (Y2~hors.P). The 
similarities or differences of these two proteins, however, require 
further investigation.
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Other pregnancy associated factors have been described in uterine fluid, 
the most widely reported one being uteroferrin (Sharp, 1980). The 
presence of uteroferrin in non-pregnant mare uterine flushingsand its 
absence from pregnant mare serum mitigate against an identity between 
02“hors.PP and the uterine protein.
There is little evidence to suggest that 02-hors.PP is an equine analogue 
of a specific human pregnancy associated protein although the increase in 
concentration of 82-hors.PP in the serum for the first few weeks, followed 
by a decline for the remainder of gestation is similar to that reported 
for PP-14 (Julkunen et al. , 1985a), Furthermore, both proteins are
secreted in the uterust
Recent research into bovine pregnancy has revealed a pregnancy specific 
protein that is first detectable in the serum 1-8 days after artificial 
insemination (Klima et al. , 1987), This protein, designated early 
pregnancy associated protein (EPAP) was detected using a similar 
immunoelectrophoretic method to that used in the detection of 82-hors.PP. 
EPAP was detected in the y-globulin area of the immunoelectrophoretic gel 
and appeared to be related to a protein present in non-pregnant serum. As 
assessed by the detection of EPAP, 91.5% of 71 sera samples were 
classified correctly to be pregnant or non-pregnant. In comparison, data 
presented in this thesis show that 81% of 16 equine sera samples 
investigated blind were correctly diagnosed to be pregnant or non­
pregnant. It is possible that EPAP in the cow and 82“h°rs»PP *-n the horse 
are the same or equivalent proteins and this is based on the following 
common factors.
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1/ Both proteins are pregnancy specific and appear within 8 days after 
mating.
2/ Both proteins appear to be biologically related to a protein present 
in the non-pregnant state.
3/ The differing electrophoretic mobilities of EPAP and 62~hors.PP may be 
due to different degrees of glycosylation.
4/ Both EPAP and 82”hors.PP have been shown to be highly accurate in the 
diagnosis of early pregnancy.
The early appearance of 82~hors.PP during pregnancy may be indicative of a 
role associated with implantation, particularly as levels of the protein 
appear to be elevated during this period. Furthermore, with respect to 
bovine pregnancy, EPAP has been shown by the ’adoptive transfer of contact 
sensitivity' to behave like EPF from sheep in suppressing the delayed 
cutaneous hypersensitivity in mice (Klima, 1985; Pitra et al., 1985). The 
similarities between 82”hors.PP and EPAP may therefore be indicative of a 
biochemical/immunological relationship between 82~hors.PP and EPF. It is 
therefore possible that f^-hors.PP rosy have an immunomodulatory role.
In recent years, the role of pregnancy associated proteins and steroids as 
potential immunomodulatory agents during pregnancy has been much 
investigated. Reproductive immunologists generally agree that the 
survival of the mammalian foetal allograft within an immunocompetent 
mother may be partly explained by local intra-uterine immunosuppressive 
mechanisms. Furthermore, such mechanisms are considered to be 
particularly important during implantation and early pregnancy. There are, 
however, a number of other theories explaining the survival of the foetal 
allograft which are not necessarily mutually exclusive. Indeed, it has 
been suggested that a number of mechanisms interplay or even synergize, 
resulting in a sophisticated immunological equilibrium that is not fully
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understood (Chaouat, 1984). Other theories include a poor immunogenic 
status of the trophoblast due to a lack of MHC antigens and the production 
of blocking antibodies as a humoral response to pregnancy.
The former theory may be more pertinent to placentae exhibiting gross 
invasive activity such as the haemochorial placenta although the invasive 
trophoblast of the equine placenta does not appear to express class I MHC 
antigens (Crump et al., 1987).
With regard to blocking antibody production, there is evidence to suggest 
that a humoral response to pregnancy is important if not critical for the 
continued survival of the foetal allograft in both the human and the 
horse. Indeed, 90% of primiparous mares develop hightitre anti-paternal 
alloantibody compared to 15-25% of primiparous women and 40-60% of 
multiparous women (Antczak et al., 1984; Doughty and Gelthorpe, 1974). 
The stimulus for this antibody production in the mare is believed to come 
from the invasive activity of the endometrial cups and .may be due to the 
expression of non-MHC antigens such as the TLX antigen (Allen et al., 
1987).
With respect to local immunosuppressive mechanisms, research has almost 
entirely concentrated on species exhibiting haemochorial placentation. 
Indeed, reservations have been expressed regarding the importance of such 
a mechanism in species with epitheliochorial placentation (Enders, 1983). 
Local immunosuppressive mechanisms are considered to be of particular 
importance in haemochorial placentae as there is direct contact between 
maternal blood and foetal trophoblast. However, the events occurring 
during implantation in the horse suggest that local immunosuppressive 
mechanisms may be important in species with more superficial placentation. 
Of particularly importance in this respect is the endometrial cup reaction
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unique to the genus Equus. During this, specialised gonadotrophin 
secreting trophoblast cells of chorionic girdle membrane origin invade the 
maternal endometrium at days 36-38 of gestation and develop into 
endometrial cups. The cups have a life span 60-100 days throughout which 
increasing numbers of lymphocytes accumulate in the surrounding stroma 
(endometrial cup lymphocytes). When the cups begin to degenerate, around 
day 80-90, the lymphocytes begin to invade the cup tissue and destroy the 
large cup cells (Allen, 1982). As a consequence of the invasive activity 
of the trophoblast cup cells, the endometrial cup reaction can be 
described as the time when the main foetal stimulus to the mother is 
greatest and consequently it is during this period that local immuno­
suppressive mechanisms may be stimulated, resulting in elevated levels of 
immunosuppressive factors. That the cups are not invaded by lymphocytes 
until day 80-90 suggests that a local immunomodulatory factor may be 
active possibly produced by the endometrial cups. Evidence has already 
been presented to show that at least one population of cells attracted to 
the endometrial cups has suppressor rather than cytotoxic activity (Kydd 
and Allen, 1986 and personal communication). In addition, preliminary 
in vitro studies suggest that the principal secretory component of the 
cups, equine chorionic gonadotrophin (eCG), may suppress lymphocyte 
proliferation (Kydd and Allen, unpublished). These studies were carried 
out using a commercial preparation of eCG,
Data presented in this thesis confirms that commercially available eCG 
(Intervet) inhibits lymphocyte proliferation in a dose dependent manner. 
The sample did not induce 100% inhibition in either the MLR or MSA which 
suggests that one or more cell populations in culture were proliferating 
despite the presence of the eCG preparation. However, evidence is also
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presented in this thesis which suggests that the inhibitory activity 
observed in the MLR and MSA may not be due to eCG but due to a contaminant 
in the hormone preparation.
This became evident when two extracts of pregnant horn allantochorion 
taken from a pregnant mare 80 days after mating were compared in terms of 
their inhibitory effects on lymphocyte stimulation. Only one of the
extracts contained endometrial cup secretion and this was reflected in its
high eCG content (251 iu/ml). The other sample contained very little 
endometrial cup secretion which was reflected in its low eCG content 
(8.6 iu/ml). As assessed using the commercially available eCG, the 
concentration of the hormone in the extract with cup secretion was found 
to be high enough for all of the observed inhibition in the MLR. The eCG
level in the other sample was, however, too low to have any effect. No
significant difference was found in the inhibitory effects of the two 
samples on lymphocyte proliferation and thus it appeared that the 
inhibitory activity of the allantochorion extract was independent of eCG 
content. Furthermore, as the hormone was present in culture with other 
inhibitory factor(s), an enhanced inhibitory effect was expected. That no 
additive effect was observed when the two allantochorion samples were 
compared suggests that the hormone itself does .not inhibit lymphocyte 
proliferation and that the commercially available eCG contains a 
contaminant with inhibitory activity.
Similar results have been obtained in a series of experiments using 
commercially available human chorionic gonadotrophin (hCG). It was 
reported that hCG inhibits PHA-induced lymphocyte proliferation, mixed 
lymphocyte reactions and antigen induced biastogenesis (Siiteri and 
Stites, 1982). In 1983, however, a more highly purified form of hCG was 
reported not to be immunosuppressive and thus the original results were
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attributed to an unknown contaminant in the more crude hormone preparation 
(Rolfe et al., 1983). The crude hCG preparations have been further 
reported to contain EPF activity and it has been suggested that this may 
be entirely responsible for the immunosuppression observed. Similarly, it 
is possible that the inhibitory effects of the crude eCG preparation may 
similarly be due to contamination.
Although it appears that eCG does not inhibit lymphocyte proliferation, 
the hormone may have other immunomodulatory effects during pregnancy. 
Indeed, it has been suggested that eCG may have a role as a physical 
barrier which covers and therefore prevents the maternal immune 
recognition of the foetal antigens (Allen, 1982). Alternatively or in 
conjunction with the above, the high carbohydrate and sialic acid content 
of eCG may give a high negative charge to both trophoblast cells and 
maternal lymphocytes leading to mutual repulsion (Allen, 1982).
The importance of the endometrial cup reaction to the successful 
maintenance of early equine pregnancy is evident from the work carried out 
on various experimental equine pregnancies. It has been shown that any 
conceptus that gives rise to any degree of endometrial cup development in 
the maternal uterus has a chance of implanting normally and proceeding to 
term (Allen et al. , 1987). As eCG is the major secretory product of the 
endometrial cups, it is possible that the endometrium and/or endometrial 
cups may secrete an immunosuppressive agent to protect them against 
rejection. This would enable the continued production of eCG facilitating 
the survival of the pregnancy because of its endocrine action. Indeed, 
Kydd and Allen (1986) have found that endometrial cup lymphocytes, 
recovered between days 55 and 70, exhibit suppressor activity.
214
Data presented in this thesis have shown that extracts of endometrial 
tissue and endometrial cup homogenate taken from a pregnant mare 60 days 
after mating are able to inhibit lymphocyte proliferation in the MLR and 
MSA, indicative of the presence of immunosuppressive activity. A similar 
inhibitory effect has also been observed with extracts of foetal membranes 
(allantochorion and amnion) taken from two pregnant mares 60 days and 80 
days after mating.
The inhibitory activity of these samples was reversed by the addition of 
conditioned medium (MLR supernatant). This suggests that factor(s) 
present in the equine endometrium and in foetal tissues may have a local 
immunosuppressive effect by inhibiting the action and/or generation of 
specific lymphokines such as IL-1 and IL-2. Furthermore, the placental 
samples were not required at the initiation of an MSA in order to inhibit 
lymphoprol if era t ion. This demonstrates that the inhibitory factors were 
effective against previously activated lymphocytes. Indeed, as assessed 
by the MSA, the inhibitory activity of the placental samples was 
independent of the time of addition up to 24-36 h. In view of the events 
that occur during lymphocyte stimulation, it is possible that the 
placental factors were blocking the IL-2 dependent stage of the immune 
response. Such an effect may be due to blocking IL-2 receptor expression, 
the binding of IL-2 to its receptor or by the inhibition of IL-2 
production. In total, it appears that intra-uterine immunomodulatory 
factors are active during early pregnancy in the horse and that some of 
these factors may suppress at the IL-2 level of the immune response.
Investigations into endometrial immunoregulatory activity in species 
exhibiting haemochorial placentation have generally focussed on human and 
murine pregnancy. In these species, a number of factors produced from a 
variety of cell types contribute to endometrial/decidual associated
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immunosuppression. Moreover, it appears that a common but not exclusive 
mechanism of immunosuppression associated with these factors is a blockade 
of the IL-2 dependent stage of immune response. A population of 
trophoblast dependent non-T lymphocytes present in murine decidua have 
been shown to release a factor which blocks the activity of IL-2 (Clark 
e t al. , 1985). Moreover, the decidual supernatant factor is similar in 
molecular weight to the human endometrial protein PP-14 which has recently 
been shown to suppress lymphocyte proliferation (Bolton et al., 1987). 
Decidual cells (Parhar and Lala, 1986) and macrophages (Tawfic et al., 
1986) have been shown to suppress T cell reactivity by the release of 
prostaglandin E2 (PGE2) which in turn inhibits the production of IL-2. In 
the light of results presented in this thesis, it appears that local 
immunoregulatory mechanisms, such as those described above, are important 
for the survival of mammalian pregnancy irrespective of the type of, 
placenta (haemochorial compared with epitheliochorial).
It has been postulated that birth is essentially the rejection of an 
allograft no longer protected by local immunosuppressive mechanisms and 
consequently, levels of proteins with immunomodulatory activity are low 
just prior to term (Siiteri and Stites, 1982). This has been demonstrated 
in human and murine pregnancy and data presented here suggests that this 
is also the case in the horse. As assessed by the MLR, an allantochorion 
extract from a placenta spontaneously aborted near to term had little 
effect on lymphocyte proliferation. The allantochorion is the outermost 
layer of the placenta and consequently a reduction in the immuno­
suppressive activity of the tissue may lead to spontaneous abortion or 
natural birth. In contrast, the suppressive activity of day 80 
allantochorion extracts were found to be greater than those of day 60 
allantochorion extracts. This suggests that the suppressive activity of
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the allantochorion may reach maximum levels early in pregnancy and then 
decrease throughout gestation in a similar manner to human imrauno- 
regulatory proteins, e.g. PP-14. These results suggest that local immuno- 
regulatory mechanisms may be particularly important during the endometrial 
cup reaction when the foetal stimulus to the mother is maximal. Indeed,
Allen e_t al_. (1987) have suggested that a major function of the
endometrial cup reaction during a normal pregnancy is to stimulate 
suppressor cell activity.
An amnion extract from the same placenta was found to have a higher level 
of inhibitory activity than similar extracts taken at day 60 and day 80. 
The amnion is the innermost membrane of the placenta and consequently, 
immunosuppressive activity associated with this tissue may not effect the 
onset of parturition but will be important in the protection of the 
foetus. The increase in suppressive activity of the amnion may be due to 
the secretion of a factor similar to AFP in the human. AFP has been shown 
to suppress human and murine lymphocyte proliferation and to increase in 
concentration during gestation (Tomasi, 1978; Yachin and Lester, 1979; 
Hau, 1986).
It has recently been stated that 10% of anything will suppress 
lymphoproliferation (Antczak and Allen, personal communication). In 
answer to this, it has been observed that term allantochorion will not 
suppress lymphocyte proliferation despite the high protein concentration 
in the lymphocyte cultures and thus this may be taken as evidence that the 
suppressive effect induced by the other samples was not solely due to the 
presence of protein.
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During human pregnancy, there is an increased activity of the maternal 
clotting system (Stirling et al., 1984), Furthermore, in the
haemochorial placenta, the pooling of maternal blood in the blood sinuses 
suggests that a thrombosis is likely to occur. The rare occurrence of 
such a thrombosis has been attributed to the presence of a number of 
factors in the placenta which function as anti-coagulants or have 
anti-platelet aggregatory activity. It has been reported that extracts of 
human term placenta specifically inhibit ADP induced platelet aggregation 
(Myatt and Elder, 1977; Hutton et al. , 1980; O ’Brien et al. , 1987) 
except in one report where the same factor inhibited ADP, collagen and 
adrenalin induced platelet aggregation.
Although it has been reported that there is an increase in levels of 
clotting factors during bovine pregnancy (Gentry et al., 1979), there is 
no data available concerning anti-platelet aggregatory activity in the 
epitheliochorial placenta.
Data is presented in this thesis illustrating the presence of a factor in 
equine term allantochorion inhibiting the aggregation of platelets in 
response to collagen. Preliminary data are also presented suggesting the 
presence of a factor in the bovine placentome which inhibits the 
aggregation of platelets in response to ADP.
The bovine activity is similar to that described in the human placenta 
although no degrading of ADP seems to occur as described in the human 
placenta. It is interesting that some bovine placentomes contain 
haematomas where maternal blood accumulates in contact with trophoblast, 
in a similar way to the pooling of maternal blood in the human placental 
sinuses. The significance of this in terms of platelet aggregation is, 
however, uncertain.
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In contrast to the human and bovine anti-aggregatory factors, the equine 
activity was specific in its inhibition of collagen induced platelet 
aggregation. This may be due to the high degree of vascularisation and 
consequently, a high collagen content of the equine term allantochorion.
In total, it appears that the presence of placental factors capable of 
inhibiting platelet aggregation is necessary in both haemochorial and 
epitheliochorial placentae in order to counteract the otherwise high risk 
of a placental thrombosis.
In conclusion, data discussed in this thesis have led to a greater 
understanding of some of the biological events that occur during equine 
pregnancy. The important findings of these studies are outlined in Figs
8.1 and 8.2. A protein specific to the pregnant state of the horse has 
been described, which is detectable in the maternal serum at day 6 after 
mating and is detectable throughout gestation. The protein (32”hors.PP) may 
be of considerable value to the horse breeding industry in terms of the 
diagnosis of pregnancy and possibly in the monitoring of foetal well 
being. As assessed during the first 21 days after mating, 32-hors.PP 
detection as an indication of pregnancy was clinically significant at the 
10% level. Further developments of this work could include the 
development of a more sensitive assay for 82”hors.PP and also an assessment of 
82-hors.PP detection as an indication of pregnancy at later stages of 
gestation. Such investigations could lead to the development of a 
reliable non-invasive pregnancy test before day 60 when oestrone sulphate 
levels can be monitored. The pattern of secretion of 32~hors.PP suggests a 
possible biological activity during implantation such as immunoregulation. 
Consequently, further investigations could also include an evaluation of 
the possible immunomodulatory properties of the protein. It has also been 
demonstrated that equine epitheliochorial placentation exhibits both
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immunomodulatory and anti-aggregatory activity with the former predominant
during early gestation (eCG phase) and the latter predominant near to term/
as described in the human haemochorial placenta. It appears that eCG may 
not be immunosuppressive but that the commercially available eCG 
preparation may contain an immunosuppressive contaminant. Equine intra­
uterine immunosuppressive mechanisms appear to be effective at the IL-2 
level of the immune response which is comparable to existing data in the 
human and murine systems. Term equine placental allantochorion inhibited 
collagen induced aggregation but had no effect on ADP induced aggregation. 
This may be due to the high degree of vascularisation in the tissue. Term 
bovine placentome extract inhibited ADP induced platelet aggregation but 
not collagen induced aggregation in a similar fashion to many human anti­
aggregatory factors. This work could be developed further in the 
characterisation of the immunoregulatory and anti-aggregatory factors 
present in the tissue extracts. In addition, further investigations could 
be carried out into their mode of action. It would also be of interest to 
investigate the immunoregulatory activity associated with non-pregnant 
endometrium for comparison to the effects of pregnant endometrium.
In total, this preliminary work has shown that there are many similarities 
in the intra-uterine immunoregulatory and anti-aggregatory activities 
between mammals exhibiting haemochorial or epitheliochorial placentation. 
The development of this work leading to the identification of some of the 
factors described may lead to the further understanding of mammalian 
placental function. It is hoped, however, that the data presented here 
will further help reproductive immunologists to solve 'the riddle of 
mammalian foetal allograft'.
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APPENDIX I: MATERIALS
ADP reagent:
Agarose:
Barbitone [Diethylbarbituric Acid]:
Biuret reagent:
Bovine Serum Albumin, Fr.V.:
Bromophenol Blue:
Collagen reagent:
Cocktail ’0 f liquid scintillant:
Collagenase:
Controlled process serum replacement [CPSR-2]: 
Coomassie Brilliant Blue:
Dulbecco’s modification of Eagles medium 
containing 20 mM/1 HEPES [DMEM]:
Foetal Calf Serum:
Folin and Ciocalteau:
Freunds complete/incomplete adjuvent:
GFC Filter paper:
Heparin Ultrogel:
Heparin Sepharose:
Incubator [CO2 humidified]:
Lymphopaque separation medium 
[relative density 1.084]:
Microtitre plates [96 well]:
Optiphase Hisafe liquid scintillant: 
Penicillin/streptomycin solution:
Sigma Chemical Co. Ltd 
Sigma Chemical Co. Ltd 
BDH Chemicals Ltd 
BDH Chemicals Ltd 
Sigma Chemical Co Ltd 
Fisons Pharmaceuticals 
Sigma Chemical Co, Ltd 
BDH Chemicals Ltd 
Boehringer-mannheim 
Sigma Chemical Co. Ltd 
Sigma Chemical Co. Ltd
Flow Laboratories, 
Northumbria Biologicals Ltd 
Flow Laboratories 
BDH Chemicals Ltd 
Sigma Chemical Co. Ltd 
Whatman Ltd 
LKB Instruments Ltd 
Pharmacia Ltd 
W.C. Heraeus Gmbh
Nycomed UK Ltd 
Beckton Dickinson UK Ltd 
LKB Instruments Ltd 
Flow Laboratories, 
Northumbria Biologicals Ltd
Phenyl Methyl Sulphonyl Fluoride (PMSF): 
Platelet aggregometer (Model 1002 ): 
Pregnant Mare Serum Gonadotrophin:
PZ-Pro-Leu-Gly-Pro-Arg:
Scintillation Counter (LKB Rackbeta 1212): 
Semi-automated cell harvester:
Sephacryl S-300:
Sodium azide:
Sodium borohydride:
Sodium-m-periodate:
Tritiated thymidine (^H-Tdr):
Trypsin EDTA:
Vacutainers (143 USP units Li Heparin; 
0.105 M sodium citrate):
Sigma Chemical Co. Ltd 
ADG Instruments Ltd 
Sigma Chemical Co. Ltd, 
Intervet
Boehringer-raannheim 
LKB Instruments Ltd 
Skatron AS, Norway 
Pharmacia Ltd 
Koch-Light Ltd 
BDH Chemicals Ltd 
Fisons Pharmaceuticals 
Amersham International 
Flow Laboratories
Beckton Dickinson UK Ltd
All other chemicals were obtained from either BDH Chemicals Ltd or Sigma 
Chemical Co. Ltd.
APPENDIX II : BUFFERS AND REAGENTS
Agarose gel layer 
BS7 Reagent
Collagenase substrate solution
Phosphate buffer (PB ;)
Phosphate buffer saline (PBS)
Sodium acetate buffer 
(0.1M; pH 4.8)
Tris/Barbitone buffer 
(0.1 M; pH 8.6)
Tris (hydroxymethyl) - aminomethane
1% agarose in Tris/Barbitone 
buffer - gel formed by steaming at 
90°C.
1 vol. Biuret reagent in 7 vol. 
2.5% w/v sodium carbonate.
10 mg PZ-Pro-Leu-Gly-Pro-Arg 
dissolved in 0.2 ml methanol and 
make up to 10 ml with tris buffer.
0.15 M Na2HP04.12H20 (82%)
0.15 M NaH2P04.2H20 (18%)
PB with 0.9% NaCl.
Acetic acid (36%)
Sodium acetate (64%)
22.4 g Diethylbarbituric acid
44.3 g Tris
0.533 g Ca - Lactate
0.650 g Sodium azide (NaN3).
Add distilled water to 1 litre to 
give a concentrated buffer. Dilute 
1:4 before use.
1.22 g Tris - make up to 100 ml 
and adjust to pH 7.1 with 1 M HC1.
APPENDIX III: ELISA ASSAY FOR eCG: BUFFERS AND REAGENTS
Plate coating buffer 
(pH 6.0)
Wash buffer and glaze 
(pH 7.0)
Conjugate buffer 
(pH 8.5)
Standard buffer 
(Ph 7.0)
20 mM Citrate
2.5 g lactose
2.5 BSA
0,5 g Sodium azide 
500 ml Deionized water
14,9 g Trimethanolamine 
52.8 g Ammonium sulphate
5.0 g BSA.
1.0 g Magnesium chloride
1.0 Sodium azide
1.0 ml Triton X-705
1.0 1 Deionized water
250 ml PBS
2.5 g BSA
0.25 g Sodium azide
Sample dilution buffer 250 ml PBS
(pH 7.0) 2.5 g BSA
0.25 g Sodium azide 
250 ul Triton X-705
Assay wash buffer 
(pH 8.0)
[20 x concentrate]
158.56 Ammonium sulphate
20.00 Trizma base 
21.28 g Trizma HC1
12.00 ml Magnesium chloride
12.00 ml 0.1 M Zinc chloride
1.00 g Sodium azide
1.00 ml Triton X-705
1.00 g SB-14 (Calbiochem) 
975 ml Deionized water
